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African animal trypanosomosis or nagana is a disease in livestock caused by various 
species of protozoan parasites belonging to the genus Trypanosoma particularly T. 
congolense, T. vivax and T. b. brucei. Nagana is the most important constraint to livestock 
and mixed crop-livestock farming in tropical Africa. Trypanosomes undergo part of their 
developmental life in their insect vector, the tsetse fly and part in their mammalian host.  
 
Measures for eradicating the continent of the tsetse fly vector include insecticidal spraying, 
targeting and trapping. Vaccine development has been hampered by the generation of an 
inexhaustible collection of variant surface glycoproteins that trypanosomes possess and 
allow for evasion of the host immune system. Anti-disease vaccines aimed at reducing the 
symptoms of the disease rather than killing the parasite itself have been demonstrated as an 
alternative approach. Trypanotolerant cattle are able to protect themselves from the 
disease-associated symptoms. They are able to mount a better antibody response to the 
CATL-like cysteine peptidase, TcoCATL, compared to trypanosusceptible breeds. Bovine 
trypanosomosis, however, continues to be controlled primarily by trypanocidal compounds 
such as isometamidium chloride, homidium and diaminazene that have been developed 
more than 50 years ago and consequently drug resistance is widespread. Trypanosomal 
cysteine peptidases have also been proven to be effective targets for chemotherapeutics. 
TcrCATL, inhibited by the vinyl sulfone pseudopeptide inhibitor K11777, was effective in 
curing or alleviating T. cruzi infection in preclinical proof-of-concept studies and has now 
entered formal preclinical drug development investigation.  
 
Understanding enzymatic as well as structural characteristics of pathogenic peptidases is 
the first step towards successful control of the disease. To date no such characterisation of 
the major cysteine peptidases from T. vivax has been conducted. Although the major 
cysteine peptidase from T. vivax, TviCATL, has not been proven as a pathogenic factor yet, 
its high sequence identity with the pathogenic counterparts such as TcrCATL and 
TcoCATL hold much speculation for TviCATLs role in pathogenocity.  
 
In the present study, native TviCATL was isolated from T. vivax Y486, purified and 
characterised. TviCATL showed to have a general sensitivity to E-64 and cystatin and has a 
substrate specificity defined by the S2 pocket. TviCATL exhibited no activity towards the 
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CATB-like substrate, Z-Arg-Arg-AMC but was able to hydrolyse Z-Phe-Arg-AMC, the 
CATL-like substrate. Leu was preferred in the P2 position and basic and non-bulky 
hydrophobic residues were accepted in the P1 and P3 positions respectively. Similar 
findings were reported for TcoCATL. The substrate specificity of TviCATL and TcoCATL 
does argue for a more restricted specificity compared to TcrCATL. This was based on the 
Glu333 in TcrCATL substituted with Leu333 in TviCATL and TcoCATL. In the case of 
TcrCATL, the Glu333 allows for the accommodation of Arg in the P2 position. Like other 
trypanosomal cysteine peptidases, TviCATL was inhibited by both chloromethyl ketones, 
Z-Gly-Leu-Phe-CMK and H-D-Val-Phe-Lys-CMK. Determining further structural and 
functional characteristics as well as whether TviCATL, like the T. congolense homolog, 
TcoCATL, acts as a pathogenic factor, would be important information to the designing of 
specific chemotherapeutic agents. 
 
To date, TcrCATL and TbrCATL (from T. b. rhodesiense) are the only trypanosomal 
CATL-like cysteine peptidases been crystallised and their tructures solved. This advantage 
has allowed for the directed design of synthetic peptidase inhibitors. The crystal structure 
of TcoCATL will be of major significance to the design of specific chemotherapeutic 
agents. Furtherrmore, understanding the dimeric conformation of TcoCATL is important 
for vaccine design as immune responses are likely to recognise the dimer specific epitopes. 
In the current study, the catalytic domain of TcoCATL and TviCATL, were recombinantly 
expressed in Pichia pastoris and purified to homogeneity. The T. congolense cysteine 
peptidase pyroglutamyl peptidase (PGP), also proven to be pathogenic in T. b. brucei, was 
recombinantly expressed in E. coli BL21 (DE3) cells and also purified to homogeneity. 
Purified cysteine peptidases along with previously purified TcoCATL dimerisation 
mutants, TcoCATL (H43W) and TcoCATL (K39F; E44P), possessing mutated residues 
involved in TcoCATL dimerisation, as well as the mutant proenzyme TcoCATL (C25A), 
were screened for crystallisation conditions using the Rigaku robotic crystallisation suite. 
One-dimensional needle-like crystals were found for TcoCATL (K39F; E44P). 
Optimisation of the TcoCATL (K39F; E44P) crystals were analysed for X-ray diffraction. 
The poor diffraction pattern prompted further optimisations for better crystal quality, 
which is presently underway. The crystal structure of TcoCATL, with some of the residues 
involved in dimerisation mutated, will be pivotal in understanding the dimerisation model. 
Furthermore, the information about the structure will be valuable for vaccine design and 
chemotherapeutics development. 
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CHAPTER 1  
LITERATURE REVIEW 
 
1.1  African Trypanosomosis 
Human African trypanosomosis, endemic to intertropical Africa, also known as sleeping 
sickness, is represented by two main species T. brucei rhodesiense and T. b. gambiense 
(Lecaille et al., 2002). It is estimated that at least 50 million people are at risk of infection 
with trypanosomes (http://who.int/tdr/diseases/tryp/default.htm). African animal 
trypanosomosis (AAT), caused by Trypanosoma congolense, T. vivax, T. evansi and T. b. 
brucei, is the most important constraint to livestock and mixed crop-livestock farming in 
tropical Africa. An area of 8.7 million km2 of the continent is infested with the tsetse fly 
vector, Glossina spp, resulting in at least 46 million cattle  and 70 million small ruminants 
being exposed to the risk of contracting the disease (Fig 1.1) (Kristjanson et al., 1999). 
                         
Figure 1.1 Distribution of (A) Glossina palpalis and (B) Glossina morsitans groups of tsetse flies 
predicted using satellite imagery (Wint and Rogers, 2000). 
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This disease affects 40 African countries and is costing the continent US $4.75 billion per 
year (Van den Bossche et al., 2010). The disease has caused considerable direct 
economical losses as costs are mainly attributed to those involved in diagnosis and 
treatment as well as the decrease in milk and meat production. The African continent 
produces one-seventieth of the animal protein per hectare that Europe produces 
(Kristjanson et al., 1999). This is generally a result of farmers’ responses to the perceived 
risk of the disease, including the reduction and, in some cases, the exclusion of livestock 
from tsetse-infested grazing lands and reduced crop production due to insufficient animal 
draft power leading to further indirect economic losses. Furthermore, the International 
Livestock Research Institute (ILRI) stated that the impact of trypanosomosis is even 
greater than these figures suggest because many of the areas inhabited by tsetse flies are 
potentially the most agriculturally productive in Africa 
(http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad90/Trypano.htm). There have been 
several approaches to controlling the disease such a trypanocides, controlling tsetse 
populations, searching for components for a multi-component vaccine and the use of 
livestock breeds that tolerate the disease (trypanotolerant breeds). The potential benefits of 
improved trypanosomosis control, in terms of meat and milk production alone, amount 700 
million US dollars per annum in Africa (Kristjanson et al., 1999).  
 
1.1.1  Classification 
African animal trypanosomes belong to the order Kinetoplastida that comprises a group of 
protozoa defined by the presence of a characteristic organelle, the kinetoplast (Vickerman, 
1969). This organelle is a large modified mitochondrion. Originally established 
classification systems of the parasite were based largely on the morphological and lifecycle 
characters in the absence of molecular data. The Kinetoplastida order was thus originally 
subdivided into the suborders Bodonina and Trypanosomatina (Vickerman, 1969). The 
parasitic bodonidae were represented by ectoparasites of fish and endoparasites of fish and 
snails. The second group comprised a single family of obligate parasites, 
Trypanosomatidae. There have been improvements in sampling taxa for phylogenetic 
studies using molecular techniques (Hamilton et al., 2004; Simpson et al., 2002; Stevens 
and Brisse, 2004). Based on new molecular data, a new system was generated which 
divided kinetoplasts into Prokinetoplastina (Ichthyobodo and Perkinsiella) and 
Metakinetoplastina (other bodonids and trypanosomatids) (Fig. 1.2) (Moreira et al., 2004).  
 


















Figure 1.2 Classification of trypanosomes (Moreira et al., 2004; Stevens and Brisse, 2004). 
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Trypanosomatids have a digenetic lifestyle, they are carried in invertebrate vectors such as 
tsetse flies, sandflies and triatomine bugs and infect all classes of vertebrates (Stevens, 
2008). The Trypanosoma genus comprises the four clades including Salivarian and 
Stercoraria clades that contain species of medical and veterinary importance and have 
become the focus of much research. The Stercoraria clade contains the species T. cruzi, 
which has a wide vertebrate host range and is the causative agent of Chagas’ disease. T. 
rangeli is infective to humans whereas T. thieleri has a wide host range, with the major 
vector being tabanid flies. The only species from the subgenus Duttonella within the 
Salivarian clade, T. vivax, represents early stage adaptation to transmission by tsetse flies 
(Lukes et al., 1997) as they are unable to undergo cyclical development in tsetse flies. The 
Trypanozoon subgenus umbrellas the widely researched T. brucei. The subspecies T. b. 
rhodesiense and T. b. gambiense are the causative agents for human African sleeping 
sickness (HAT), both transmitted by tsetse flies. T. congolense, T. simiae and T.godfreyi 
are species of the subgenus Nannomonas. T. congolense along with T. vivax and T. b. 
brucei are frequently encountered pathogens of African livestock, causing the disease 
Nagana. On the other hand, T. evansi, part of the Trypanozoon subgenus, causes Surra, a 
severe wasting disease in livestock. T. evansi is mechanically transmitted by biting flies, 
namely tabanids.  
 
1.1.2  Morphology of African trypanosomes 
Trypanosomal parasites are unicellular organisms which vary between 8 and 24 μm. The 
streamlined parasites are tapered at both the anterior and posterior ends to assist in the 
efficient movement through the bloodstream. Trypanosomes have a highly organised 
exoskeleton (Vickerman, 1969) and along with the pellicular microtubules, which cover 
the entire cell surface beneath the cell membrane of the parasite, give the structure of the 
trypanosome as well as allowing movement and flexibility (Stevens and Brisse, 2004; 
Taylor and Authié, 2004). The flagellum, produced by the parabasal body (Fig.1.3) is 
essential for mobility. Unlike T. vivax and T. brucei, T. congolense lacks a free flagellum. 
This difference has been utilised for diagnostics using microscopy (Eisler et al., 2004). The 
invagination of the plasma membrane where the flagellum attaches to the trypanosome is 
known as the flagellar pocket. The flagellar pocket is generally the site for endo- and 
exocytosis, where protein trafficking and recycling of cellular proteins takes place. 
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The single mitochondrion that trypanosomes possess runs from the posterior to the anterior 
end. The posterior end of the mitochondrion comprises the specialised area known as the 
kinetoplast. The kinetoplast contains between 10-20% of the trypanosomal DNA 
(Vickerman, 1969). The kinetoplast is significantly larger in T. vivax compared to T. 
congolense which is exploited for diagnostics (Eisler et al., 2004).  
 
 
Figure 1.3 Schematic diagram of a trypanosome of the T.  brucei group in its intermediate bloodstream 
form, illustrating the major organelles. (Acquired from International Livestock Research Institute’s 
website www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad88/Trypanosomiasis.htm accessed 02.10.11). 
 
 
1.1.3  Life cycle of African trypanosomes 
Trypanosomes are digenetic parasites and as a result of this the parasite undergoes a series 
of pleomorphic events that are necessary for the successful transmission from the vector to 
the host and vice versa (Fig. 1.4). Trypanosomes undergo part of their developmental life 
in their insect vector, the tsetse fly or other invertebrate depending on trypanosome species 
and part in their mammalian host (Roditi and Lehane, 2008). Three developmental forms 
of the trypanosome undergo cell multiplication: the non-infective procyclic and 
epimastigote forms in the tsetse fly and the long slender bloodstream forms in the 
mammalian host (El-Sayed et al., 2000). The developmental forms that do not undergo 
multiplication are the infective matacyclic and short stumpy (not shown in Fig. 1.4) forms.  
 
 




Metacyclic forms are 
injected into the skin 
of a host 
Metacyclic forms 
- Do not divide 
- Aquire a VSG coat 
Epimastigote forms 
- Multiply in the 
proboscis 
- Stick to the 
salivary glands 
Procyclic forms 
- Multiply in the 
gut  
- Aquire a 
procyclin coat 
Blood stream forms are 
taken up by the tsetse fly 
as it feeds on an infected 
animal 
Blood stream forms 
- Multiply by binary fission 
-  clonal and well as sexual 
depending species 
- Undergo antigenic variation 
(VSG coat) 
- Infective to other mammals 
when differentiated in short 
stumpy  forms 
 Figure 1.4 The life-cycle of T. congolense (Authié, 1994). 
 
 
As the fly takes in a blood meal from the infected mammalian host, there are two forms 
that can potentially be ingested. These include the normal slender bloodstream forms or the 
short stumpy, non-replicating forms. Only the short stumpy forms of the trypanosome are 
thought able to survive the onslaught of potent peptidases present in the saliva and midgut 
of the tsetse fly. The variable surface glycoprotein (VSG) coat of the surviving stumpy 
forms is shed and replaced with an invariant glycoprotein coat composed of procyclic 
acidic repetitive proteins (PARPs), commonly referred to as procyclins, which are attached 
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to the membrane via glycosylphosphatidylinositol (GPI) anchors (El-Sayed et al., 2000). 
The procyclic forms colonise the ectoperitrophic space and reach very high densities in the 
midgut. To complete part of the life-cycle in the insect vector, the procyclics forms must 
migrate to the salivary glands via the foregut and the proboscis. In the case of T. vivax, 
development within the vector is confined entirely to the proboscis and lacks the procyclic 
stage (Stevens and Brisse, 2004) 
 
In the salivary glands, the epimastigote form develops. This form attaches to the epithelium 
and proliferates to give rise to the mammalian infective non-dividing metacyclic form. It is 
the metacyclic form that expresses the VSG that is evident on the surface of the parasite. 
These metacyclic forms are transmitted to a susceptible mammal during the vector’s blood 
meal. The existence of mating in trypanosomes has been documented for T. brucei (Gibson 
and Stevens, 1999)  and T. congolense (Holzmuller et al., 2010). As a result of this, 
trypanosomes can use strategies from clonal reproduction, by binary fission, to sexual 
recombination by mating, to adapt to various environmental conditions.  
 
1.1.4  Genetic organisation of trypanosomes  
Trypanosomes possess two genomes, one within the nucleus and the other within the 
kinetoplast. The kinetoplast DNA is arranged into an interlinked network of minicircles (1 
kb) and maxicircles (~ 22 kb) (El-Sayed et al., 2000). The maxicircles have conserved 
sequences and encode for mostly ribosomal RNA and mitochondrial proteins whilst 
minicircles occur in a very high copy number and comprise variable sequences that encode 
for a wide variety of proteins (Vather, 2010). To date, the T. brucei nuclear genome has 
been completely sequenced (Berriman et al., 2005). The knowledge of nuclear genome has 
provided information for trypanosomal genomes such as T. congolense and T. vivax (Morty 
et al., 2006). T. brucei has a 3.5 x 107 bp genome which is approximately the size of the 
Plasmodium falciparum genome (Dame et al., 1996). The nuclear genome of trypanosomes 
is of low complexity, with most of it being diploid. The VSG genes as well as the VSG 
expression sites and some of the mini-chromosomes are haploid (El-Sayed et al., 2000). 
 
1.1.5  Antigenic variation in trypanosomes 
Antigenic variation involves changes in the identity of the VSG (Vickerman, 1978). The 
entire surface of the bloodstream and metacyclic forms of the trypanosome, including the 
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flagellum, is covered with VSG. Each variant is termed a distinct variable antigen type 
(VAT). It is thought that the surface coat is there to provide general protection against host 
resistant mechanisms and therefore shield invariant surface antigens from immune 
recognition. Furthermore, the antigenic variation system in trypanosomes ensures survival 
within the mammalian bloodstream and allows transmission to the next host via the tsetse 
vector (Morrison et al., 2009).  
 
The stochastic switching to a different VAT which allows for evasion of the host immune 
system causes prolonged trypanosome infection (Barrett et al., 2003; Donelson, 2003; 
McCulloch, 2004). The rate of VSG switching is up to 10-3 switches/parasite/5-10 h 
generation time (Turner and Barry, 1989). VSG switching in itself is a mechanism to evade 
the host immune system. However, VSG also has several other effects on the immune 
system such as induction of autoantibodies by the non-specific polyclonal activation of B-
cells (Buza and Naessens, 1999) as well as cytokines, namely tumour necrosis factor 
(TNF)-α (Morrison et al., 2009).  
 
Sites for VSG transcription (VSG expression site) are found directly proximal to the 
telomeres (Hertz-Fowler et al., 2008). Subtelomeres also harbour silent VSG arrays 
(Berriman et al., 2005). The VSG gene array contains a large portion of pseudogenes 
which combine to form functional VSG ‘mosaics’ (Marcello and Barry, 2007), which 
provide a critical resource during antigenic variation. In order for VSGs to switch their 
identity certain switching mechanisms have to occur. There are two modes of switching: 
transcriptional switching, where a single actively transcribed VSG expression site is 
silenced and a silent expression site becomes actively transcribed, and recombination 
reactions (Morrison et al., 2009).  
 
1.2  Pathogenesis of African animal trypanosomosis 
There is a large amount of intraspecies variation in the pathogenocity of different parasite 
stocks, especially stocks isolated form distinct geographical regions (Taylor and Authié, 
2004). Haematic trypanosomes such as T. congolense and T. vivax are found in the blood 
vessels of hosts, whilst humoral trypanosomes, such as T. b. brucei, T. evansi and T. 
equiperdum are found in the extravascular compartment and tissues (Lonsdale-Eccles and 
Grab, 2002). Furthermore, acute haemorrhagic and non-haemorrhagic disease can be found 
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in cattle when infected with T. vivax from East and West Africa respectively. Generally, 
there are three main phases of bovine trypanosomosis. These include the early acute phase, 
stabilisation and chronic phase (Taylor and Authié, 2004). In the acute phase, there is a 
continuous detectable level of trypanosomes in the blood. Fever is high and anaemia can 
develop (Andrianarivo et al., 1995; Murray and Dexter, 1988). Furthermore the spleen and 
lymph nodes are enlarged. Very often death of infected animals can occur in this acute 
phase as there is a continuous drop in the haematocrit value (packed cell volume) (Taylor 
and Authié, 2004). Stabilisation only occurs in cattle that are able to stabilise the packed 
cell volume. Generally stabilisation can occur after 6-8 weeks, whilst the parasitaemia 
becomes intermittent.  The packed cell volume may fluctuate at low levels for months or 
years. The chronic stage occurs when cattle develop cachexia, impaired milk productivity 
and oestrous cycle. The chronic phase can lead to death and self-cure to, a persistent carrier 
state (Taylor and Authié, 2004).  
 
During the infection process, once drained from the afferent and efferent lymphatics, the 
lymphoid organs, liver, bone marrow, heart, central nervous system, endocrine and 
reproductive organs become affected (Mattioli et al., 1999). The metacyclic trypanosomes 
deposited in the skin undergo multiplication. Extensive oedema occurs and a chancre 
develops as a result of degranulation of mast cells in the skin. After a period of 
multiplication trypanosomes appear in the afferent lymph nodes. The cellularity of the 
afferent lymph increases significantly and is characterised by CD4+, CD8+ and B 
lymphocytes (Sileghem and Naessens, 1995; Uzonna et al., 1998). Splenomegaly is a 
feature of the ‘acute’ or parasitaemic phase of the infection and is mainly a result of 
lymphocyte sequestration and an expanded macrophage population (Noël et al., 2002). 
This is notably seen in the red pulp of the spleen, as there is an expansion of the red pulp.  
 
The co-evolution of trypanosomes with their host have allowed for trypanosomes to divert 
and alter the numerous steps that lead to the hosts immune response. As a result of this the 
hosts’ immune response does not necessarily lead to protection but to immunopathology 
disorders. Immunopathology disorders include production of autoantibodies, immune 
suppression of T- and B-lymphocytes and dysregulation of the cytokine network 
(Vincendeau and Bouteille, 2006). The pluripotent cytokine, IL-10, is upregulated in 
mononuclear cells derived from the peripheral blood, lymph nodes and spleen of infected 
cattle. IL-10 has the ability to down-regulate IFN-γ. In terms of Type-1 cytokine 
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production, susceptible mice produce more IFN-γ than resistant mice (Tabel et al., 2000) 
and inhibiting IFN-γ causes a marked increase in survival (Uzonna et al., 1998). It has been 
proposed that mice die from Systemic Inflammatory Syndrome (SIRS) mediated by IFN-γ 
(Stijlemans et al., 2007).  
 
1.3  Diagnosis of African animal trypanosomosis 
Generally herdsman or technical personnel conducting diagnostic tests operate under the 
most adverse physical and economic conditions. African herdsmen usually rely on the 
clinical features of the disease for diagnosis The clinical signs of acute bovine 
trypanosomosis include anaemia, weight-loss, roughness of hair coat, enlargement of 
peripheral lymph nodes, pyrexia and abortion (Eisler et al., 2004). The presumptive 
diagnosis, based on clinical signs, is usually followed by the administration of trypanocidal 
drugs, with a positive response to treatment being interpreted as a confirmation of 
diagnosis.  
 
Parasitological diagnosis rely on blood smears fixed with methanol and stained with 
Giemsa followed by light microscope examination (Eisler et al., 2004). This technique is 
not sensitive and cannot detect low parasite levels which are often characteristic of 
infection in livestock. The haematocrit centrifugation technique (Woo, 1970), involves 
centrifugation of a microhaematocrit capillary tube containing the infected blood sample 
and examination of the buffy coat-plasma interface. In an improvement of this method the 
buffy coat plasma interface is placed on a microscope slide and dark-ground or phase 
contrast illumination is used to detect the parasites (Murray et al., 1977). Other methods for 
diagnosis were developed such as the sub-inoculation method, where blood is taken from a 
suspected infected case and injecting it into another species such as immunosuppressed 
rodents or mice where levels of parasitaemia develop very quickly (Eisler et al., 2004). 
However, like in the case of T. vivax, mouse sub-inoculations fail to pick up infections. An 
in vitro culture method has also been developed. The kit for the in vitro isolation of 
trypanosomes (KIVI) was developed for T. b. gambiense in human trypanosomosis 
infections (Aerts et al., 1992) and has also been shown to detect T. b. brucei in animals 
with more sensitivity than parasitological techniques (McNamara et al., 1995).  
 
The low levels of parasitaemia has made serodiagnostics appropriate for the detection of 
trypanosomes in animals. The card agglutination trypanosomosis test (CATT) (Akol et al., 
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1999) is very suitable for field use in Africa, whereby infected blood serum antibodies will 
agglutinate with card antigens (antigens blotted onto a nitrocellulose card) based on the 
antigenic VATs. This method is suitable for T. b. gambiense which has highly conserved 
VATs, however, for T. congolense and T. vivax, there is difficulty in identifying suitable 
VATs and therefore this assay is not suitable (Luckins, 1992). The CATT/T. evansi 
diagnostic kit uses a freeze dried suspension of purified, fixed and stained trypanosomes of 
a cloned predominant VAT (VAT RoTat 1.2) of T. evansi on a card agglutination to detect 
antibodies from T. evansi infected animals (Reid and Copeman, 2003). 
 
An antibody-detection ELISA relies on the specific antibodies in the infected sample to 
bind to a specific antigen and is itself detected by means of an enzyme-labelled anti-species 
(anti-bovine) conjugate (Eisler et al., 2004). The major advantage of any ELISA detection 
is that it can be performed without very specialised equipment. Crude trypanosomal 
antigen preparations fractionated at different percentages of ammonium sulfate have been 
used for the detection of antibodies in T. evansi infected cattle (Reid and Copeman, 2003). 
The three antigen preparations, labelled according to the ammonium sulfate fractionation, 
20-40%, 40-50% and >50%, were compared against the CATT/T. evansi test (Bajyana 
Songa and Hamers, 1988). The “40-50%” antigen preparation had the greatest 
discriminatory power between non-infected and T. evansi infected cattle. Furthermore, the 
antigen preparation was significantly more sensitive than the CATT/T. evansi test. The 
indirect ELISAs using denatured crude trypanosomal antigen preparations for T. 
congolense (TcAGd) and T. vivax (TcAGd), which resulted in the development of an 
ELISA kit (I-TAB ELISA) has been used for the detection of anti-trypanosomal antibodies 
in bovine serum (Rebeski et al., 2001). This ELISA has also been used for T. viax and T. 
congolense infected goats (Lejon et al., 2003). The ELISA was able to detect antibodies 
from T. congolense infected goats with 100% sensitivity. However there was extensive 
cross reactions of the ELISA with sera from T. vivax and T. brucei infected goats. One of 
the most important obstacles to antibody-detection ELISAs is that antibodies can persist in 
the host far longer than the infectious agent does (Boulangé et al., 2002; Van den Bossche 
et al., 2000). However, the heat shock protein 70/BiP inhibition ELISA for the diagnosis of 
bovine trypanosomosis was able to show seroconversion within three months after drug 
treatment in experimentally infected animals, suggesting that it could be a useful tool for 
monitoring the efficiency of treatment (Bossard et al., 2010). Furthermore, the antigen-
detection ELISA overcomes the obstacle by detecting antigen rather than antibody in the 
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infected host. The double-sandwich ELISA method was shown to detect antigens, with 
antisera raised against T. congolense, in rabbits and goats within 10-14 days of infection in 
T. congolense and these antigens disappeared 21 days after trypanocidal drug treatment 
(Rae and Luckins, 1984). An antigen detection ELISA for species specific diagnosis, 
developed at the Animal Production of Health unit, Atomic Energy Agency (IAEA) 
Agriculture laboratory, Seibersdorf, Austria, uses the monoclonal antibodies [T.b.r.7 
(IgM)] (Nantulya et al., 1987), [T.c.39 (IgM)] (Masake and Nantulya, 1991), [T.v.27 
(IgG1)] (Nantulya et al., 1992) for T. b. brucei, T. congolense and T. vivax respectively. 
However, this antigen detection ELISA does have poor sensitivity and specificity (Eisler et 
al., 1998). 
 
Molecular methods, such as PCR, for detecting livestock-infective trypanosomes has 
evolved as one of the most specific and sensitive methods of diagnosis. Some research has 
focused on multiple species identification with a single primer (Desquesnes et al., 2001). 
Furthermore, a PCR-ELISA assay, using universal PCR amplifying trypanosome DNA 
followed by an ELISA-based hybridization with three highly-specifc probes, has been 
developed and can differentiate between T. congolense and T. vivax (Cabrera et al., 2009). 
In spite of the good specificity and sensitivity, molecular biology techniques are not 
commonly used due to cost and lack of skilled personnel in diagnostic laboratories in 
developing countries (Thekisoe et al., 2007). The loop-mediated isothermal amplification 
(LAMP) of T. b. gambiense, T. b. rhodesiense, T. congolense, T. cruzi and T. evansi DNA 
with specific primers overcomes many of the molecular diagnostic drawbacks (Thekisoe et 
al., 2007). Under isothermal or constant temperature conditions, auto-cycling strand 
displacement of trypanosomal DNA is performed by the Bst DNA polymerase (Thekisoe et 
al., 2007). The amplification is rapid, taking about a 1 h, requires only a heat bath, can 
amplify trypanosome DNA from blotted blood (Mori et al., 2001) on filter paper and 
produces large amounts of DNA that can visualised with the naked eye in the test tube 
(Mori et al., 2001).  
 
1.4  Trypanotolerance 
Many years of selection in tsetse-infested areas allowed for taurine breeds of cattle in 
West-Africa to develop a reduced susceptibility to trypanosomosis.  The term 
trypanotolerance was defined as the trait that confers the capacity to survive and remain 
productive after trypanosome infection (Murray et al., 1982). Generally, trypanotolerant 
   13 
 
cattle have reduced mortality, blood trypanosome levels and severe anaemia and their 
reproductive performance is better than indicine breeds such as Boran cattle (Bos indicus) 
(Naessens, 2006). Such observations were made under laboratory conditions between 
trypanotolerant N’Dama calves (B. taurus) and susceptible Boran calves. Trypanotolerance 
has been suggested to be multi-factorial, involving both non-immunological and 
immunological mechanisms (Authié, 1994).  
 
Efforts to identify genes that may confer trypanotolerance have been made. Serial analysis 
of gene expression (SAGE) has been used to identify the change of leukocyte number in 
N’Dama after infection by T. congolense (Maillard et al., 2004; Maillard et al., 2005). 
N’Damas have a comparative advantage over Boran cattle in erythropoietic 
responsiveness. The receptor for the glycoprotein hormone controlling erythropoiesis, 
erythropoietin, has significantly higher transcription levels in the bone marrow of 
N’Damas, compared to Borans with T. congolense infection.  
 
The role of hematopoietic cells in trypanotolerance has also been previously investigated. 
As illustrated by placing a Boran and an N’Dama embryo in the recipient mother, resulting 
in bone marrow chimerism in twin calves, N’Dama cattle haemopoietic cells in anaemia 
control and parasitaemia were not linked (Naessens et al., 2003). It has also been recently 
shown that expression levels of serum amyloid A, an acute phase protein, working as part 
of the host’s effector molecules in the innate immune system is elevated in N’Dama cattle 
when compared to Boran cattle in experimental infection with T. congolense (Meade et al., 
2009) 
 
There is no difference between trypanotolerant and susceptible cattle regarding the 
production of antibodies against the main target for the humoral immune response, VSG 
(Pinder et al., 1984). There are however, parasitic antigens that are released into the 
bloodstream of the host upon parasite lysis by anti-VSG antibodies. These antigens can 
induce pathology and trypanotolerant cattle may possess the ability to resist the disease 
better through a more effective immune response to these antigens (Authié, 1994). Western 
blotting has illustrated that a 33 kDa CATL-like cysteine peptidase, namely TcoCATL 
(Mbawa et al., 1992), induce the production of reactive IgG1 antibodies in trypanotolerant 
cattle (Authié et al., 1993). This antibody response is one of the clear differences between 
N’Dama and Boran cattle (Taylor et al., 1996).  
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1.5  Control of African Animal Trypanosomosis 
 
1.5.1 .Chemotherapy 
Over most of sub-Saharan Africa, bovine trypanosomosis continues to be controlled 
primarily by chemotherapeutic agents such as Samorin® (isometamidium chloride), 
Ethidium® (homidium) and Berenil® (diaminazene). However these main drugs registered 
to treat African trypanosomosis have mostly been used for more than 50 years (Kroubi et 
al., 2011). Ongoing research is, however, facilitating the development of drugs that are 
more therapeutic, combat resistance and possess fewer side effects.  
 
The compound isometamidium chloride (ISM; Samorin®, Trypanidium®, Veridium®) 
(Table 1.1) has been used a prophylactic drug for livestock suffering primarily from T. 
congolense infection and can provide up to six months protection. ISM is a conjugate of 
homidium (Ethidium®) and diaminazene (Berenil®) molecules (Delespaux and de Koning, 
2007).  The main mode of action of ISM is proposed to be the cleavage of kinetoplast 
DNA-topoisomerase complexes, causing the desegregation of the minicircle network 
within the kinetoplast (Shapiro and Englund, 1990). The kinetoplast is the primary site for 
ISM accumulation in T. brucei and T. congolense (Boibessot et al., 2002).  
 
Diaminazene has limited prophylactic properties and major therapeutic properties. 
Diaminazene is relatively cheap and widely available (Bruning, 1996). This is possibly 
why it is used as a first-line of treatment for sick livestock. However rapid clearance of the 
drug from the body has contributed to the development of resistance (Delespaux and de 
Koning, 2007).  
 
There are to two major strategies for trypanosomal drug usage in African trypanosomosis 
infections. The first is routine block treatments where prophylactic drugs, mainly ISM, are 
used at predetermined intervals based on prophylaxis duration. The second is strategic 
block treatments using prophylactic drugs when animals succumbing to infection reach a 
predetermined threshold of parasitaemia (Holmes et al., 2004). Recent work has focused on 
drug delivery systems to improve drug therapeutic efficacy, optimise the drug’s 
pharmacokinetic properties and reduce its toxicity (Kroubi et al., 2011). The ultimate goal 
for drug delivery systems is to optimise ADME (absorption, distribution, metabolism and 
elimination) and at present several strategies aimed at improving ADME are under
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development which include the inclusion of drugs into liposomes, polymeric miscelles, 
cyclodextrins and nanoparticles (Kroubi et al., 2011). Diminazene liposomes have been 
studied in a mouse model of T. b. brucei and T. evansi infection (Yongsheng et al., 1996). 
The experiment demonstrated that encapsulated diminazene was more active than the free 
drug, did not give side effects and had a longer half-life and efficacy in the mice. A further 
study showed that a lipid, water-insoluble drug conjugate made of distearate, tristearate 
and diolate with diminazene has increased adherence to the brain endothelial vessels, thus 
being able to cross the blood-brain barrier (Chang et al., 2009). 
 
1.5.2  Tsetse control 
One of the principal strategies in controlling African trypanosomosis is to eradicate or 
control tsetses fly populations. Due to the absence of vaccines and effective and affordable 
drugs, the African Union, in 2002, initiated a new continent-wide initiative to rid the entire 
continent of the tsetse vector: the Pan African Tsetse and Trypanosomosis Eradication 
Campaign (PATTEC) (Symeonakis et al., 2007). The three major strategies that have been 
adopted to rid the continent of such a vector include insecticidal spraying, insecticidal traps 
and the sterile insect technique. Targets and traps have been used extensively in small 
agriculture settings (Vale, 1993), focusing on trapping of tsetse flies on water (Laveissiere 
et al., 2011). 
 
Tsetse flies are susceptible to most insecticides. However, as part of the life cycle, the 
juvenile tsetse fly development takes place several centimetres below ground and this 
determined the approach to insecticide delivery such as  ground spraying using hand-held 
or vehicle mounted fogging machines as well as sequential aerosol technique using aircraft 
(Allsopp and Hursey, 2004). Insecticides include the organochlorines such as DDT 
(Campbell and West, 1952), dieldrin and endosulfan and the more recently developed 
synthetic pyrethroids (Allsopp and Hursey, 2004). Bioaccumulation of the organochlorines 
made them very effective over a long time period but ultimately led to their international 
ban (Allsopp and Hursey, 2004). Endosulfan does not have the same potential for 
bioaccumulation and because of its wide availability at reasonable cost, was a suitable 
choice for non-residual aerosol applications from aircraft.  
However, the discovery of synthetic pyrethroids led to the development of deltamethrin 
that is much more powerful than the organochlorines and has low mammalian toxicity and 
a very broad invertebrate spectrum (Elliott et al., 1974). Sterile insect technique is a 
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genetic population suppression approach that involves sustained, systematic release of 
irradiated sterile male insects among the wild population (Aksoy, 2003). In combination 
with trapping and insecticide spraying, it has been a successful tsetse eradication technique 
in contained areas such as Zanzibar (Vreysen et al., 2000). 
 
1.5.3  Vaccine development 
As trypanosomes are able to continuously evade the host antibody response with the 
generation of an inexhaustible collection of VSGs, using killed parasites as a vaccine is not 
an option. Non-variable antigen-based vaccines have been explored. Trypanosomes do 
express a number of less variable surface antigens. These include the multiple copy-
number invariant surface glycoproteins (ISGs), evenly distributed on the surface of the 
bloodstream-stage trypanosomes. Induction of antibodies against ISG75 was a prominent 
result during flagellar pocket vaccination, indicating that this protein is immunogenic by 
itself, despite its heavy glycosylation (Radwanska et al., 2000). However mice immunised 
with ISG75 demonstrated no protection upon challenge with T. b. brucei (Tran et al., 
2008). It was found that the effective B cell memory response was abolished. As Magez et 
al. (2009) observed that vaccination still remains the best theoretical option, in order for an 
anti-trypanosome vaccine to be effective, it should have the ability to eliminate all 
circulating parasites prior to B cell memory suppression or destruction. 
 
Alternatively, transmission blocking vaccines (TBVs) are aimed at reducing transmission 
of the trypanosome through immunisation of the host against insect parasite stages. The 
antibodies circulating in the host blood would be transferred to the tsetse fly in the blood-
meal. This type of vaccine would ultimately interfere with the parasite life cycle in the 
tsetse fly by targeting specific interactions that are required for parasite development, 
reduce the vector fitness and block parasitaemia onset in the host (Magez et al., 2009). The 
presence of anti-procyclic T. b. brucei and T. congolense antibodies in tsetse blood-meals 
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Pharmaceutical characteristics Activity against Drawbacks 
Diamidine 
Diaminazene* 
(Berenil®, Veriben®)  
1955 
Intramuscular and intravenous.  
Uptake by carrier-mediated transport (Bray et al., 
2003; de Koning et al., 2004). 
Inhibition of the kinetoplasmatic DNA 
biosynthesis (Balana-Fouce et al., 1986; Karvonen 






Licensed just for veterinary 
use. Does not cross the blood-
brain barrier (Reinert, 1999).  
Rapid decrease of the drug  
plasma concentration and slow  
elimination. Side effects and 
numerous resistant strains 
(Ainanshe et al., 1992; de 
Koning et al., 2004; 








Especially effective on domestic 
animals infected by T. evansi (Lun et al., 1991) 
and T. equiperdum. Not effective 





Resistant strains. Rapidly  
Metabolised in the plasma and 
major side effects.  
 
Phenanthridine 








Uptake by passive diffusion.  









Resistant strains and numerous 
side effects (Boid et al., 1989; 
Ndoutamia et al., 1993). 
Table adapted from Kroubi et al. (2011) and Holmes et al. (2004) 
* Group I compounds: produce their in vivo trypanocidal effect immediately 
‡ Group II compounds: produce their in vivo trypanocidal effect only after a latent period of 24 hours. 
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have been reported to suppress the development of the respective parasites in Glossina 
morsitans (Maudlin et al., 1984). However, this vaccine approach does have an ethical 
problem in that it does not protect the vaccinated individual against the infection but would 
however ultimately result in reduced numbers of infectious vectors.  
 
Anti-disease vaccines, aimed at reducing the symptoms of the disease rather than killing 
the parasite, first developed for malaria (Playfair et al., 1990), have been considered as an 
alternative approach to conventional vaccines (Authié, 1994). Trypanotolerant cattle do not 
show the disease-associated symptoms (Authié et al., 2001) and are able to mount an 
antibody response to the proteolytic enzyme, TcoCATL. The artificial induction of 
antibodies against the peptidase could render a diseases-susceptible host more tolerant 
(Authié et al., 1992; Lalmanach et al., 2002). 
 
1.6  Proteolytic enzymes 
Proteolytic enzymes release amino acids, peptides, and proteins from larger peptides and 
proteins (Rawlings et al., 2008). Peptidases, often synonymous with proteolytic enzymes, 
catalyse the cleavage of amide linkages or peptide bonds in proteins (Rawlings et al., 2008) 
and can either have endopeptidase activity whereby the polypeptide chain is cleaved within 
the chain or amino or carboxy peptidase activity where only the N- or C- terminal residue 
is cleaved off (Sajid and McKerrow, 2002). There are seven classes of peptidases, four 
catalytic types, cysteine, serine, aspartic and metallo, were recognised by Rawlings and 
Barrett (1993). The fifth catalytic type, possessing an N-terminal threonine that acts as a 
nucleophile, was later discovered (Rawlings and Barrett, 1999). Glutamate (Fujinaga et al., 
2004) and the more recently discovered peptidases that cleave themselves at asparagine 
residues (Rawlings et al., 2011) make up the sixth and seven classes respectively. The 
clans, within the seven classes, usually show evolutionary relationships by their similar 
tertiary structures, catalytic site residues or sequence motifs (Caffrey and Steverding, 
2009). 
 
1.6.1  Cysteine peptidases 
Cysteine peptidases are also referred to as thiol or sulfhydryl peptidases and contain a 
cysteine in the catalytic site. Cysteine peptidases are a diverse group of enzymes found in 
all living organisms. In humans they are important in the immune system,  protein renewal 
processes and the resorption of bone cartilage, where imbalances of these peptidases can 
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lead to diseases such as cancer, immune system defects, osteoporosis and rheumatoid 
arthritis (Tastan Bishop and Kroon, 2011). In parasites they have several diverse functions. 
They allow parasites to bore through cellular and tissue barriers, degrade host proteins, 
manipulate the host immune system and elude host immune responses (Atkinson et al., 
2009; Sajid and McKerrow, 2002; Tastan Bishop and Kroon, 2011). Inhibition of P. 
falciparum cysteine peptidases has a marked affect on reducing P. falciparum merozoite 
invasion of erythrocytes (Olaya and Wasserman, 1991), demonstrating the role cysteine 
peptidase play in cell invasion. Furthermore, T. cruzi’s major cysteine peptidase TcrCATL, 
has been linked to plasma leakage in post-capillary venules and may recruit macrophages 
for invasion (Svensjo et al., 1997).  
 
For cysteine peptidases there are ten clans recognised (CA, CD, CE, CF, CH, CL, CM, 
CN, CO and C- family of cysteine peptidases not assigned to a particular clan (Caffrey and 
Steverding, 2009).  Clan CA alone contains 20 families (Barrett and Rawlings, 2004). The 
C1 family, which will be the focus of the present study, contains the archetypal plant 
cysteine peptidase, papain, and the mammalian cathepsins B, C, K, L and S (Caffrey and 
Steverding, 2009).  
 
Clan CA cysteine peptidases possess highly conserved cysteine, histidine and asparagine 
residues making up the catalytic triad found in the active site. These residues are embedded 
in highly conserved peptide motifs, CGSCWAFS, H(G/A)VXXVG(Y/W) and 
YWXIXNSWXXWG (triad residues in bold) (Lecaille et al., 2002). Other conserved 
residues include the ERF/WNIN motif which is characteristic of the CATL-like subfamily 
(Karrer et al., 1993). The motif which is absent in CATB-like peptidases, is, however, 
found in Trypanosoma cysteine peptidases, with the last two residues in the motif replaced 
by alanine (Caffrey et al., 2001). The catalytic site of these peptidases is located within the 
substrate binding region which has a set of subsites or binding pockets (Lecaille et al., 
2002; Smooker et al., 2010). These subsites bind the substrate amino acid residues in the 
N- and C-terminal direction of the scissile bond. The subsites in the N-terminal direction 
are termed S1, S2, S3…Sn and those in the C-terminal direction are termed S1’, S2’, 
S3’…Sn’ (Schechter and Berger, 1967) (Fig. 1.5). The corresponding substrate (or 
inhibitor) amino acids residues binding to the specific subsites are termed P1, P2, P3…Pn 
and P1’, P2’, P3’…Pn’. Members of the clan CA have a substrate specificity defined by the 
S2 pocket, with hydrolysis of small peptides that contain Phe in P2 typical of CATL and 
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those with Arg in P2 typical of CATB (Barrett and Rawlings, 2004; Sajid and McKerrow, 
2002). 
 
CATL, CATB (Caffrey and Steverding, 2009) and papain-like peptidase (Lecaille et al., 
2002) translation products comprise of a signal peptide, a propeptide and a catalytic 
domain with the latter representing the mature proteolytically active enzyme. The 
propeptide is multifunctional. It acts as a scaffold for protein folding of the catalytic 
domain (Schilling et al., 2001), operates as a chaperone for transport of the proenzyme to 
the endolysosomal compartment (Nissler et al., 1998) and acts as a high-affinity reversible 




Figure 1.5 Schematic diagram of a peptidase active site based on the Schechter and Berger notation 
(Smooker et al., 2010). 
 
 
The overall 3-dimensional fold of cathepsin and papain-like cysteine peptidases is highly 
conserved. The structure consists of an L and R domain with a central helix and a β-barrel 
motif being the most prominent features respectively (Fig. 1.6) (Turk et al., 2000). Two of 
the three residues forming the catalytic triad, Cys and His, are positioned at the N-terminus 
of the central helix of the L domain and the part of the β-barrel structure of the R-domain 
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      L domain                           R domain 
 
Figure 1.6. Ribbon fold of mammalian CATL. CATL-like cysteine peptidases follow a common papain 3-
dimensional framework with an L and R domain and V-shaped active site cleft. The active site cleft is where 




1.6.2  General mechanism of hydrolysis by cysteine peptidases 
In the cysteine peptidase the nucleophile that attacks the scissile peptide bond is the 
sulfhydryl group of a cysteine residue (Barrett and Rawlings, 2004). The thiol group is 
enhanced as a nucleophile due to the close proximity of an active site histidine which acts 
as a proton donor/general base (Sajid and McKerrow, 2002) (Fig. 1.7). The sulfhydryl 
group and imidazole of cysteine and histidine respectively give rise to the thiolate-
imidazolium charged diad. This is often stabilised by the highly conserved asparagine 
(Sajid and McKerrow, 2002). During the hydrolysis of a peptide the sulfhydryl cysteine 
attacks the carbonyl carbon of the scissile bond of the bound substrate and forms a 
tetrahedral intermediate (Fig 1.7) (Lecaille et al., 2002) which is generally stabilised by the 
oxyanion hole. The highly conserved glutamine comprises the oxyanion hole and is very 
important as an electrophilic centre to stabilise the tetrahedral intermediate (Sajid and 
McKerrow, 2002). Following acylation, release of the N-terminal portion of the substrate, 
restoration of the deprotonated histidine and formation of thioester bond, deacylation 


























Figure 1.7 Reaction mechanism for cysteine peptidase by means of the catalytic triad (Lecaille et al., 
2002) 
 
1.6.3  Parasite cysteine peptidases 
With regards to African trypanosomes, three major CATL-like cysteine peptidases have 
been studied, TbrCATL, TbbCATL and TcoCATL. TviCATL, the major CATL-like 
cysteine peptidase from T. vivax has been studied to a much lesser extent. TcrCATL, from 
T. cruzi, which is the most advanced in pre-clinical investigations for target-based drug 
development in curing Chaga’s disease, shares 59% and 45% identity with TbbCATL and 
mammalian CATL respectively (Eakin et al., 1992) and 57% with TcoCATL. Like 
mammalian CATL, the major trypanosomal cysteine peptidases are synthesised as pre-pro-
proteins (Cazzulo et al., 1989; Eakin et al., 1992; Sakanari et al., 1997). 
 
However, unlike their mammalian homologs, an additional 11-13 kDa C-terminus 
extension, of unknown function, is separated from the mature catalytic domain of 
trypanosomal cysteine peptidases by a poly-threonine (TcrCATL and TviCATL) or poly-
proline (TbbCATL and TcoCATL) sequence (Caffrey et al., 2000). Parasite cysteine 
peptidases also have a Cys-His-Asn catalytic triad (Caffrey and Steverding, 2009; Sajid 
and McKerrow, 2002).  
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1.6.3.1  Physiological functions of parasite cysteine peptidases 
Parasite cysteine peptidases are virulence factors and have been shown to contribute to 
disease pathogenesis (Caffrey and Steverding, 2009). RNAi against TbbCATL reduced 
crossing of the blood brain barrier in an in vitro model (Abdulla et al., 2008). In the case of 
the widely studied T. cruzi, amastigote replication, intracellular development and host cell 
invasion have been implicated with TcrCATL function (Aparicio et al., 2004). 
Furthermore, the CATL-like peptidases from related parasites, Leishmania spp., have also 
been shown to be involved in cellular invasion. Knockout of nineteen genes of the lmcpb 
tandem array from L. mexicana, coding for nineteen highly related CATL-like peptidases, 
resulted in a decrease of parasite virulence (Frame et al., 2000) with decline in percentage 
of infected host cells (Mottram et al., 1996). Metacaspases, part of clan CD, which contain 
a histidine and cysteine catalytic diad, are important virulence factors too. T. b. brucei 
possess three metacaspase genes. Helms et al (2006) demonstrated, through gene deletion, 
that three of the of the metacaspases, MCA2, MCA3 and MCA5 are involved in recycling 
processes of RAB11-positive endosomes. This recycling is, however, independent of VSG 
recycling.  
 
TcoCATL (Mbawa et al., 1992) and TbbCATL (Troeberg et al., 1996) have been shown to 
degrade a range of proteins, such as bovine fibrinogen, bovine serum albumin and 
ovalbumin at physiological pH in vitro. The cysteine peptidase from Trichomonas 
vaginalis, the causative agent of trichomoniasis, displayed activity against collagen IV, 
fibronectin and haemoglobin (Mendoza-Lopez et al., 2000) Additionally, falcipain-2, a 
CATL-like cysteine peptidase from Plasmodium falciparum, cleaves erythrocyte skeleton 
proteins such as ankyrin (Dua et al., 2001). T. b. brucei type I PGP (pyroglutamyl 
peptidase), belonging to the C15 family of cysteine peptidases, removed the N-terminal 
pyroglutamic acid blocking groups from thyrotrophin-releasing hormone and 
gonadotropin-releasing hormone, dramatically reducing the half-life of these neural 
peptides (Morty et al., 2006).  
 
TbbCATL (Troeberg et al., 1996), TcrCATL (Chagas et al., 1997) and TcoCATL are 
active a neutral pH allowing the peptidases to interact with host proteins in a physiological 
environment (Lalmanach et al., 2002). Furthermore, the recombinant catalytic domain of 
TviCATL is also active close to physiological pH (Vather, 2010).  Although there are 
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natural endogenous host cysteine peptidase inhibitors, incomplete enzyme inhibition with 
such inhibitors has been documented (Lonsdale-Eccles et al., 1995; Wiser et al., 1997). In 
some instances, biologically active molecules have been released from such inhibition and 
as a result may play a role in pathology. TcrCATL has been able to display kininogenase 
activity in vitro (Del Nery et al., 1997). Initial work on TcoCATL interaction with bovine 
kininogens indicated that the interaction does not achieve complete enzyme inhibition and 
triggers the release of kinins (Lalmanach et al., 2002).  
 
1.6.3.2  Biochemical characterisation of parasite CATL peptidases 
Clan CA peptidases are characterised by their sensitivity to the general cysteine peptidase 
inhibitor E-64 and by having substrate specificity defined by the S2 pocket (Sajid and 
McKerrow, 2002). TcoCATL has a distinct preference for the presence of a basic amino 
acid (Arg of Lys) in the P1 position (Mbawa et al., 1992). Furthermore, TcoCATL 
hydrolyses peptides with hydrophobic or aromatic side chains, such as Phe or Leu, in the 
P2 position. These are features common to many protozoan cysteine peptidases such as the 
type I CATL-like peptidases from Leishmania (Robertson and Coombs, 1990), TcrCATL 
(Chagas et al., 1997), TbbCATL (Troeberg et al., 1996), TbrCATL (Caffrey et al., 2001) 
and falcipain-2 (Shenai et al., 2000). These CATL-like peptidases, besides TcrCATL, 
poorly cleave the characteristic CATB substrate Z-Arg-Arg-AMC. The ability of CATB to 
hydrolyse Abz-Arg-Arg-AMC is due to the Glu residue at position 205 (papain 
numbering), also found in TcrCATL, lining the S2 subsite. The inability of TcoCATL to 
hydrolyse the CATB substrate is due to the Leu205 is the S2 pocket. The substitution of a 
glutamic acid by a leucyl residue does not allow for the accommodation of Arg in P2 of 
TcoCATL (Lecaille et al., 2001) and therefore the superimposition model of TcoCATL and 
TcrCATL does argue strongly for a more restricted specificity for TcoCATL (Fig. 1.8). 
Mutating the Gly, lining the S2 pocket, to Glu in LmaCATB, a CATB peptidase possessing 
CATL-like substrate specificity, allowed for cleavage of Z-Arg-Arg-AMC (Chan et al., 
1999). Both TcoCATL (Mbawa et al., 1992) and TbrCATL (Troeberg et al., 1996) have 
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1.6.3.3  Trypanosomal peptidases as targets for drug design 
To date, TcrCATL (McGrath et al., 1995) and TbrCATL (Kerr et al., 2009) are the only 
trypanosomal CATL-like cysteine peptidases that have been crystallised and their 
structures solved. This advantage has allowed for the directed design of synthetic peptidase 
inhibitors. Inhibitors, such as the irreversible dipeptidyl substrate-analogues coupled to the 
reactive fluoromethylketone (CH2F, FMK) or diazomethylketone (CHN2, CMK) groups 
have been widely researched for selectively inhibiting the parasitic cysteine peptidases. A 
number of chloromethylketones, fluoromethylketones and diazomethylketones (DMK), 
which inhibit cysteine peptidases, are able to kill bloodstream forms of T. b. brucei in vitro 
(Troeberg et al., 1999). 
 
Furthermore, Mbawa et al. (1992) reported that some peptidyldiazomethylketones (Z-Leu-
Leu-Met-CHN2, Z-Leu-Met-CHN2 and Z-Leu-Lys-CHN2) were trypanocidal when tested 
against T. congolense in vitro. However a new generation of inhibitors, the vinyl sulfone 
group (Palmer et al., 1995), that have a peptidomimetic, rather than a peptidyl backbone, 
have better selectivity for cysteine peptidases over serine peptidases and stable inactivation 











Figure 1.8 Structure of the S2 subsite of TcoCATL and TcrCATL. Structure of the S2 subsite of 
TcoCATL (grey). The S2 subsite of TcrCATL (black), corresponding to the cruzipain/Z-Tyr-Ala-FMK 
complex, is superimposed. The red arrow indicates the residue difference, Leu205 for congopain and Glu 205 
for TcrCATL. For the sake of clarity, only the tyrosyl residue of Z-Tyr-Ala-FMK is represented (blue arrow). 
Residue numbers correspond to papain numbering (Lecaille et al., 2001). 
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The peptidomimetic vinyl sulfone, K11777, which targets TcrCATL, is lethal to T. cruzi 
parasites both in vitro and in animal models of disease  and is an example of ‘chemical 
knockout’ of a the TcrCATL gene (Engel et al., 1998a; Engel et al., 1998b). Furthermore, 
the vinyl sulfone K11777 was very effective in killing bloodstream forms of T. b. brucei 
(Troeberg et al., 1999). The inhibitor, which has no significant toxicity to rodent or canine 
hosts (Abdulla et al., 2007), is currently completing pre-clinical testing for the treatment of 
Chaga’s disease. It is imperative that the crystal structures of pathogenic factors be 
determined to provide information to help guide the design of specific drugs. 
 
1.7  Protein crystallisation 
In order for protein crystals to form, ordered clusters of protein molecules, nuclei, need to 
form. The level of supersaturation, as shown by the supersaturated regions of the phase 
diagram (Fig. 1.9), must be high enough to initiate nucleation and then support crystal 
growth (McPherson et al., 1995). However higher levels of supersaturation are required for 
nuclei to form than for subsequent crystal growth. The level of supersaturation for 
spontaneous nucleation to occur and for crystal growth support is known as the labile and 
metastable zone respectively (Luft and DeTitta, 2009) (Fig. 1.9). As protein crystals grow, 
more protein is sequestered from the surrounding solution, causing the concentration of 
protein in the surrounding solution to decrease. As a result of crystal growth, the level of 
supersaturation is continually lowered until a state of equilibrium between the crystal (a 
solid phase) and the surrounding solution (liquid phase) is reached (Luft and DeTitta, 
2009). The solid phase, the protein crystal, will redissolve if the solution becomes 
undersaturated.  
 
The sequence of steps involved in the crystallisation process is shown in Fig. 1.10. 
Preliminary protein preparation, prior information and characterisation are critical to 
crystallisation trials. Recombinant DNA technology provides a means of making specific 
changes to protein character to improve the chances of crystallisation (Gilliland and 
















Figure 1.9 Phase diagram for protein crystallisation.  The y axis is the macromolecule concentration and 
the x axis is the crystallising reagent concentration. The crystallising reagent is a chemical whose 
concentration is inversely related to the macromolecule solubility. The supersaturated region is divided in 
three zones, the precipitation, labile and metastable. The thick dark line represents the limit of solubility, 
where below it the solution is undersaturated (Luft and DeTitta, 2009). 
 
 
a large amount of highly purified protein for crystallisation (Rupp, 2009). Furthermore, 
altering protein sequence and mutating specific residues in a protein sequence have 
improved recombinant protein solubility and stability in several instances. The protein 
concentration, quoted in the Protein Data Bank, for successful crystallisation is 14 mg/ml. 
However, proteins have been crystallised at much lower concentrations and as Rupp 
(2009) describes as a general guideline, any concentrations from 2-10 mg/ml is sufficient.  
 
The choice of crystallisation technique also plays a role in the success of crystallisation. It 
has been demonstrated that drop shape and volume as well as distance of drop from the 
reservoir affects the results (Luft et al., 1996). The DST-NRF financially supported Rigaku 
crystallisation robotic suite, at the University of KwaZulu-Natal, uses the sitting drop 
vapour diffusion technique, where the vapour-phase equilibration between an 
undersaturated protein solution and a dehydrating solution leads to a supersaturated state. 
Other techniques include batch and liquid diffusion. The approach to supersaturation 
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changes with the crystallisation method as each method has a unique path through the 
reconsidered. 
iffracting protein crystals can be used for structure determination. However, non-
diffracting crystals require further optimisation of crystallisation conditions. 
 
phase diagram (Luft and DeTitta, 2009).  
 
Random screening or custom screening can be used for initial screens. Protein solubility 
screens can be performed prior to crystallisation screens in order to determine the 
appropriate protein concentration for crystallisation. This generally involves probing the 
solubility of proteins at different concentrations in different buffers and crystallising 
reagents to produce a supersaturation curve of the protein (Benvenuti and Mangani, 2007). 
In this way, screens can be designed to reach the metastable zone. There are also 
commercially available kits to test the solubility of proteins. If limited screening is chosen 
initially, conditions need to be carefully decided on in order to maximise the chances of 
getting a crystallisation hit. If there are crystallisation conditions available of related 
previously crystallised proteins (similar enzyme character and sequence), then a screen 
design may be based on these conditions. However, there is the other approach of fast 
screening using commercial screens that have a large screening set and are said to reduce 
or remove the cycles of optimisation later (Newman, 2009). If screening, even after 
optimisation, produces no positive results, protein constructs need to be 
D
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Figure 1.10 Sequence of steps in a crystallisation project. Adapted from Rupp and Wang (2004). 
 
 
1.7.1  Parasitic cysteine peptidase crystal structures 
As mentioned earlier, the overall 3-dimensional fold of cathepsin and papain-like cysteine 
peptidases is highly conserved consisting of an L and R domain with a central helix and a 
β-barrel motif respectively. Charged buried residues that form electrostatic interactions at 
the interface of the two domains in papain, and which are conserved in all known 
quences of trypanosomal cysteine peptidases, are involved in the catalytic mechanism of 
ain 
ith an active-site cleft. Certain helices in the L domain differ from papain, however, the 
se
cysteine peptidases. These interdomain electrostatic interactions, which are also found in 
mammalian cathepsins H and L, have been conserved during evolution to ensure proper 
folding and stability of cysteine peptidases of the papain family (Kamphuis et al., 1985).   
 
TcrCATL was the first trypanosomal cysteine peptidase to be crystallised. The refined 
crystal structure of TcrCATL in complex with Z-Phe-Ala-FMK was compared to the 
structure of papain (McGrath et al., 1995). The main fold comprises of an L and R dom
w
antiparallel β-structure of the R domain as well as the catalytic site is isostructural for 
papain and TcrCATL (McGrath et al., 1995). An extra helix is created from residues of the 
C-terminus of TcrCATL. Superimposition of TcrCATL (in complex with Z-Phe-Ala-
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FMK) with inhibitor-bound papain and free papain showed that TcrCATL is similar in 
structure to inhibitor-bound papain (McGrath et al., 1995). Therefore, the inter-domain 
cleft widens upon binding of inhibitor.  
 
The predicted 3D structure of TcoCATL, based on the sequence identity with TcrCATL, 
follows a common framework of an L and R domain with an active-site cleft found for 
papain-like cysteine peptidases (Fig 1.11). The catalytic triad, Cys 25, His 159 and Asn 
75, and the residues defining the extended substrate-binding site are located in the cleft 
45 to penetrate deeper into the S1’ subsite (Kerr et al., 2009). This 
revents the phenyl sulfone of K11777 to lie flat in the subsite. 
 motif (Hogg et al., 2006). A comparative structural analysis of the 
1
between the R domain and the L domain (Lecaille et al., 2001). Although there is a 
homology based model of TcoCATL, TcoCATL has been demonstrated to dimerise. The 
dimeric formation is yet to be determined (Ndlovu, 2010). 
 
The common papain two-domain fold is also evident for TbrCATL (Kerr et al., 2009). The 
commonality between TcrCATL and TbrCATL in the papain-like fold allowed for 
superimposing the two structures. There is a striking difference in the S1’ subsite of the two 
enzymes. The phenyl-sulfone group in the P1’ position of the K11777 inhibitor in complex 
with TbrCATL is flipped approximately 90° out of the active site in relation to the 
TcrCATL-K11777 complex (Fig. 1.11) (Kerr et al., 2009). The substitution of Trp for the 
slightly less bulky Phe at position 144 in TbrCATL allows the amino acid residue to more 
readily access a deep, buried pocket in the bottom of the S1’ subsite, consequently allowing 
the neighbouring Met 1
p
 
The polypeptide chain of the mature CATL-like cysteine peptidase from P. falciparum, 
falcipain-2, folds as a prototypical structure of papain-like proteases, with two distinct 
domains separated by a long central substrate binding cleft containing the active site (Hogg 
et al., 2006). The L domain is predominantly α-helical (α2, α3, α4) with several long 
disulfide-stabilised segments lacking regular secondary structure, whereas the R domain 
contains a large antiparallel β-sheet (β2-β7-β3-β4-β5-β6). Additional structural features 
that are unique to the falcipain-2 subfamily (with members such as the vivapain, from P. 
vivax and berghepain, P. bergheii homologues) include a 17-residue N-terminal extension 
and a 14-residue β-hairpin protuberance extending from β4 and β5 that comprises the 
hemoglobin binding
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falcipain-2 active site with that of TcrCATL suggests that existing vinyl sulfone inhibitors 
e may be useful starting compounds for rational design 
-like peptidase through a 
ombination of two “gatekeeper” residues at the bottom of the S2 subsite (Kerr et al., 
). Falcipain-3 does share the common framework of papain-like cysteine peptidases. 
However, as was reported that falcipain-3 deviates slightly from the classical papain fold in 
at there are two insertions on either terminus, unique to plasmodial cysteine peptidases 
(Kerr et al., 2009). 
 
.8  Objectives of present study 
Trypanosomal cysteine peptidases are of major pathological importance. It is therefore 
ital that such peptidases be structurally and functionally characterised. CATL-like 
ysteine peptidases from T. congolense (Mbawa et al., 1992), T. cruzi (Cazzulo et al., 
990), T. b. rhodesiense (Caffrey et al., 2001) and T. b. brucei (Troeberg et al., 1996) have 
een previously characterised. However, no cysteine peptidase has to date been 
haracterised from T. vivax. CATL-like sequences from African and South American 
olates of T. vivax have been evaluated for their suitability as genetic markers for 
opulation structure analysis and diagnosis (Cortez et al., 2009). 
designed against cysteine peptidas
of novel antimalarials.  
 
The CATL-like cysteine peptidases from the parasitic liver fluke, Fasciola hepatica, 
FheproCL1Gly25, with the replacement of Cys 25 with Gly, also comprises of a mature 
domain which is bi-lobed and substrate-binding cleft running between the two lobes of the 
enzyme, characteristic of the papain fold (Stack et al., 2008). However, FheproCL1Gly25 
has unique “gatekeeper” residues 157 and 158 at the entrance of the active-site pocket. 






































Figure 1.11 The ribbon superimposition model of TcoCATL and phenyl sulfone flipping in TbrCATL. 
(A) The ribbon plot superimposition of a homology-based TcoCATL (grey) model (catalytic domain) and of 
TcrCATL (black). The Cys25 residue of the catalytic triad is indicated in the cleft bet
B 
ween the R and L 
domain (Lalmanach et al., 2002). (B) Ribbon representation and detailed inlay of the S1’ subsite of TcrCATL 
ale blue) and TbrCATL (yellow). Important residues in subsite opening are depicted in ball and stick (p
representation. Bound ligands are coloured as their respective peptidase partners (Kerr et al., 2009). 
 
 
The analysis of the CATL-like amino acid sequence in the present study did reveal that 
there were distinct regions in the T. vivax CATL-like sequences, which like other cysteine 
peptidases could be inferred to represent the pre-, pro-, central catalytic domain (with the 
cysteine, histidine and asparagine catalytic triad) and C-terminal extension. Determining 
whether T. vivax CATL-like peptidases are pathogenic factors and similar in structure, 
function and character to other pathogenic trypanosomal CATL-like peptidases would be 
pivotal to the design of a general inhibitor for trypanosomal cysteine peptidases.  
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In the present study, native TviCATL was purified from bloodstream T. vivax strain 486 
and biochemically characterised for substrate specificity, pH optimum, ability to digest 
bovine fibrinogen and inhibition studies using both reversible are irreversible inhibitors. 
The results obtained for this part of the study were presented in Chapter 2. 
 
Trypanotolerant cattle infected with T. congolense have shown to develop prominent IgG 
responses to TcoCATL (Authié et al., 1993). It is for this reason that TcoCATL is being 
evaluated as an anti-disease vaccine candidate to reduce the symptoms of the disease. 
nderstanding the dimeric conformation of TcoCATL will facilitate improving 
apping TcoCATL epitopes, important for vaccine design. Furthermore, 
reening inhibitors that are structurally suited for TcoCATL is important for inhibitor 
design. To date, TcrCATL (McGrath et al., 1995) and TbrCATL (Kerr et al., 2009) are the 
nly trypanosomal CATL-like cysteine peptidases that have been crystallised and 
structures solved. This advantage has allowed for the directed design of synthetic peptidase 
inhibitors.  
 
In the second half of the study the catalytic domains of TcoCATL and TviCATL, as well as 
the full-length PGP, were recombinantly expressed and purified. These proteins along with 
TcoCATL dimerisation mutants, TcoCATL (H43W), TcoCATL (K39F; E44P) and the 
proenzyme mutant TcoCATL (C25A) were screened for a suitable crystallisation condition 
using the Rigaku robotic crystallisation suite. Crystallisation hits for TcoCATL (K39F; 
E44P) were further optimised. The results of these studies are presented in Chapter 3. 
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CHAPTER 2 
 PURIFICATION AND CHARACTERISATION OF NATIVE 
TviCATL FROM Trypanosoma vivax 
 
2.1  INTRODUCTION 
Livestock trypanosomosis (Nagana) is a chronic disease with major economic impact 
in tropical countries. The disease is caused by tsetse-transmitted haemoprotozoa 
Trypanosoma congolense, T. vivax and T. brucei brucei. Nagana causes estimated 
losses to African agriculture of US $4.75 billion per year (Van den Bossche et al., 
2010), affecting about 10 million km2 of sub-Saharan Africa (Kabayo, 2002). 
Currently there is no vaccine for trypanosomosis and although a pan-African tsetse fly 
and trypanosomosis eradication programme, under the auspices of the Organisation of 
African Unity (OAU), has been launched (Lalmanach et al., 2002), studies aimed at 
identifying potential targets for new trypanocidal drugs have been running 
concurrently. The three compounds, diaminazene, isometamidium and ethidium have 
been used for more than 50 years (Delespaux et al., 2010) and as a consequence drug 
resistance of T. congolense has been reported in 17 countries of sub-Saharan Africa 
(Delespaux et al., 2008). These compounds are thus no longer effective for large and 
small-scale treatment.   
 
There are many hurdles facing the development of a vaccine against trypanosomosis. 
One of the major obstacles is the phenomenon of antigenic variation that trypanosomes 
possess. Trypanosomes are able to switch their variant surface glycoprotein (VSG) 
coat, giving rise to a new antigenically distinct trypanosome population (Donelson, 
2003), thereby evading the host immune system. TcoCATL, the major CATL-like 
cysteine peptidases from T. congolense, has been shown to act as a pathogenic factor 
in T. congolense-infected cattle (Authié et al., 2001). In addition, trypanotolerant cattle 
infected with T. congolense were found to develop prominent IgG responses to 
TcoCATL (Authié et al., 1993). Consequently TcoCATL is being evaluated as an 
“anti-disease” vaccine candidate with the aim to reduce the symptoms of the disease, 
rather than eliminating the parasite. 
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It has previously been established that parasite peptidases are promising 
chemotherapeutic or vaccine targets (McKerrow, 1999; McKerrow et al., 1999). 
Besides the many roles that such peptidases play, further attention has focused on the 
clan CA peptidases with family C1 (CATB and CATL-like) peptidases being of major 
interest. Parasitic CATL-like cysteine peptidases are critical to the life-cycle and 
pathogenocity of many parasites (Sajid and McKerrow, 2002). In the case of the 
widely studied T. cruzi, amastigote replication, intracellular development (Franke de 
Cazzulo et al., 1994) and host cell invasion (Aparicio et al., 2004) have been 
implicated with TcrCATL function. TcoCATL (Mbawa et al., 1992) and TbbCATL 
(Troeberg et al., 1996) degrade a range of proteins in vitro.  
 
Like TbbCATL and TcrCATL, TcoCATL is active at neutral pH allowing it to interact 
with host proteins in a physiological environment (Lalmanach et al., 2002). 
Furthermore, the recombinant catalytic domain of TviCATL is also active close to 
physiological pH (Vather, 2010). General substrate specificity for these CATL-like 
peptidases is defined by the S2 pocket (Fig. 2.1). They are capable of hydrolysing 
peptides with a hydrophobic or aromatic residue in the P2 position. Although there are 
physiological natural cysteine peptidase inhibitors, incomplete enzyme inhibition with 
such inhibitors has been documented (Lonsdale-Eccles et al., 1995; Wiser et al., 1997). 
In some instances, biologically active molecules have been released from such 
inhibition and as a result may play a role in pathology. TcrCATL has been able to 
display kininogenase activity in vitro (Del Nery et al., 1997). The structure/function 
relationship and catalytic mechanism of this C1 peptidase family is known, which 
provides a foundation for the synthetic and high throughput computational drug design 
based of ligand screening (Sajid and McKerrow, 2002). Adding to this, K11777, a 
selective vinyl sulfone-derivitised pseudopeptide inhibitor of TcrCATL, which has 
undergone rodent and dog toxicology tests, (McKerrow et al., 2008), was effective in 
curing or alleviating T. cruzi infection in preclinical proof-of-concept studies and has 
now entered formal preclinical drug development investigation (McKerrow et al., 
2009). 
 
CATL-like cysteine peptidases contain a signal peptide, a pro-peptide and a catalytic 
domain (Sajid and McKerrow, 2002). The catalytic domain consists of the highly 
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conserved catalytic triad (Cys, His and Asn) (Fig. 2.1). However, 16% of the parasitic 
protozoa C1 peptidases do not appear to have the classic catalytic triad (Atkinson et 
al., 2009; Pillay et al., 2010). Kinetoplastid CATL-like peptidases also have a unique 
highly conserved 11-13 kDa C-terminal extension (Boulangé et al., 2001; Caffrey and 
Steverding, 2009). The mature catalytic domain is separated from the C-terminal 
extension by a poly-threonine (TcrCATL and TviCATL) or poly-proline (TbbCATL 
and TcoCATL) tract. The definitive biological function of the C-terminal extension is 
not yet known (Caffrey et al., 2000). 
 
Trypanosomal cysteine peptidases from T. congolense (Mbawa et al., 1992), T. cruzi 
(Cazzulo et al., 1990), and T. b. brucei (Troeberg et al., 1996) have been previously 
characterised. Additionally a novel cysteine peptidases from T. evansi have recently 
been recognised, which is inhibited by the cysteine peptidase inhibitor E-64, active at 
acidic pH and retains activity in serum samples of rats infected with T. evansi (Yadav 
et al., 2011). However, to date no cysteine peptidase has been characterised from T. 
vivax. Endopeptidase variation among the different life-cycle stages of West- and East-
African T. vivax has, however, been previously reported (Mbawa et al., 1992). For 
diagnostic and genetic marking in population structure analysis, CATL-like sequences, 
from African and South American isolates of T. vivax, have been evaluated (Cortez et 
al., 2009). Analysis of the T. vivax CATL-like amino acid sequences (Fig. 2.1) show 
that there are typical cysteine peptidase sequences representing the pre-, pro, central 
catalytic domain (with the cysteine, histidine and asparagine catalytic triad) and a C-
terminal extension.  
 
Whether T. vivax CATL-like peptidases are pathogenic factors is still to be determined. 
However, pivotal to the design of a general inhibitor is the confirmation of whether or 
not T. vivax CATL-like peptidases act as pathogenic factors and possess similarity in 
structure, function and character to other trypanosomal CATL-like peptidases. In the 
present study the purification and enzymatic characterisation of native TviCATL from 
T. vivax Y486 is reported. The results showed that native TviCATL shares similar 
enzymatic characteristics with those of other major trypanosomal cysteine peptidases, 
TcoCATL, TcrCATL and TbbCATL, as well as the recombinant catalytic domain of 
TviCATL.  
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TcoCATL       MPRSEMTRTLRFSVGLLAVAACFVPVALGVLHAEQSLQQQFAAFKQKYSRSYKDATEEAF 60 
TbrCATL       MPRTEMVRFVRLPVVLLAMAACLASVALGSLHVEESLEMRFAAFKKKYGKVYKDAKEEAF 60 
TviCATL       -------MHAHALVTLLAAAVSVAPAAMAVLRADGPVEPLFAAFKQKYGRSYGTAAEEAF 53 
TcrCATL1      ---MSGWARALLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAEEAF 57 
TcrCATL2      ---MSGWARALSLAAVLVVMACLVPAATASLHAEETLASQFAEFKQKHGRVYGSAAEEAF 57 
                           . :*.  ......* . *:.: .:   ** **:*:.: *  * **** 
 
TcoCATL       RFRVFKQNMERAKEEAAANPYATFGVTRFSDMSPEEFRATYHNGAEYYAAALKRPRKVVN 120 
TbrCATL       RFRAFEENMEQAKIQAAANPYATFGVTPFSDMTREEFRARYRNGASYFAAAQKRLRKTVN 120 
TviCATL       RLRVFEDNMRRSRMYAAANPHATFGVTPFSDLTPEEFRTRYHNGERHFEAARGRVRTLVQ 113 
TcrCATL1      RLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVPVK 117 
TcrCATL2      RLSVFRANLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAEERARVPVD 117 
              *: .*. *:  ::  *****:****** ***:: ****: *:**  :: **  * *  *. 
 
TcoCATL       VSTGKAPEAVDWRKKGAVTPVKDQGQCGSCWAFSAIGNIEGQWKVAGHELTSLSEQMLVS 180 
TbrCATL       VTTGRAPAAVDWREKGAVTPVKDQGQCGSCWAFSTIGNIEGQWQVAGNPLVSLSEQMLVS 180 
TviCATL       VPPGKAPAAVDWRRKGAVTPVKDQGRCGSCWSFSAIGNIEGQWAAAGNPLTSLSEQMLVS 173 
TcrCATL1      VEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVS 177 
TcrCATL2      VEVVGAPAAKDWREEGAVTAVKNQGICGSCWAFAAIGNIEGQWFLAGNPLTRLSEQMLVS 177 
              *    ** * *** .****.**:** *****:*::***:* **  **: *. ******** 
 
TcoCATL       CDTNDFGCEGGLMDDAFKWIVSSNKGNVFTEQSYPYASGGGNVPTCDKSGKVVGAKIRDH 240 
TbrCATL       CDTIDFGCGGGLMDNAFNWIVNSNGGNVFTEASYPYVSGNGEQPQCQMNGHEIGAAITDH 240 
TviCATL       CDTTDSGCSGGLMDNAFEWIVKENSGKVYTEKSYPYVSGGGEEPPCKPRGHEVGATITGH 233 
TcrCATL1      CDKTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATITGH 237 
TcrCATL2      CDNTNSGCGGGLSSKAFEWIVQENNGAVYTEDSYPYHSCIGIKLPCKDSDRTVGATITGH 237 
              **. : ** *** ..**:***..* * *:** **** *  *    *   .: :** * .* 
 
TcoCATL       VDLPEDENAIAEWLAKNGPVAIAVDATSFQSYTGGVLTSCISEHLDHGVLLVGYDDTSKP 300 
TbrCATL       VDLPQDEDAIAAYLAENGPLAIAVDATSFMDYNGGILTSCTSEQLDHGVLLVGYNDSSNP 300 
TviCATL       VDIPHDEDAIAKYLADNGPVAVAVDATTFMSYSGGVVTSCTSEALNHGVLLVGYNDSSKP 293 
TcrCATL1      VELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSAAV 297 
TcrCATL2      VELPQDEAQIAASGAVKGPLSVAVDASSWFFYTGGVLTNCVSKRLSHAVLLVGYNDSAAV 297 
                *::*.**  **   * :**:::****:::  *.**::*.* *: *.*.******:*::   
 
TcoCATL       PYWIIKNSWSKGWGEEGYSALRR-HNQCLMKNLPSSAVVSG-----PPPPP--------- 345 
TbrCATL       PYWIIKNSWSNMWGEDGYIRIEKGTNQCLMNQAVSSAVVGGPTPPPPPPPP--------- 351 
TviCATL       PYWIIKNSWSSSWGEKGYIRIEKGTNQCLVAQLASSAVVGGPGPTPTPTPTTTTTTTAPG 353 
TcrCATL1      PYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVGGPGPTPEPTTTTTTSAPGP- 356 
TcrCATL2      PYWIIKNSWTTHWGEGGYIRIAKGSNQCLVKEEVSSAVVGGPGTTPEPTTTTTTSAPGP- 356 
                *********:. *** **  : :  ****: :  *****.*      *...          
 
TcoCATL       PTPTFTQELCEGAECQSKCTKATFPTGKCVQLSGAGSVIASCGSNNLTQIVYPLSSSCSG 405 
TbrCATL       PSATFTQDFCEGKGCTKGCSHATFPTGECVQTTGVGSVIATCGASNLTQIIYPLSRSCSG 411 
TviCATL       PSSSFTKTLCSGDDCADNCSATVYNTNTCIRLGALGSMVATCGAGVLELKAYMQNEQCTG 413 
TcrCATL1      SPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCSG 416 
TcrCATL2      SPSYFVQMSCTDAACSVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHCSG 416 
              ... *.:  * .  *   *  ..  *. *:   .  * :.:**:  *    :  .  *:* 
 
TcoCATL       FSVPLTVPLDKCLPIVIGSVMYECSDKAP---TESARLVRHE--------- 444 
TbrCATL       LSVPITVPLDKCIPILIGSVEYHCSTNPP---TKAARLVPHQ--------- 450 
TviCATL       TPERLSLPLDKCLASLNVSTRYHCNYGAP---AEARRPAMHN--------- 452 
TcrCATL1      PSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLADVDRQRRHQPYHSRHRRL 467 
TcrCATL2      PSVRSSVPLNKCNRLIRGSVEFFRSSNSSGRLADVDRQRRYQPYHSRHRRL 467 
                .   ::**:**   :  *. :  .  ..   :.  *   ::          
 
Figure 2.1 Sequence alignment of TviCATL with other trypanosomal cysteine peptidases. Shown 
here are the amino acid residues composing part of the signal and propeptide (yellow box), catalytic 
domain and (red box) C-terminal extension (purple box) of TcoCATL (T. congolense, EMBL accession 
no. L25130 (Boulangé et al., 2001), TbrCATL (T. brucei rhodesiense, accession no. CAA38238 (Pamer 
et al., 1990), TviCATL (T. vivax, accession no. CCD21670.1) and TcrCATL 1 and 2 (T. cruzi, accession 
no. M84342 (Eakin et al., 1992) and M90067 (Lima et al., 1994) respectively. Alignment was 
conducted using ClustalW software (Chenna et al., 2003). Blue arrows indicate the positions of the 
catalytic triad residues. Green arrow indicates predicted critical residue around the S2 pocket for 
substrate binding.  
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2.2  MATERIALS AND METHODS 
      2.2.1  Materials 
Enzyme purification and quantification:  
Q-Sepharose, Sephacryl S-200, Cyclohexamide and Histopaque® 1077 were purchased 
from Sigma (Germany). DE-52 cellulose (DEAE) resin was purchased from Whatman 
International (England). BCATM Protein Assay Kit and 10 kDa cut-off Snakeskin® 
pleated dialysis tubing were from Pierce (Rockford, IL, USA). Nunc-ImmunoTM 96-
well plates were purchased from Nunc Intermed (Denmark).  
 
Antibodies:  
Polyclonal antibodies were previously raised in chickens against the C-terminal 
extension of TviCATL and affinity purified (Mkhize, 2003). Rabbit anti-chicken IgY 




BALB/c mice were obtained from the Bioresources Unit at the University of 
KwaZulu-Natal (Westville campus). 
  
Enzyme assays:  
The peptide substrates H-D-Val-Leu-Lys-7-amino-4-methylcoumarin (AMC), H-D-
Val-Leu-Lys-AMC, H-D-Ala-Leu-Lys-AMC, H-Ala-Phe-Lys-AMC, H-Pro-Phe-Arg-
AMC, methoxy-succinyl (MeoSuc)-Asp-Tyr-Met-AMC were obtained from Bachem 
(King of Prussia, PA, USA). Benzyloxycarbonyl (Z)-Phe-Arg-AMC, Z-Gly-Pro-Arg-
AMC, Z-Gly-Gly-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-AMC, Z-Gly-Arg-Arg-AMC, 
Z-Ala-Arg-Arg-AMC, E-64, leupeptin, chymostatin, chicken egg white cystatin, 
antipain, bestatin, ethylenediaminetetra-acetic acid (EDTA), pepstatin A, iodoacetic 
acid (IAA), iodoacetamide (IAM), phenylmethylsulfonylfluoride (PMSF), N-tosyl-L-
lysyl chloromethylketone (TLCK) and N-tosyl-L-phenylalanyl chloromethylketone 
(TPCK) were obtained from Sigma (Munich, Germany). Nunc Black 96-well plates 
were purchased from Nunc Intermed (Denmark).  
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2.2.2  Isolation of T. vivax  
Cryosuspensions of bloodstream forms of T. vivax strain Y486 stabilite were thawed 
from liquid nitrogen storage and diluted as required with phosphate saline glucose 
(PSG) [57 mM Na2HPO4, 3 mM NaH2PO4, 42 mM NaCl, 50 mM glucose and 1mM 
hypoxanthine]. The viability of the cryosuspended parasites was confirmed by 
microscopic examination. Two BALB/c mice were injected intraperitoneally with 106 
parasites. This allowed the development of high parasitaemia in 6 days. The blood 
parasitaemia was monitored daily by microscopic examination (400x magnification) of 
blood taken from the tail vein. When high parasitaemia was evident, blood was 
collected by cardiac puncture and placed into anticoagulant. Approval for procedures 
involving mice was obtained from the University of KwaZulu-Natal animal ethics 
committee, reference number 036/09/Animal. Attempts were made to use Wistar rats 
as an alternate means to expand parasite numbers. However, even after 
immunosuppressing the rat with 0.5 ml of a 50 mg/ml cyclohexamide, no satisfactory 
level of parasitaemia was produced following infection with T. vivax strain Y486.  
 
Parasites were purified from blood components by anion exchange chromatography on 
DE-52 resin (Lanham and Godfrey, 1970) followed by Histopaque® 1077 (Sigma, 
Munich, Germany). Briefly 20 g of DE-52 resin was suspended in 80 ml of phosphate 
buffered saline (PBS) [100 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl and 137 mM 
NaCl, pH 8.0). The resin was allowed to settle in a column (30 x 120 mm) overnight at 
4°C. The column was washed with 1 column volume of PBS followed by equilibration 
with one column of PSG. The infected mouse blood was added to the column with the 
tap closed to ensure that the blood settled. The tap was then opened and the eluate was 
collected as 1 ml fractions. Trypanosomes generally pass through the gel unhindered 
and erythrocytes and other blood components bind to the gel (Lanham and Godfrey, 
1970). Parasites were detected in the eluate by placing a drop of eluate on a 
microscope slide and examining it under a microscope (400 x magnification). PSG was 
continually added to the column until no more parasites were present in the eluate. To 
remove any contaminating erythrocytes or blood components, Histopaque® 1077 was 
used in a 1:1 ratio with the eluant and centrifuged (400 x g, 30 min, RT). The opaque 
trypanosome layer was carefully aspirated, parasites counted using a haemocytometer 
(Agar Scientific, England) and stored in 70% (v/v) PSG, 30% (v/v) glycerol at -80°C 
until further use.  
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       2.2.3  Purification of TviCATL 
Lysing parasites: 
Parasites (approx. 8.5 x 107) were suspended in ice cold 0.1% (w/v) Brij-35 (9 ml) and 
incubated for 10 min on ice to facilitate lysis. 10 x PBS (pH 7.4, 1 ml) was added. The 
suspension was clarified by centrifugation (10 000 x g, 5 min, 4°C) and used 
immediately for enzyme purification using three phase partitioning. 
 
Three phase partitioning (TPP): 
No purification of TviCATL to electrophoretic homogeneity has been reported to date. 
So a new purification method was devised. Three phase partitioning (Pike and 
Dennison, 1989) was chosen as the initial purification step. Tertiary butanol [30% 
(v/v) of total mixture volume] and ammonium sulfate [(w/v) of the total mixture 
volume] were mixed with the sample solution. Tertiary butanol is infinitely miscible 
with water, but becomes increasingly less miscible when salt is added. As a result of 
this addition of ammonium sulfate to a tertiary butanol-protein mixture, proteins 
precipitate and a concentrated, dehydrated pellet between the salt and butanol layers is 
formed (Pike and Dennison, 1989). Since different proteins precipitate out at different 
salt concentrations, incremental addition of ammonium sulfate allows crude 
purification of proteins from a mixture. In the case of TviCATL, tertiary butanol and 
increasing percentages of ammonium sulfate [0-10%, 10-20%, 20-25% and 25-30% 
(w/v)] were added to optimise TviCATL isolation. The solution was centrifuged (10 
000 x g, 10 min, RT), in a swing out rotor, after each round of ammonium sulfate 
addition and the protein precipitate was dissolved in Tris-HCl buffer [0.02 M, pH 7.6, 
0.02% (w/v) NaN3] before being assayed against H-D-Val-Leu-Lys-AMC for enzyme 
activity. The H-D-Val-Leu-Lys-AMC activity from the T. vivax lysate was shown to 
precipitate between 10 and 20% [(w/v) of the total volume] ammonium sulfate. For 
large scale purification of TviCATL, the final 20% (w/v) ammonium sulfate TviCATL-
containing pellet was resuspended in a minimal volume of Tris-HCl buffer.  
 
Ion exchange chromatography: 
Following the initial isolation using TPP, further purification was affected using anion 
exchange chromatography onto a Q-Sepharose. The TviCATL-containing sample was 
loaded onto Q-Sepharose (26 x 110 mm, flow rate 1 cm/min, 4°C), which had been 
previously equilibrated with Q-Sepharose equilibration buffer [0.02 M Tris-HCl, pH 
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7.6, 0.02% (w/v) NaN3,]. After elution of unbound material, as monitored by A280 
reading returning to base line, a gradient of 0 to 1 M NaCl in Q-Sepharose 
equilibration buffer was applied over 5 column volumes followed by one column 
volume of Q-Sepharose elution buffer containing 1 M NaCl. Eluted fractions were 
analysed by measuring the A280 as well as running peak A280 fractions on a SDS-PAGE 
gel (Section 2.2.5) followed by silver staining (Section 2.2.5).  
 
Molecular exclusion chromatography (MEC): 
For further purification of TviCATL, molecular exclusion chromatography was 
conducted using a Sephacryl-200 HR column (25 x 650 mm, flow rate of 0.2 cm/min, 
4°C). The resin has a fractionation range of 5 – 250 kDa. The column was equilibrated 
with one column volume of MEC buffer [0.02 M Tris-HCl, pH 7.6, 0.02% (w/v) 
NaN3,]. Thereafter, the column was calibrated with 3 ml of calibration solution [2 
mg/ml blue dextran (2000 kDa), 5 mg/ml of each BSA (68 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (30 kDa) and myoglobin (16.7 kDa)]. The availability constant 
(Kav) was determined for each protein where the elution volume (Ve) of blue dextran 
denotes the void volume (Vo) and Vt is the total volumn. A Fischer’s plot relating Kav to 














Figure 2.2 Fischer’s plot for the estimation of protein Mr from MEC data. The calibration solution 
was applied to a Sephacryl-200 HR column (25 x 650 mm, flow rate of 0.2 cm/min, 4°C) in MEC buffer 
[0.02 M Tris-HCl, pH 7.6, 0.02% (w/v) NaN3,]. The availability constant (Kav) for each protein 
standard was determined. The equation of the trendline is y = -7.7502x + 5.4469 with a correlation 
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2.2.4  Quantification of TviCATL 
The purified native TviCATL was quantified by using two methods, namely, BCATM 
Protein Assay Kit (Pierce, Rockford, IL, USA) and the Bradford protein assay 
(Bradford, 1976). The BCATM Protein Assay Kit contains a working reagent that 
includes bicinchoninic acid (Smith et al., 1985). The combination of Cu2+ to Cu+ 
reduction by protein in an alkaline medium with the highly sensitive colorimetric 
detection of Cu+ by bicinchoninic acid allows for protein quantification (Smith et al., 
1985). The BCA/copper complex exhibits a strong linear absorbance at 562 nm with 
increasing protein concentration. The BCA colour formation is highly influenced by 
the amino acids cysteine, tyrosine and tryptophan. For the construction of a standard 
curve (Fig. 2.3), triplicate samples of known concentrations of bovine serum albumin 
(BSA) [0.025 – 2 mg/ml] were mixed with the working reagent (sample to working 
reagent ratio = 1:20) and placed in a Nunc® 96 well plate. The plate was covered and 
incubated at 37°C for 30 min. Colour change was measured at 562 nm using the 
FLUORStar Optima Spectrophotometer (BMG Labtech, Offenburg, Germany). The 
























Figure 2.3 Standard curve for BCA protein quantification assay. Bovine serum albumin (BSA) 
samples of known concentrations (0.025 – 2 mg/ml) were measured at 562 nm in order to construct a 





The Bradford protein determination method involves the binding of dye proteins, 
specifically arginine residues (Compton and Jones, 1985), causing a shift in the 
absorption maximum of the dye from 465 nm (red) to 595 nm (blue). A standard curve 
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was constructed using ovalbumin in a range of 1 – 5 μg (Fig. 2.4). Briefly, 
quintuplicate samples of 0 – 50 μl of the 100 μg/ml ovalbumin standard solution were 
diluted to 50 μl with dH2O and 950 μl of Bradford dye [50 mg Serva blue G in 50 ml 
of 88% (v/v) phosphoric acid and 23.5 ml 99.5% (v/v) ethanol]. After colour 
development (2 min), the A595 was recorded. The standard curve was used to determine 




























Figure 2.4 Bradford protein calibration curve. Ovalbumin solutions (1-5 μg) were used as standard 
solutions and their absorbance, following mixing with Bradford reagent, read at 595 nm. The equation of 
the trend line is given by y = 0.0338x – 0.0014, with a correlation coefficient of 0.9988. 
 
 
       2.2.5  SDS-PAGE gel analysis of TviCATL 
The SDS-PAGE method, described by Laemmli (1970), was used to analyse protein 
samples. A discontinuous buffer system consisting of both a stacking buffer (500 mM 
Tris-HCl, pH 6.8) and a separating buffer (1.5 M Tris-HCl, pH 8.8) was used. The 
protein samples were treated with a reducing treatment buffer [125 mM Tris-HCl, 4% 
(w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol]. Disulfide bonds of 
protein are reduced by 2-mercaptoethanol. This allows SDS to interact efficiently with 
the protein to mask the charge of the protein with the negative charge of SDS (Shapiro 
et al., 1967). Therefore, all proteins will migrate anionically and can be separated 
based on differences in molecular weight when subjected to an electric field in the 
polyacrylamide gel (Weber and Osborn, 1969). The relative migration distance of the 
protein is inversely proportional to the molecular weight. Electrophoresis was 
conducted at 18 mA per gel for 1.5 hours in tank buffer [250 mM Tris-HCl buffer, pH 
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8.3, 192 mM glycine, 0.1% (w/v) SDS] using the BioRad Mini Protein III 
electrophoresis equipment (BioRad, USA). A calibration curve was constructed from 
the molecular weight markers of known size and was used to determine the molecular 






































b (97 kDa) 
log Mr 
Figure 2.5 Reducing SDS-PAGE calibration curve. To determine the molecular weights of protein 
samples of unknown size, low range protein markers of known size were separated alongside samples to 
be analysed. The relative mobility of low range protein markers were measured and plotted against 
logMr. The equation of the trendline was y = -4.4346x + 9.4134, with a correlation coefficient of 
0.9845. 
 
To visualise electrophoresed proteins, SDS-PAGE gels were stained with Coomassie 
Blue [0.125% Coomassie Blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid] for 
4 hours. This detection system usually has a detection limit of 50 – 100 ng of protein. 
For more sensitive detection, silver staining (Blum et al., 1987) was used. In this 
technique, following electrophoresis, the gel was placed in a meticulously clean glass 
dish and washed with washing solution [50% (v/v) ethanol] (3 x 20 min). The gel was 
subsequently soaked in pretreatment solution [0.2% (w/v) Na2S2O3.5H2O], which 
considerably reduces the intensity of background staining by preventing the 
precipitation of insoluble silver complexes on the surface of the gel. Following rinsing 
in dH2O (3 x 20 min), the gel was soaked in impregnation solution [0.2% (w/v) 
AgNO3, 0.028% (v/v) formaldehyde] for 20 min. The gel was rinsed again in dH2O (3 
x 20 s) and immersed in developing solution [6% (v/v) Na2CO3, 0.0004% (w/v) 
Na2S2O3.5H2O, 0.0185% (v/v) formaldehyde] until protein bands were visualised. 
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Development was stopped by soaking the gel in stopping solution [50% (v/v) 
methanol, 12% (v/v) acetic acid] for 10 min.  
 
2.2.6  Western blot analysis of TviCATL 
Proteins separated on a Laemmli SDS-PAGE gel were transferred from the gel onto 
nitrocellulose membranes using a wet blotter (BioRad Hercules, CA, USA) in transfer 
buffer [45 mM Tris-HCl, 173 mM glycine, 0.1% (w/v) SDS] at 40 mA (for 8 x 7 cm 
gels) for 16 hours according to Towbin et al (1979). Once transfer was complete, the 
nitrocellulose membrane was stained with Ponceau S [0.1% (w/v) Ponceau S in 1% 
(v/v) glacial acetic acid). When the protein bands were visible, the positions of the 
molecular weights markers were marked with a pencil. The nitrocellulose membrane 
was subsequently destained in dH2O. After soaking the nitrocellulose in blocking 
solution [5% (w/v) fat-free milk powder in Tris buffered saline (TBS) (20 mM Tris-
HCl buffer, pH 7.4, 200 mM NaCl)], the membrane was probed with chicken anti-C-
terminal extension of TviCATL IgY diluted in 0.5% (w/v) BSA-TBS for 2 hours at 
RT. Following washing in TBS (3 x 5min), the membrane was incubated in rabbit anti-
IgY conjugated to HRPO diluted in 0.5% (w/v) BSA-TBS. Lastly the membrane was 
placed in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol, 
0.0015% (v/v) H2O2 in TBS).  
 
2.2.7  Enzymatic characterisation 
Active site titration with E-64: 
The determination of the concentration of active TviCATL, using the irreversible 
inhibitor E-64 was done according to Barrett et al (1982). Briefly, enzyme [1 μM 
diluted in 0.1% (w/v) Brij-35] was incubated with E-64 (0-1 μM diluted in 0.1% Brij-
35) in TcoCATL assay buffer (100 mM) for 30 min at 37°C. Thereafter, hydrolysis of 
H-D-Val-Leu-Lys-AMC (20 μM) was measured [excitation 360 nm; emission 460 nm 
(Ex360 nm; Em460 nm)] in a FLUORStar Optima spectrophotometer (BMG Labtech, 
Offenburg, Germany). The active concentration of TviCATL was determined by 
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Gelatin SDS-PAGE analysis: 
Proteolytic activity was analysed on a standard Laemmli SDS-PAGE gel, modified as 
described by Heussen and Dowdle (1980). A 1% (w/v) gelatin solution was prepared 
by dissolving in running gel buffer (1.5 ml) at 37°C. The gelatin solution was added to 
the remaining running gel buffer (2.25 ml) and solutions for casting a 12.5 % SDS-
PAGE gel (described in Section 2.2.5). After electrophoresis, the running gel was 
soaked in two changes of 2.5% (v/v) Triton X-100 for an hour at room temperature to 
effect the removal of SDS. The gel was incubated in TcoCATL assay buffer [100 mM 
Bis-Tris buffer, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 6 mM DTT] for 3 hours at 
37°C. The gel was stained with amido black solution [0.1% (w/v) amido black, 30% 
(v/v) methanol, 10% (v/v) acetic acid, 60% (v/v) water] for 1 hour. The gel was 
destained in several washes of destaining solution [30% (v/v) methanol, 10% (v/v) 
acetic acid, 60% (v/v) water].  
 
      Proteolysis of bovine fibrinogen: 
Proteolytic activity was also tested against the protein substrate bovine fibrinogen as 
previously described (Rautenberg et al., 1982). Degradation at 1:100 but not 1:1000 
and 1:500 molar ratios of enzyme:fibrinogen were found with native TbbCATL 
(Troeberg, 1997) So as a starting point, a 1:100 molar ratio of enzyme:fibrinogen was 
used. Briefly, 0.088 μM of purified native and recombinant TviCATL (Vather, 2010) 
were incubated at 37°C with 0.88 μM and 8.8 μM of bovine fibrinogen respectively 
and removed at various time points. Proteolysis was stopped by the addition of 1 mM 
E-64 and samples were analysed on a 12.5% reducing SDS-PAGE gel.  
 
Effect of pH on enzymatic activity: 
For the determination of the pH-optimum for TviCATL, constant ionic strength 
acetate/Mes/Tris (AMT) buffers (100 mM Na-acetate, 200 mM Tris-HCl, 100 mM 
Mes, 8 mM DTT and 4 mM EDTA), titrated from pH 4.0 to pH 9.0, in 1.0 increments 
with NaOH or HCl (Ellis and Morrison, 1982)  were prepared. Enzyme [1.5 ng diluted 
in 0.1% (w/v) Brij-35] was incubated with each buffer of a different pH for 5 min at 
37°C. The substrate, H-D-Val-Leu-Lys-AMC (20 μM) was added to the solutions and 
the fluorescence measured (Ex360 nm; Em460 nm) FLUORStar Optima spectrophotometer 
(BMG Labtech, Offenburg, Germany). 
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       2.2.8  Determination of kinetic constants 
AMC standard curve: 
The amount of fluorescence released during the hydrolysis of synthetic peptides was 
quantified by an AMC calibration curve (Fig. 2.6). Dilutions of AMC (0.5 – 15 μM) 
were prepared in TcoCATL assay buffer and reading the fluorescence (Ex360 nm; 



























Figure 2.6 Standard curve relating amount of AMC to fluorescence (Ex360 nm; Em460 nm). The 




Substrate specificity for TviCATL was established by preincubation of enzyme as 
determined by E-64 titration [1.5 ng active enzyme, diluted in 0.1% (w/v) Brij-35] in 
TcoCATL assay buffer for 5 min at 37°C before substrate was added. The initial 
steady-state velocity (v0) was determined by continuous assay for a range of substrate 
concentrations (2.5 – 50 μM) using the FLUORStar Optima spectrophotometer (BMG 
Labtech, Offenburg, Germany) at an excitation of 360 nm and an emission wavelength 
of 460 nm. The kinetic constants Km and Vmax were determined by hyberbolic 
regression of the kinetic data using Hyper32© software data (1991 – 2003, Dr. J.S. 
Easterby, University of Liverpool, Liverpool, UK). The kcat was determined from kcat = 
Vmax/[E]0, where [E]0 represents the active enzyme concentrations (Salvesen and 
Nagase, 1989).   
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Reversible inhibition of TviCATL: 
The inhibition kinetic constant (Ki) was determined as described by Salvesen and 
Nagase (1989). The uninhibited rate of H-D-Val-Leu-Lys-AMC substrate hydrolysis 
(v0) was first established by incubating enzyme [1.5 ng active enzyme diluted in 0.1% 
(w/v) Brij-35] in TcoCATL assay buffer for 10 min at 37°C, followed by adding 20 
μM of H-D-Val-Leu-Lys-AMC and then reading the fluorescence (Ex360 nm; Em460 nm) 
for 5 min using the FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, 
Germany). Thereafter, inhibitor was added at a 20-fold molar excess over enzyme (not 
exceeding 5% of the total assay volume) and a new steady-state velocity determined in 
the presence of inhibitor (vi). Under these conditions, the apparent inhibition constant 
in the presence of substrate (Ki(app)) was calculated by v0/vi = 1 + [I]/Ki(app) (Salvesen 
and Nagase, 1989), where [I]/Ki(app) is the slope from the plot of  v0/vi  against [I]. The 
true equilibrium inhibitor constant, Ki, for competitive reversible inhibitors accounts 
for the presence of substrate and is given by Ki = Ki(app)/1 + [S]/Km, where [S] denotes 
substrate concentration. 
 
       Irreversible inhibition of TviCATL: 
The effect of irreversible inhibitors on TviCATL activity was determined under pseudo 
first-order conditions, with inhibitor concentration 50 times greater than the enzyme 
concentration (Salvesen and Nagase, 1989). TviCATL [1.5 ng active enzyme diluted in 
0.1% (w/v) Brij-35] was incubated at 37°C with TcoCATL assay buffer and 
irreversible inhibitor (28 nM) to initiate inactivation. Aliquots were removed at 5 
minute intervals over a for 1 hour assay period, and residual activity (vt) determined 
against 20 μM H-D-Val-Leu-Lys-AMC. The pseudo first-order inhibition constant 
(kobs) was obtained from the plot of In vt/v0 versus time where v0 represents the initial 
enzymatic activity, prior to the addition of irreversible inhibitor. The apparent second-
order inhibition rate constant (ka) was obtained from the relationship ka = kobs/[I], 
where [I] represents the inhibitor concentration. The time required for the free enzyme 
to decrease by 50% (half-life, t1/2) during the reaction of the enzyme with the 
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2.3  RESULTS 
2.3.1  Purification of native TviCATL 
The T. vivax parasites were isolated from the blood of two BALB/c mice by using 
anion exchange chromatography on a DE-52 resin followed by the use of Histopaque® 
1077, resulting in the collection of 8.5 x 107 parasites. The parasites were lysed and 
TPP was used as an initial isolation step to purify native TviCATL. TPP was optimised 
by adding increasing amounts of ammonium sulfate successively to parasite lysate. As 
it has been previously determined that the synthetic substrate H-D-Val-Leu-Lys-AMC 
is the preferred substrate for the recombinant catalytic domain of TviCATL (Vather, 
2010), this substrate was used in an activity assay to determine the optimal percentage 
ammonium sulfate to affect native TviCATL precipitation (Fig. 2.7). The H-D-Val-
Leu-Lys-AMC-hydrolysing activity from T. vivax was shown to precipitate between 
10 and 20% (w/v of the total volume) ammonium sulfate. As a result the 10-20% 
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Figure 2.7 Optimisation of TPP for the isolation of TviCATL from T. vivax. Increasing percentages 
of ammonium sulfate were added to T. vivax lysate containing 30% (v/v of total volume) t-butanol and 
centrifuged. Each protein precipitate was resuspended and assayed against H-D-Val-Leu-Lys-AMC. 
Each reading is the average of three independent readings. 
 
 
The 10-20% ammonium sulfate cut from TPP was further purified by anion exchange 
chromatography (Fig. 2.8). Native TviCATL eluted at 0.6 M NaCl as shown by the 
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single peak of absorbance at 280 nm (fractions 40 to 53, Fig. 2.8) and analysis by 
reducing SDS-PAGE (Fig. 2.9). Proteins from Fig. 2.9, Panel A, were further analysed 












































































Figure 2.8 Purification of native TviCATL on a Q-Sepharose anion exchange column. The 10–20% 
ammonium sulfate TPP cut was loaded onto the Q-Sepharose column (26 x 110 mm, flow rate 1 
ml/min,) pre-equilibrated in Q-Sepharose equilibration buffer [0.02 M Tris-HCl, pH 7.6, 0.02% (w/v) 
NaN3]. Bound material was eluted with a 0–1 M NaCl gradient (-) and monitored by reading the 




Four major proteins with Mr values of 27, 56, 68 and 92 kDa were visualised (Fig. 
2.9). The 56 and 68 kDa proteins constituted the bulk of the peak absorbance readings. 
Western blot analysis using chicken anti-TviCATL C-terminal extension peptide 









   51 
 
 





















1                  2       3      4       5       6       7                                        1       2       3        4       5      6       7       8       9        kDa kDa 
                                         A                                                                             B 
 
Figure 2.9 Silver stained reducing SDS-PAGE (12.5%) gel of fractions eluted from the Q-
Sepharose anion exchange column. Samples (2 μg) were reduced by boiling in 2-mercaptoethanol 
before loading onto the SDS-PAGE gel. Panel A: lane 1, molecular weight markers; lanes 2-7, Q-












   
Figure 2.10 Western blot analysis of fractions eluted from Q-Sepharose. Proteins were 
electrophoresed on a 12.5% reducing SDS-PAGE gel and electroblotted onto a nitrocellulose 
membrane. The transferred protein was probed with chicken anti-TviCATL C-terminal extension 
peptide antibodies (5 μg/ml) followed by rabbit anti-IgY-HRPO conjugate (1:12 000). The blot was 
developed with substrate solution that comprised of 4-chloro-1-naphthol/H2O2. Lane 1, molecular 
weight markers; lanes 2-7, Q-Sepharose fractions 40-45. 
 
 
Following anion exchange chromatography, fractions 40-42 (protein seen in lanes 2-4 
of Fig. 2.9), were pooled, concentrated and loaded on a gel filtration chromatography 
column (Fig. 2.11). Only fractions 40-42 were used as previous attempts at purifying 
the 56 kDa TviCATL protein from fractions containing the 68 kDa protein were 
unsuccessful. Fractions corresponding to the A280 peak (Fig. 2.11) were analysed on a 
reducing SDS-PAGE gel (Fig. 2.11 B) and showed as a 56 kDa band but a 27 kDa 
contaminating protein could be observed.  
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As evident by the decrease in total protein levels, shown in the purification table 
(Table 2.1), TPP proved to be a very efficient crude purification method, removing 
large quantities of extraneous trypanosomal proteins from TviCATL. Anion exchange 
chromatography allowed for a successful step in native TviCATL isolation as indicated 
by an increase in specific activity. 
 
 
A                                                                                            B 
 



























Vo                              68 kDa        16.7 kDa 
Figure 2.11 Purification of native TviCATL on a Sephacryl-200 molecular exclusion column. Panel 
A, elution profile on a Sephacryl-200 column (25 x 650 mm, flow rate of 1ml/min), previously 
equilibrated with MEC buffer [0.02 M Tris-HCl, pH 7.6, 0.02% (w/v) NaN3,]. The column was 
calibrated with blue dextran (2000 kDa), bovine serum albumin (68 kDa), ovalbumin (44 kDa) and 
myoglobulin (16.7 kDa). Fractions collected were monitored by reading absorbance at 280 nm. Panel B, 
reducing 12.5% SDS-PAGE gel analysis of native TviCATL peak fractions. Lane 1, molecular weight 















Purification     
(-fold) Yield (%) 
parasite lysate 17.65 1.90 0.11 1.00       100.00 
TPP   8.19 1.36 0.17 1.55 71.58 
IEC   1.47 1.18 0.80 7.27 62.10 
MEC   0.60 0.51 0.85 7.73 26.84 
 a Protein concentration determined by BCATM Protein assay kit.  
 b Hydrolysis of H-D-Val-Leu-Lys-AMC was measured in enzyme assay buffer [100 mM Bis-Tris  
   buffer, pH 6.5, 4 mM EDTA, 8 mM DTT, 0.02% (w/v) NaN3] at 37°C. 
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       2.3.2  Enzymatic characterisation of native TviCATL 
Active site titration of TviCATL carried out using E-64 as an active-site titrant. Native 
TviCATL was only ~10% active (Fig. 2.12). TviCATL did however possess 
gelatinolytic activity (Fig. 2.13). This activity is comparable to that of recombinant 
TviCATL (Vather, 2010). However TviCATL did not show any hydrolysis of the 
gelatin under standard conditions. Only after an extended incubation period (9 hours) 
was hydrolysis seen. This is consistent with the extended incubation periods of 
bloodstream forms of T. vivax lysate hydrolysing fibrinogen-containing SDS-PAGE 

























Figure 2.12 Active site-titration of native TviCATL. A constant amount of native TviCATL (1 μM) 
was incubated with varying concentrations of E-64 (0-1 μM) for 5 min at 37°C. Hydrolysis of H-D-Val-
Leu-Lys-AMC was measured for each sample.  Each data point reflects the mean activity ± SD (n = 3). 
 
 
Recombinant TviCATL readily digested the α- (67 kDa) and β-chains (56 kDa) of 
fibrinogen after 1 hour of incubation (Fig. 2.14A). The γ-chain remained intact after the 
hour of incubation. Although not as definitive as the ability of recombinant TviCATL, 
native TviCATL was able to digest the β-chain (Fig. 2.14B). The amount of α- and γ-
chain did decrease after incubation with native TviCATL, suggesting that there was a 
small amount of proteolysis.  
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Figure 2.13 Gelatin-containing SDS-PAGE of purified native TviCATL. Non-reduced native 
TviCATL (20 μg, lane 2) was loaded onto a 12.5% gelatin-containing gel. Molecular masses in kDa are 
indicated on the left (lane 1).  
 
 A                                      B 
   1         2        3                                 2          3 
kDa  
 96 
α  68 










Figure 2.14 Activity of purified TviCATL against bovine fibrinogen. (A) 8.8 μM bovine fibrinogen 
incubated without (lane 1) and with (lane 2) 0.088 μM purified recombinant TviCATL for 1 hour at 37°C. 
(B) 0.88 μM bovine fibrinogen incubated without (lane 1) and with (lane 2) 0.088 μM purified native 
TviCATL overnight at 37°C. Proteolysis was stopped by the addition of 1 mM E-64 and samples were 
analysed on a reducing 12.5% SDS-PAGE gel. The molecular mass of fibrinogen α-chain is 67 kDa, the β-
chain 56 kDa and the γ-chain, 47 kDa. 
 
 
The pH optimum for maximal activity of TviCATL was determined using constant ionic 
strength AMT buffers at different pH values (Ellis and Morrison, 1982). Enzyme activity 
of TviCATL, at the different pH values was determined by measuring hydrolysis of H-D-
Val-Leu-Lys-AMC. Native TviCATL was able to maintain some activity at very acidic and 
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alkaline pH values, 25% activity at pH 4.0 and 40% activity at pH 9.0 (Fig. 2.15). This pH 
profile is very similar to that of recombinant TviCATL. However, for recombinant 
































Figure 2.15 pH activity profile of native TviCATL over a pH range of 4.0-9.0. The constant ionic strength 
Acetate-Mes-Tris buffers were used to determine the optimum pH for maximal hydrolysis of H-D-Val-Leu-
Lys-AMC by native TviCATL. Each data point reflects the mean activity ± SD (n = 3). 
 
TviCATL hydrolysis of substrates was calculated from Lineweaver-Burk plots (Fig. 2.16). 
Kinetic values were tabulated in Table 2.2. For native TviCATL, hydrolysis of H-D-Ala-
Leu-Lys-AMC was slightly higher than that of H-D-Val-Leu-Lys-AMC as evidenced by 
the higher kcat/Km value obtained for the former substrate (Table 2.2). Leu was preferred 
over Phe in P2 as the hydrolysis of H-Ala-Phe-Lys-AMC was far too slow to be measured 
experimentally. Arg was not preferred in the P2 position, as Z-Ala-Arg-Arg-AMC was not 
hydrolysed. This conclusion is supported by the fact that TviCATL was able to hydrolyse 
substrates with an Ala at P3 (H-D-Ala-Leu-Lys-AMC) and an Arg in P1 (Z-Phe-Arg-
AMC). Consistent with the properties of the family C1, clan CA, TviCATL has a substrate 
specificity defined by the S2 pocket (Sajid and McKerrow, 2002). The nonpolar Ala and 
Val were both accepted in the P3 position. This was confirmed by the fact that the kcat/Km 
values for H-D-Val-Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC did not differ 
significantly. Pro, however, was not favoured in the P3 position as there was a 1-fold 
decrease in kcat/Km for H-Pro-Phe-Arg-AMC compared to Z-Phe-Arg-AMC. The fact that 
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activity was seen in the presence and absence of N-terminal blocked groups (Z-Phe-Arg-
AMC and H-D-Val-Leu-Lys-AMC respectively), demonstrates that TviCATL possesses 
exo- and endopeptidase activity. TviCATL, however does not possess the typical 
mammalian CATB activity due to the lack of Z-Arg-Arg-AMC hydrolysis. Furthermore, 
aminopeptidase activity is not a characteristic of TviCATL as there was a lack of ability to 
hydrolyse Z-Arg-AMC.  
 
                       Z-Phe-Arg-AMC                                                                     H-D-Pro-Phe-Arg-AMC 














Figure 2.16 Lineweaver-Burk plot of various substrates hydrolysed by TviCATL from T. vivax. 
TviCATL was incubated with fluorogenic substrates hydrolysis of substrates was measured at Ex360 nm and 
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Table 2.2  Kinetic parameters for the hydrolysis of fluorogenic substrates by native 
TviCATLa 
Substrate Km (µM) kcat (s-1)
kcat/Km
(s-1mM-1)
Z-Phe-Arg-AMC 146.00 2.70 18.49
H-D-Val-Leu-Lys-AMC 83.70 5.04 60.21
H-D-Ala-Leu-Lys-AMC 7.74 0.56 72.42
H-Pro-Phe-Arg-AMC 128.60 1.01  7.85
H-Ala-Phe-Lys-AMC NDb ND ND
    a  Enzyme was incubated  with substrates in 100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8 
mM DTT at 37°C. Km values and the Michaelis-Menten plots were calculated using the Hyper® 32 software 
(J.S Easterby). b Not determined as reaction was too slow to be measured experimentally. No activity was 
detected against Z-Gly-Pro-Arg-AMC, Z-Gly-Gly-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-AMC, Z-Gly-Arg-
Arg-AMC, Z-Ala-Arg-Arg-AMC and Meosuc-Asp-Tyr-Met-AMC. 
 
A series of different competitive reversible inhibitors that can variously inhibit serine, 
cysteine, aspartic or metallo peptidases were tested for their ability to inhibit TviCATL 
(Table 2.3). The lack of inhibition by EDTA reinforces the observation that TviCATL is 
not metal ion dependent. Furthermore, TviCATL is not inhibited by pepstatin A, a typical 
aspartic peptidases inhibitor. The cysteine peptidase inhibitor, cystatin, was the most 
effective inhibitor with a Ki value of 0.50 mM. This Ki is at least 1-fold lower than that of 
chymostatin and antipain Ki values. Although the results shown in Table 2.2 provides no 
evidence of Phe being accepted in the P1 position, the inhibition by chymostatin suggests 
that Phe is accepted at such a position since chymostatin contains a Phe (attached to an 
aldehyde) in the P1 position. Consistent with the lack of hydrolysis of the aminopeptidase 
substrate, Z-Arg-AMC (Table 2.2), bestatin, an aminopeptidase inhibitor was unable to 
inhibit TviCATL. 
 
Z-Gly-Leu-Phe-CMK and H-D-Val-Phe-Lys-CMK were both able to inhibit TviCATL 
(Table 2.4). Consistent with its P2 preference, Z-Gly-Leu-Phe-CMK, with Leu in P2, was 
able to inhibit TviCATL better than H-D-Val-Phe-Lys-CMK. No inhibition was noted for 
typical serine peptidase inhibitors, PMSF, TLCK and TPCK. The alkylating thiol group 
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inhibitors, iodoacetamide and iodoacetic acid successfully inhibited TviCATL. No 
significant difference in t1/2 and ka was seen between these inhibitors.  
 
Table 2.3  Competitive reversible inhibitors of native TviCATLa 
Inhibitorb Ki (mM) (x103)
Leupeptin 1.24 
Chymostatin 4.50 
Antipain         15.05 









  a Enzymes were incubated  with inhibitors in 100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8  
      mM DTT at 37°C.  
    b   No inhibition was observed with bestatin (10 µM), EDTA (10 mM) or pepstatin A (1 µM).  
    c  Chicken egg white 
 
 
Table 2.4  Irreversible inhibitors of native TviCATL a 
Inhibitor b    ka (mM-1.s-1)c t1/2 (s) 
Z-Gly-Leu-Phe-CMK 89.50 ± 11.21 254 
Iodoacetamide 35 ± 2.76 652 
Iodoacetic acid 31.50 ± 1.01 724 
H-D-Val-Phe-Lys-CMK 74.02 ± 6.23 321 
  a Enzymes were incubated with inhibitors in 100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8 
mM DTT at 37°C. No inhibition was detected with Boc-VLGK-CHN2-HoAC, PMSF, 
phenylmethanesulfonyl fluoride; TLCK, Nα-Tosyl-Lys-chloromethyl ketone and TPCK, L-1-tosylamido-2-
phenylethyl chloromethyl ketone. 
      b 28 nM of inhibitor used. 
      c Data reflect the mean ka ± S.D. (n=3). 
 
 
2.4  DISCUSSION 
Since drug resistance in T. congolense has been reported in 17 African countries of sub-
Saharan Africa (Delespaux et al., 2008) and the African agriculture loss due to 
trypanosomosis is US $ 4.75 billion per year (Van den Bossche et al., 2010) show that new 
measures need to be put in place to control the disease. The ability of TcoCATL to degrade 
   59 
 
a range of proteins in vitro (Mbawa et al., 1992) and the fact that chloromethylketones, 
fluoromethylketones and diazomethylketones kill bloodstream forms of T. b. brucei in 
vitro (Troeberg et al., 1999) and some peptidyldiazomethylketones (Z-Leu-Leu-Met-
CHN2, Z-Leu-Met-CHN2 and Z-Leu-Lys-CHN2) are trypanocidal against T. congolense in 
vitro (Mbawa et al., 1992) provide promising possibilities for drug and vaccine 
development. Furthermore, preclinical proof-of-concept studies of K11777 with TcrCATL 
provide hope for chemotherapeutics (Kerr et al., 2009).  
 
The results presented here show that a cysteine peptidase, TviCATL, has been purified and 
characterised for the first time from T. vivax strain Y486. The initial growth of parasites in 
BALB/c mice presented an alternative to harvesting parasites grown in rats. Rodent models 
have been shown to be resistant to T. vivax infection (Terry, 1957) and as a result, would 
not have given a high enough level of parasitaemia to obtain sufficient numbers of 
parasites for enzyme isolates. A satisfactory yield of native TviCATL was purified from 
the parasites. Likewise, native TcoCATL yielded 24% enzyme (Mbawa et al., 1992). 
However, the yield for native TbbCATL, 5.3%, was less (Troeberg et al., 1996). The initial 
purification step used for native TviCATL was TPP, removing more than half of the 
extraneous trypanosomal total protein content. As has previously been described by Pike 
and Dennison (1989), this technique is cheap, effective and easy to perform. The 
chromatography procedures, ion exchange chromatography and molecular exclusion 
chromatography for native TviCATL proved to be successful final purification methods, 
yielding pure protein. As seen from the total protein, TviCATL constitutes as much as 3.4 
% of the total T. vivax protein content. Similarly, as much as 0.5-1.5% of the total T. 
congolense protein content may be cysteine peptidases as was purified by thiopropyl-
Sepharose affinity chromatography followed by molecular exclusion chromatography 
(Mbawa et al., 1992).  
 
Similar to the recombinant catalytic domain of TviCATL (Vather, 2010), native TviCATL 
possesses most of its activity around neutral pH. The only variation between native and 
recombinant catalytic domain TviCATL (Vather, 2010) pH profile, is the ability of the 
recombinant catalytic domain of TviCATL to remain active at acidic pH values. Whether 
or not the C-terminal extension of TviCATL influences the activity at acidic pH values 
values is still to be determined. It has, however, been shown that full length TbrCATL as 
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well as truncated TbrCATL (without the C-terminal extension) have very similar pH 
profiles (Caffrey et al., 2001). Native TcrCATL (Chagas et al., 1997), TcoCATL (Chagas 
et al., 1997; Mbawa et al., 1992) and TbbCATL (Troeberg et al., 1996) have pH optima 
slightly more acidic than native TviCATL.  
 
TviCATL efficiently hydrolysed H-D-Val-Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC. 
However, the inability to hydrolyse H-Ala-Phe-Lys-AMC demonstrates that Leu is 
favoured over Phe in P2. Further support for such slight preference was deduced from the 
lower kcat/Km values obtained for H-Pro-Phe-Arg-AMC and Z-Phe-Arg-AMC compared to 
the substrate with Leu in P2. It was concluded that Leu was preferred for the P2 position 
and Lys for the P1 position. Similar trends have been seen for both TcrCATL and 
TbrCATL, studied using a completely diversified positional scanning synthetic 
combinatorial library, where fluorogenic peptide substrates were used that allowed for the 
construction of substrate libraries to rapidly identify the primary and extended specificity 
of peptidases (Choe et al., 2006; Harris et al., 2000). Experimentally, recombinant 
TcrCATL and TbrCATL showed a marked preference for a hydrophobic residue at P2 with 
Leu being favoured. Both native TcoCATL (Mbawa et al., 1992) and TbbCATL (Troeberg 
et al., 1996) rapidly hydrolyse substrates with basic residues such as Arg or Lys in P1 and 
hydrophobic residues such as Phe and Leu in P2. However there was a slight preference for 
Phe in the P2 position in both cases. It has also been recently reported that TcoCATL has a 
clear preference for Leu in P2 and Lys in the P1 position (Pillay et al., 2010).  
 
It has been previously shown, recombinant TcrCATL2 (a cysteine peptidase isoform) has a 
marked preference for Leu over Phe (dos Reis et al., 2006), whereas recombinant 
TcrCATL accepts Phe and Leu in the P2 position with only a slight preference for Leu 
(Lima et al., 2001). This suggests that the S2 pocket of TcrCATL2 might be more restricted 
than that of TcrCATL. Structural studies of TcrCATL have shown that, when in complex 
with irreversible inhibitors, Leu189, Ala258 and Leu282 (TcrCATL numbering as in Fig. 
2.1) line the S2 pocket and readily accommodate the Phe residue at P2, which interacts with 
the enzyme’s backbone via the carbonyl of Gly188 (Brinen et al., 2000). However, as was 
reported that the Ser258 substitution found in recombinant TcrCATL2, combined with the 
proximal change of Met190 to Ser190 may ultimately influence the enzyme’s S2 specificity 
(dos Reis et al., 2006). In the case of TviCATL, residues that also supposedly line the S2 
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pocket (based on the sequence alignment in Fig. 2.1) are similar to TcrCATL and do not 
possess the changes, found for TcrCATL2, in the lining of the S2 pocket. This supports the 
observation that TviCATL has only a slight preference for Leu over Phe in the S2 position. 
Recent data have shown that a novel cysteine peptidase from Plasmodium vivax, VX-4, 
along with two other cysteine peptidases from P. vivax, VX-2 and VX-3 prefer Leu over 
Phe in the P2 position at pH 5.5 and pH 6.5 (Na et al., 2010). It is of interest that preference 
of Leu over Phe in P2 is a feature observed in mammalian CATS and CATK, but not with 
CATL or CATB (Choe et al., 2006). The inability of both native and recombinant 
TviCATL to hydrolyse Z-Arg-Arg-AMC demonstrates that lack of a CATB-like character. 
However, native and recombinant TcrCATL have the ability to hydrolyze substrates 
containing the positively charged residue, Arg, in P2 (Judice et al., 2001; Lima et al., 1992; 
Nery et al., 1997). This has been attributed to the presence of the Glu 333 (green arrow in 
Fig. 2.1) residue at the bottom of the S2 pocket, which interacts with the positive charge, 
stabilising basic residues in the pocket (Gillmor et al., 1997). In the case of TcoCATL and 
TviCATL, as shown in the sequence alignment (Fig. 2.1), a Leu residue instead of a Glu 
residue occupies this position which suggests that there would be a difficulty in 
accommodating Arg in the P2 position. For TbrCATL, an Ala residue occupies this 
position and has been previously shown that it too is unable to degrade substrates with an 
Arg in P2 (Caffrey et al., 2001). 
 
Native TviCATL was effectively inhibited by chicken egg white cystatin, similar to that of 
native TcoCATL (Mbawa et al., 1992) and TcrCATL (Lima et al., 2001). It was previously 
speculated that because of conserved sequences amongst cystatins and the highly similar 
sequences of trypanosomal cysteine peptidases to those of the mammalian hosts, 
trypanosomal cysteine peptidases are likely to be inhibited by cystatins in the bloodstream 
of mammalian hosts (Troeberg et al., 1996). The peptidyl-diazomethane inhibitor based on 
a conserved sequence of cystatins, Z-RLVG-CHN2, inhibits native TcoCATL and 
TcrCATL (Chagas et al., 1997), however the mammalian homologs such as CATB and 
CATL are inhibited to a greater extent with such peptidyl-diazomethane inhibitors. 
Although no such cystatin-conserved peptidyl-diazomethane inhibitor was tested for 
TviCATL, it can be considered that such an inhibitor would be able to effectively inhibit 
TviCATL, based on the similarity in P2 specificity of TviCATL and mammalian CATL.  
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The hydrophobic nature of the P2-binding subsite was further confirmed by the ability of 
both Z-Gly-Leu-Phe-CMK and H-D-Val-Phe-Lys-CMK, to inhibit native TviCATL. Native 
TcoCATL is inhibited by Z-Leu-Met-CHN2 and Z-Leu-Lys-CHN2, with hydrophobic 
groups in P2 (Leu) and either a hydrophobic or basic residue in the P1-binding subsite 
(Mbawa et al., 1992). Although not tested in the present study, vinyl sulfones have been 
proven to have desirable attributes including selectivity and stable inactivation of the target 
enzyme (Palmer et al., 1995). Both vinyl sulfones, K11017 (Mu-Leu-Pph-VSPh) and 
K11777 (N-Mpip-Phe-Hph-VSPh) have been tested with recombinant falcipain-3 (cysteine 
peptidase from Plasmodium falciparum), TcrCATL and TbrCATL (Kerr et al., 2009). Both 
vinyl sulfones have a homophenylalanine in the P1 position with variation at P2; Leu for 
K11017 and Phe for K11777. K11017 has also been tested against native TbbCATL and 
was one of the most effective tested inhibitors (Troeberg et al., 1999). It can be suggested 
that such a vinyl sulfone will be able to effectively inhibit TviCATL as Z-Gly-Leu-Phe-
CMK, with a Leu in P2 and a Phe in P1 was an efficient inhibitor. The homophenylalanine 
group, with its extra branch was chosen for such synthetic inhibitors as it was previously 
observed that the incorporation of the homophenylalanine side chain at P1 resulted in 
inhibitors that were not degraded by human peptidases, in contrast to natural amino acids at 
this position (Huang et al., 2003).  
 
Clan CA peptidases are characterised by their sensitivity to the general cysteine peptidase 
inhibitor E-64 and have a substrate specificity defined by the S2 pocket (Sajid and 
McKerrow, 2002). Our data indicate that such characterisation of both native and 
recombinant TviCATL is consistent with that of Clan CA peptidases. Whether or not 
TviCATL, like the T. congolense counterpart, TcoCATL, acts as a pathogenic factor, is still 
to be determined. Further structural and functional characterisation of TviCATL in T. vivax 
will be useful in facilitating the understanding of such a cysteine peptidase.  
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CHAPTER 3  





3.1  INTRODUCTION 
African animal trypanosomosis (Nagana) is a widespread disease, affects 40 African 
countries and is costing the African continent US $4.75 billion per year (Van den Bossche 
et al., 2010). T. congolense along with T. vivax and T. brucei brucei are the three main 
trypanosomal species that infect livestock with the former two species the most 
pathogenic, causing Nagana. There are three main phases of bovine trypanosomosis. These 
include the early acute phase, stabilisation and chronic phase (Taylor and Authié, 2004). 
Acute phase is usually accompanied by a fever and anaemia. Cachexia, impairment of milk 
productivity and oestrous cycle are signs of the chronic phase. The chronic phase can lead 
to death, self-cure or to a persistent carrier state.  
 
West-African taurine breeds of cattle have a reduced susceptibility to the disease, 
trypanosomosis. The reduced susceptibility is commonly referred to as trypanotolerance 
and is defined as the trait that confers the capacity to survive and remain productive during 
and after trypanosome infection (Murray et al., 1982). Trypanotolerant cattle have reduced 
mortality, trypanosome levels, anaemia and furthermore, reproductive performance is 
better than indicine breeds such as Boran cattle (Bos indicus) (Naessens, 2006). 
Trypanotolerant cattle are able to mount an antibody response to the cysteine peptidase, 
TcoCATL (Lalmanach et al., 2002) better than trypanosusceptible cattle breeds.  
 
The trypanocidal compounds such as isometamidium chloride, homidium (bromide and 
chloride) and diaminazene are used for primary control of the disease (Holmes et al., 
2004). However these drugs have been used for more than 50 years and as a result drug 
resistance has developed (Kroubi et al., 2011). Other major strategies for controlling the 
disease include eradication or control of the tsetses fly vector. Vaccination strategies have 
been hampered by the ability of trypanosomes to continuously evade the host antibody 
response with the generation of an inexhaustible collection of variable surface 
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glycoproteins (VSGs). Non-variable antigen-based and anti-disease vaccines (Authié, 
1994) have been seen as alternative approaches. For the anti-disease vaccine approach, the 
artificial induction of antibodies against TcoCATL could render a disease-susceptible host 
more tolerant (Authié et al., 1992; Lalmanach et al., 2002). 
 
Like mammalian CATL, TcoCATL and other trypanosomal cysteine peptidases hydrolyse 
substrates using the catalytic triad, Cys25, His159, Asn175 (papain numbering). 
Trypanosomal CATL-like cysteine peptidases, like the mammalian homologs, are 
synthesised as pre-pro-proteins (Cazzulo et al., 1989; Eakin et al., 1992; Sakanari et al., 
1997). However, unlike their mammalian counterparts, an additional 11-13 kDa C-terminal 
extension, of unknown function, is separated from the catalytic domain by poly-threonine 
(TcrCATL and TviCATL) or poly-proline (TbbCATL and TcoCATL) sequences. 
 
Trypanosomal cysteine peptidases offer good targets for chemotherapy. A large amount of 
evidence supports this. TbbCATL has been linked to the ability of T. b. brucei to cross the 
blood brain barrier (Abdulla et al., 2008). Amastigote replication, intracellular 
development and host cell invasion have been implicated with TcrCATL function. 
(Aparicio et al., 2004). Besides the link to trypanotolerance, TcoCATL degrades a range of 
proteins in vitro (Mbawa et al., 1992). Like TbbCATL and TcrCATL, TcoCATL is active 
at neutral pH allowing it to interact with host proteins in a physiological environment 
(Lalmanach et al., 2002). Incomplete trypanosomal cysteine peptidase inhibition with host 
cysteine peptidase inhibitors has been documented (Lonsdale-Eccles et al., 1995; Wiser et 
al., 1997). In some cases, biologically active molecules have been released from such 
inhibition and as a result may play a role in pathology. Pyroglutamyl peptidase I (PGP), 
which has a slightly different catalytic triad (Glu instead of Asn), is entirely responsible for 
the reduced plasma half-life of thyrothrophin releasing hormone and partially responsible 
for the reduced half-life of gonadothrophin releasing hormone in T. b. brucei infected 
rodents (Morty et al., 2006). T. congolense PGP has similar enzyme activity to T. b. brucei 
PGP (Mucache, 2011). The cysteine peptidase inhibitor, E-64, which binds to the thiol 
group of the active-site Cys residue, capable of inhibiting TbbCATL (Troeberg et al., 
1996), TcrCATL (Lima et al., 2001), TcoCATL (Mbawa et al., 1992) and TviCATL 
(Chapter 2 of this dissertation), does not inhibit T. congolense PGP (Mucache, 2011). The 
three-dimensional structures of the peptidases are thus required to explain this difference in 
susceptibility to E-64 inhibition. 
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Inhibitors, such as the irreversible dipeptidyl substrate analogues coupled to reactive 
fluoromethylketone (CH2F) or diazomethylketone (CHN2) groups have been widely 
researched for selectively inhibiting the parasitic cysteine peptidases. Some 
peptidyldiazomethylketones (Z-Leu-Leu-Met-CHN2, Z-Leu-Met-CHN2 and Z-Leu-Lys-
CHN2) were trypanocidal when tested against bloodstream forms of T. congolense  
(Mbawa et al., 1992) and T. b. brucei in vitro (Troeberg et al., 1999). Peptidyl 
fluoromethylketones limited the survival of T. cruzi trypomastigotes (Ashall et al., 1990). 
A proposed binding mode for these peptidyldiazomethylketones have shown that the 
peptide component is bound by specificity subsites S1, S2 and S3 (Barrett et al., 1982). The 
availability of crystal structures has allowed for the directed design of synthetic peptidase 
inhibitors (Chen et al., 2008). The peptidomimetic vinyl sulfone, K11777 (N-Mpip-Phe-
Hph-VSPh), which targets TcrCATL, is lethal to T. cruzi parasites both in vitro and in 
animal models of the disease (Engel et al., 1998a; Engel et al., 1998b) and is an example of 
‘chemical knockout’ of the TcrCATL gene. The crystal structure of recombinant TcrCATL 
in complex with K11017 (Mu-Leu-Hph-VSPh) shows that the hydrophobic residue in the 
P2 position is able to make contact with the S2 subsite of TcrCATL as the S2 subsite is 
lined with non-polar residues (Bryant et al., 2009; Kerr et al., 2009). Furthermore, the 
phenyl vinyl sulphone in the in the P1’ position is able to rest on the floor of the S1’ subsite 
and covalently bind with the active-site Cys residue (Chen et al., 2008). The Mu rather 
than the N-Mpip group in the P3 position is better accommodated by TbrCATL, from T. b. 
rhodesiense, and TcrCATL as it is able to make more polar interactions through bridging 
water molecules (Kerr et al., 2009). The K11777, which has no significant toxicity to 
rodent or canine hosts (Abdulla et al., 2007), is currently completing pre-clinical testing for 
the treatment of Chaga’s disease. 
 
To date the structure of TcoCATL has not been elucidated. The only two trypanosomal 
cysteine peptidase structures determined are those of TcrCATL (Eakin et al., 1993; 
McGrath et al., 1995) and TbrCATL (Kerr et al., 2009). TcoCATL shares 68% sequence 
identity with the central catalytic domain of TcrCATL (Lalmanach et al., 2002). The 
predicted 3D structure of TcoCATL, based on the sequence homology with TcrCATL, 
follows a common framework found for papain-like cysteine peptidases (Fig. 1.6, Chapter 
1 of this dissertation). The framework consists of two domains: the L domain, which is 
mainly α helical; and the R domain, which is mostly composed of antiparallel β sheets 
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(Lecaille et al., 2001) (Fig. 1.11, Chapter 1 of this dissertation). The catalytic triad and the 
residues defining the extended substrate-binding site are located in the cleft between the R 
domain and the L domain (Lecaille et al., 2001). TcoCATL, based on the hydrophobic 
pocket of the S2 subsite, has a more restricted specificity than TcrCATL (Chagas et al., 
1997) and was previously confirmed using the superimposition model of TcoCATL and 
TcrCATL (Lecaille et al., 2001). However, unlike TcrCATL, TcoCATL is monomeric at 
acidic pH and dimeric at neutral pH (Boulangé et al., 2011). Antibodies directed against 
TcoCATL are better at recognising the dimeric form (Boulangé et al., 2011). It is therefore 
crucial to understand the dimerisation mechanism of TcoCATL. Some of the amino acid 
residues, that have been shown to be involved in dimerisation through a salt bridge, were 
shown through site-directed mutagenesis to be Lys39, His43 and Glu44 (Ndlovu, 2010). At 
physiological pH the His43 is deprotonated resulting in a salt bridge between Lys39 and 
Glu44, thus forming a β-turn, giving the protein dimeric conformation (Ndlovu, 2010). 
Mutating Lys39 and Glu44 to Phe39 and Pro44, prevents salt bridge formation resulting in 
a monomeric TcoCATL conformation. Furthermore, as previously speculated, mutating 
His43 to Trp43 reults in the protein existing as a dimer (Ndlovu, 2010).  
 
Structural genomics initiatives have demonstrated that for a given protein construct, the 
initial likelihood of obtaining a crystal is between 30%-40% (Rupp, 2009) and the 
probability of a crystal to yield usable diffraction data again only ranges between 30%-
40%. That is why it is imperative that the crystallisation strategy be carefully selected and 
that careful observation and interpretation is carried out to increase the chances of 
crystallisation. Various strategies can be employed which include commercially available 
crystallisation screens, which screens a wide variety of conditions, or limiting screening 
based on information collected from proteins of similar sequence and character that have 
been crystallised (Fig.1.10, Chapter 1 of this dissertation). Generally, commercially 
available screens are used to maximise the chances of producing well-diffracting crystals 
initially (Rupp, 2009). If positive results are found from initial screening, optimisation 
screens can be done. These usually include exploring the phase diagram (Fig.1.9, Chapter 
1 of this dissertation), or level of supersaturation, for the protein in a certain crystallising 
reagent (Benvenuti and Mangani, 2007) and adding various additives such as detergents, 
reducing agents and heavy metal compounds to the screens. If after several optimisation 
screens no positive results are obtained, protein construct manipulation presents a further 
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avenue to explore in order to obtain crystals. Non-diffracting crystals also require further 
optimisation by either mutation of amino acid residues, changing the protein construct 
and/or screening of the protein with other crystallising reagents and buffers.  
 
In the present study, the catalytic domain of TcoCATL and TviCATL, as well as the full-
length pyroglutamyl peptidase, PGP, were recombinantly expressed and purified. These 
proteins along with TcoCATL dimerisation mutants, TcoCATL (H43W), TcoCATL 
(K39F; E44P) and the proenzyme mutant TcoCATL (C25A), were screened for suitable 
crystallisation conditions using the recently acquired Rigaku robotic crystallisation suite 
(Rigaku Automation Inc., USA), to establish the technology at our Institution. 
Crystallisation hits for TcoCATL (K39F; E44P) were further optimised and their X-ray 
diffracting ability evaluated. 
 
3.2  MATERIALS AND METHODS 
3.2.1  Materials 
P. pastoris expression and purification:  
Glycerol stocks of P. pastoris GS115 cells containing recombinant pPic9-TcoCATL and 
pPic9-TviCATL were obtained from Dr A Boulangé (University of KwaZulu-Natal, 
Pietermaritzburg) and Professor Theo Baltz (University Victor Segalen, Bordeaux, France) 
respectively. Ten mg/ml of purified and concentrated TcoCATL (H43W), TcoCATL 
(C25A) and TcoCATL (K39F; E44P) were supplied by Hlumani Ndlovu (Ndlovu, 2010). 
SP Sephadex C-25, Sephacryl S-200, 10 kDa cut-off Snakeskin® pleated dialysis tubing, 
tetracycline, ampicillin and chloramphenicol were purchased from Sigma (Munich, 
Germany). The VersaDoc imaging system using Quantity One software was purchased 
from Bio-Rad (USA). Ultrospec 2100 pro spectrophotometer was from Amersham 
Biosciences (Sweden). Whatman No. 1 filter paper was purchased from Whatman 
(England). Centriprep ultrafiltration devices with YM-10 membrane were purchased from 
Millipore (MA, USA).  
 
E. coli expression and purification: 
Glycerol stocks of E. coli BL21 (DE3) containing pGEX4T1-PGP were obtained from 
Mucache (2011). Ampicillin and reduced glutathione were purchased from Sigma 
(Munich, Germany). GST-bind column was purchased from Sigma (Munich, 
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Germany).Thrombin and a thrombin cleavage buffer and were purchased from Novagen 
(WI, USA). Poly-Prep® chromatography columns were from Biorad (USA). 
 
Antibodies: 
Anti-peptide antibodies were produced in chickens against a peptide corresponding to the 
22 N-terminal residues of TcoCATL (Mkhize, 2003). Antibodies against the recombinant 
C25A mutant full length inactive form of TviCATL (ΔFLTviCATL) were raised in 
chickens (Vather, 2010). The rabbit anti-IgY-HRPO conjugate was obtained from Sigma 




The peptide substrate, Z-Phe-Arg-AMC, pGlu-AMC and the inhibitor E-64 were 
purchased from Sigma (Munich, Germany). Nunc Black 96-well plates were purchased 
from NuncIntermed (Denmark). The plates were read in a FLUORStar Optima 
Spectrophotometer (BMG Labtech, Offenburg, Germany). 
 
Crystallisation: 
Joint Centre for Structural Genomics (JSCG) + and the pH, anion and cation testing 
(PACT) commercial screens were purchased from Molecular Dimensions (United 
Kingdom). The Alchemist II, CrystalTrakTM software, UV DesktopMinstrel, Phoenix 
software and Gallery 160 Plate Hotel were all purchased from Rigaku Automation, Inc. 
(USA). Sitting-drop crystallisation plates (96 wells), deep-well blocks (96 wells) and UV 
crystallisation plate sealants were all purchased from Molecular Dimensions (United 
Kingdom). Capillary tubes were from Marienfeld-Superior (Germany). Crystals in 
capillary tubes were viewed using an Olympus CKX41 Inverted Microscope (Wirsam, 
South Africa). Cell culture plates (24-wells) were purchased from SPL Lifesciences 
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3.2.2  Expression of the recombinant catalytic domains of TviCATL and TcoCATL in   
P. pastoris 
The glycerol stocks of P. pastoris GS115 cells containing pPic9-TcoCATL and pPic9-
TviCATL were streaked on YPD plates [1% (w/v) yeast extract, 2% (w/v) peptone, 2% 
(w/v) dextrose, 15 g/l bacteriological agar] containing ampicillin (50 µg/ml). The plates 
were incubated at 30ºC for 3 days. Liquid YPD (100 ml) containing ampicillin (50 µg/ml) 
was inoculated with a single colony of P. pastoris yeast. The culture was incubated at 30ºC 
in a baffled flask on an orbital shaking incubator for 2 days. The culture was transferred 
into 1 L BMGY [1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate 
buffer, pH 6.5, containing 1.34% (w/v) yeast nitrogen base without amino acids (YNB)]. 
The culture was grown at 30ºC for a further 2 days (until OD600 of 4-6 was reached) to 
increase biomass. Cells were pelleted (6000×g, 10 min, RT) and resuspended in 500 ml 
buffered minimal medium [BMM, 100 mM potassium phosphate buffer, pH 6.5 containing 
1.34% (w/v) YNB, 0.0004% (w/v) biotin, 5% (v/v) methanol]. The culture was grown in a 
baffled flask covered with 3 layers of cheesecloth to facilitate aeration, and incubated in an 
orbital shaking incubator at 30ºC for 4 days to allow for protein expression. The culture 
was supplemented with 0.5% (v/v) methanol daily to induce protein expression. Cells were 
pelleted (6000×g, 10 min, RT) and supernatants were used for purification of protein. 
 
3.2.3  Purification of recombinant TviCATL and TcoCATL 
Three phase partitioning (TPP): 
Three phase partitioning was carried out according to Section 2.2.3. However, the P. 
pastoris expression supernatants were filtered through Whatman No. 1 filter paper and 
adjusted to pH 4.2 with phosphoric acid prior to the addition of ammonium sulfate and t-
butanol. pH adjustment allowed for CATL-like peptidases to be processed autocatalytically 
to mature proteins. Tertiary-butanol [30% (v/v) final concentration] and ammonium sulfate 
(40% of final volume) were added and stirred until completely dissolved. Supernatant 
mixtures were centrifuged (6000 x g, 10 min, 4ºC) in a pre-chilled spin-out rotor. The 
protein layers were collected at the interface between the t-butanol and aqueous phases and 
re-dissolved in dialysis buffer (PBS, comprising 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.2).  
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Cation exchange chromatography: 
TcoCATL was further purified using cation exchange chromatography. A sulfopropyl (SP) 
Sephadex C-25 cation exchange column (15 x 100 mm) was equilibrated with 50 mM 
sodium acetate buffer, pH 4.2. Dialysed protein was cycled overnight through the column 
at 4ºC (0.5 cm/min). Following cycling, the column was washed with 5 column volumes of 
50 mM sodium acetate buffer, pH 4.2. Bound protein was eluted with a linear NaCl 
gradient from 0 to 1 M in 50 mM sodium acetate buffer, pH 4.2 over 5 column volumes. 
Elution of protein was monitored by measuring the absorbance of each fraction at 280 nm. 
The column was washed with 1 M NaCl (5 column volumes) to remove traces of bound 
proteins. The column was regenerated using one column volume each of 0.1 M HCl and 
0.1 M NaOH. Sodium acetate buffer (50 mM, pH 4.2, 5 column volumes) was further 
added to re-equilibrate the column. 
 
Molecular exclusion chromatography: 
TcoCATL was further purified by molecular exclusion chromatography using a Sephacryl 
S-200 HR column as described in Section 2.2.3. 
 
Concentration of protein: 
Protein was concentrated by ultrafiltration (Centriprep Ultrafiltration device with YM-10 
membrane). Once protein samples were centrifuged (3000 x g, 30 min, 4ºC), the filtrate in 
the filtrate collector as well as the concentrated sample were collected and stored at -80ºC 
until analysed by SDS-PAGE.  
 
Active site titration and inhibition of TcoCATL: 
The determination of the concentration of active TcoCATL was done by active site 
titration with E-64 as described in Section 2.2.7. 
 
3.2.4  Expression of pyroglutamyl peptidase (PGP) 
Glycerol stocks of recombinant E. coli BL21 (DE3) containing pGEX4T1-PGP (Mucache, 
2011) were streaked onto 2x YT plates [1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% 
(w/v) NaCl, 15 g/l bacteriological agar] containing ampicillin (100μg/ml) and incubated 
overnight at 37ºC. Single colonies were picked and grown in liquid 2x YT (100 ml) 
overnight at 37ºC. The overnight culture was transferred into fresh 2x YT liquid media 
(900 ml) containing ampicillin (50 μg/ml). The culture was incubated at 37ºC until an 
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OD600 of 1 was reached whereupon IPTG (0.1 M) was added to induce expression. The 
culture was incubated for a further 4 hours at 37ºC. Cells were pelleted by centrifugation 
(2000 x g, 10 min, 4ºC) followed by resuspension of cells in 20 ml PBS-Tween pH 7.2 
[PBS containing 0.1% (v/v) Tween-20]. To facilitate lysing of the cells, lysozyme was 
added (1 mg/ml) and cells were freeze-thawed (-20ºC; RT) followed by sonication on ice 
for 4 x 30 s with 10 s intervals. Lysed cells were centrifuged (5000 x g, 10 min, 4ºC). The 
supernatant was filtered through Whatman No. 1 filter paper and the peptidase inhibitor, E-
64 (1 mM) was added.  
 
3.2.5  Purification of PGP 
Swollen lyophilised glutathione S-transferase affinity resin (1 ml), packed in a Poly-Prep® 
chromatography column (Bio-Rad, USA), was equilibrated with 20 column volumes of 
PBS (pH 7.4). The filtered supernatant was cycled overnight (4ºC) through the column. To 
remove all unbound material, the resin was washed with 15 column volumes of PBS 
containing 1% (v/v) Triton X-100. Following washing, the column was equilibrated with 
20 column volumes of thrombin cleavage buffer (20 mM Tris-HCl, pH 8.4, 150 mM NaCl, 
2.5 mM CaCl2). Thrombin (5 U) was mixed with thrombin cleavage buffer (1 ml) and 
added to the resin. The thrombin was incubated overnight in the column with gentle 
rocking (RT). The thrombin cleaved the PGP from the GST fusion tag and PGP was 
directly collected from the column. The column was washed with a further 10 column 
volumes of thrombin cleavage buffer to collect any residual PGP left in the column. Bound 
GST and any uncleaved fusion PGP were eluted from the resin with 10 mM reduced 
glutathione (10 ml in PBS, pH 7.4). Fractions containing PGP, as analysed by SDS-PAGE, 
were pooled and concentrated. The addition of 5 column volumes of 100 mM sodium 
borate buffer containing 500 mM NaCl, pH 8.0 followed by 5 column volumes of distilled 
water, 5 column volumes 100 mM sodium acetate buffer containing 500 mM NaCl, pH 4.0 
and a further 5 column volumes of distilled water, was used to regenerate the column. The 
resin was stored in PBS with 0.2% (w/v) NaN3 at 4ºC. 
 
3.2.6  Enzyme activity of PGP 
PGP (1.5 ng) diluted in Brij-35 [0.1% (v/v)] was incubated in enzyme assay buffer (100 
mM Tris-HCl buffer, pH 8.0) at 37°C for 10 min. pGlu-AMC was added (0-100 μM) and 
fluorescence was measured (Ex360 nm and Em460 nm) over 10 cycles in the Fluostar Optima 
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spectrophotometer (BMG Labtach, Germany). Enzyme activity was measured against 
blanks (0-100 μM substrate in enzyme assay buffer). 
 
3.2.7  Quantification of protein 
Purified TcoCATL, TviCATL and PGP were quantified by the methods described in 
Section 2.2.4. Protein was also quantified using a method that involved running equal 
volumes of BSA standards (0.125 – 2 mg/ml) and purified recombinant protein sample on 
a 12.5% reducing SDS-PAGE gel. Proteins bands were visualised by staining with 
Coomassie blue R-250 staining and destaining as described in Section 2.2.5 (Fig 3.1). The 
concentration of recombinant protein was estimated using the “density at tool counter” 







Figure 3.1 Direct visualisation on a reducing 12.5% SDS-PAGE gel for the estimation of recombinant 
protein concentration. Lane 1, molecular weight marker; lanes 2-8, BSA standards (2-0.125 mg/ml); lane 9, 
1/10 dilution of purified PGP; lane 10, 1/20 dilution of purified PGP. 
 
3.2.8  SDS-PAGE gel analysis of recombinant protein 
The SDS-PAGE method (Laemmli, 1970), was used to visualise and analyse protein 
samples as described in Section 2.2.5. 
 
3.2.9  Western blot analysis of recombinant protein 
Western blots of recombinant proteins were carried as described in Section 2.2.6 using 
primary antibodies as anti-TcoCATL N-terminal IgY for TcoCATL and anti-ΔFLM 
TviCATL IgY for TviCATL. The secondary antibody used was rabbit anti-IgY-HRPO 
conjugate.  
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3.2.10  Optimisation of TcoCATL crystallisation conditions 
Prior to designing a screen for TcoCATL crystallisation conditions, a precrystallisation 
trial (Rupp, 2009) was done. One μl of protein was mixed with 1 μl of the highly 
concentrated precipitant, PEG 6000 [30% (w/v)] on parafilm (Pechiney Plastic Packaging, 
IL, USA). The drop was observed immediately under an Olympus CKX41 Inverted 
Microscope (Wirsam, South Africa). Precipitation was an indicator that the protein was 
sufficiently concentrated to crystallise. Optimisation studies were initially carried out for 
TcoCATL. The Protein Data Bank (http://www.rcsb.org/pdb/home/home.do) was used to 
search for proteins with similar sequences to TcoCATL that had been crystallised. Proteins 
identified included native papain (Kamphuis et al., 1984) native papain in complex with a 
recombinant cysteine protease inhibitor derived from T. b. brucei (Alphey and Hunter, 
2006), native papain-E-64 complex (Varughese et al., 1989), human CATL-E-64 complex 
(Fujishima et al., 1997), recombinant TcrCATL in complex with Z-Phe-Arg-CH2F 
(McGrath et al., 1995) or with K11777 (Kerr et al., 2009), recombinant TbrCATL catalytic 
domain in complex with K11777 as well as falcipain-3 (cysteine peptidase from 
Plasmodium falciparum) in complex with K11017 (Kerr et al., 2009). The crystallisation 
conditions for each protein were used to design a crystallisation screen (Fig. 3.2.). 
CrysPred predictor (Kantardjieff and Rupp, 2004) was also used to explore possible pH 
values, based on the proteins’ pI values to incorporate into the screen design (Fig. 3.2). 
Reagents made to be dispensed into a deep well block (Section 3.2.12) included sodium 
citrate (1.6 M), imidazole (1 M, one stock at pH 6.5 and the other at pH 8.5), ammonium 
sulfate (4 M), HEPES (1 M, one stock at pH 6.5 and the other at pH 8.5) and 50% (w/v) 
PEG 6000. A crystallisation plate (described in Section 3.2.11) was prepared for the 
screen. Two different ratios of protein were tested in the subwells of the crystallisation 



























Figure 3.2. Screen design for TcoCATL in crystallisation plate. The top half of the plate (A-E) was used 
to screen TcoCATL with Na-citrate and ammonium sulfate in imidazole (increments of 0.5 in pH values) and 
HEPES (increments of 0.67 in pH values) buffers respectively. In the bottom half of the plate (F-H) different 
PEG 6000 concentrations were tested in HEPES pH values (column 1-5, increments of 0.5 in pH values; 
column 6-12, increments of 0.17 in pH values) and ammonium sulfate concentrations. Protein:crystallant 
ratios tested were 50:50 (green coloured subwell) and 60:40 (blue coloured subwell). The total volume of the 
crystallisation drop was 0.6 μl. 
 
 
3.2.11  Setting up crystallisation screens for recombinant proteins 
The Rigaku CrystalTrak™ application software allows capturing and recording of 
information on protein crystallisation experiments. In order to manage crystallisation 
screen designs, a crystallisation plate needs to be “created” in CrystalTrakTM. 
Crystallisation plates for TcoCATL, TcoCATL mutants, TviCATL and PGP recombinant 
proteins were set up for screens described in Section 3.2.10 and later for the JCSG+ and 
PACT commercial screens (Molecular Dimensions, United Kingdom). Crystallisation plate 
information for screening the crystallisation conditions for each recombinant protein was 
entered into the Plates view in the Setup tab (Fig 3.3). This allows stored images in the 
CrystalTrak™ results section to be filed under a plate name. Plates were named according 
to the screen used and protein screened (e.g. JSCG+TcoCATL). The commercial screen 
designs used were selected from the list of commercial screen designs stored on the 
CrystalTrakTM. For personalised optimisation screens, screens were designed by using the 
screen design option on the CrystalTrakTM (described in Section 3.2.12). A unique barcode 
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ID was assigned to the plate. The barcode was printed and stuck to the plate to allow for 
the correct storage of the plate in the Rigaku Gallery 160 Plate and scheduled imaging 
HotelTM. As there are two subwells for each of the 96 reservoirs in the sitting-drop plate, 
two different ratios of protein:precipitant were tested. The ratios of 67:33 and 50:50 for 
protein:precipitant were selected for the first and second subwell respectively. The total 
volume selected for the drops in each subwell was 0.6 μl. 
 
 
Figure 3.3 Creating and managing a crystallisation plate on CrystalTrakTM. For each plate the name, 
screen design and barcode were created. The amount of protein and crystallant for each subwell of the plate 
were also noted. 
 
3.2.12  Setting up deep well blocks containing crystallisation screen solutions on    
CrystalTrakTM for export to Alchemist IITM 
A deep well block (96 x 1 ml wells) was used to prepare the crystallisation optimisation 
screen. Commercially available screen designs are already stored on the CrystalTrakTM and 
do not have to be designed. For personalised optimisation screens, the CrystalTrakTM is 
used to design the composition of each well in the deep well block. For example for the 
optimisation of crystallisation conditions for TcoCATL (K39F; E44P), two designs, one 
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for PEG 3350 and the other for PEG 6000, were made. Design names were assigned as 
PEG6000_OPT and PEG3350_OPT. The 96 wells, characteristic of the deep well block, 
appeared on the right hand side of the screen (Fig. 3.4). Wells were selected and PEG and 
buffer pH gradients were “added”. The screen design was exported to the Rigaku 
Alchemist IITM software. The Alchemist IITM system is a robotic liquid dispensing unit that 
is able to dispense liquid into a deep well block from stock solutions. 
 
 
Figure 3.4 Screen design on the CrystalTrakTM software. The 96-wells, characteristic of the wells of the 
deep well block are highlighted and chemicals are added for gradient design.  
 
Stock solutions were made, which included sodium citrate buffer (1 M, one at pH 5.0 and 
one at pH 5.5), 50% (w/v) PEG 6000 and 50% (w/v) PEG 3350 and dH2O. The Alchemist 
IITM system was then used to dispense liquid into the deep well block. A crystallisation 
plate, with information about the plate stored in the CrystalTrakTM software and the 
PhoenixTM was used to dispense the solutions comprising the screen (from the deep well 
block wells) and the protein into the crystallisation plate. This plate, like the initial 
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commercial screening plates was loaded in the Gallery 160 Plate HotelTM and scheduled 
inspections of crystallisation drops from plates were recorded. 
 
3.2.13  Using the PhoenixTM for liquid dispensing into the crystallisation plate  
The dispensing of the protein and crystallant screen solutions into the crystallisation plate 
was done by the multiposition, high-throughput liquid-handling robotic stage called the 
PhoenixTM. The PhoenixTM system has Microsoft Windows-based software that allows for 
creating protocols from a list of commands. A specific protocol for the initial screening of 
the crystallisation conditions for the recombinant proteins using the designed screens was 
created (Fig 3.5). Once the protein and crystallant were dispensed into the 96-well sitting-
drop plate, the plate was immediately sealed with sealant (UV sealant) and subsequently 
loaded into a cassette in the Rigaku Gallery 160 Plate HotelTM. The plate was lodged into a 
cassette within the Rigaku Gallery 160 Plate HotelTM. The crystallisation plate is scanned 
and the plates barcode is added to the inventory list and the schedule list on the 
DesktopMinstrelTM system.  
3
 
3.2.14  Scoring images from screening recombinant proteins  
The images of plates taken at scheduled time intervals are shown on the 
DesktopMinstrelTM UV system can be annotated using the CrystalTrakTM Imaging and 
scoring feature in the Results tab. Scoring is divided into four categories on the 
CrystalTrakTM: clear, precipitate, crystal and other (Fig. 3.6). Based on precipitation 
results, crystallisation drops can either have “good” or “bad” precipitate. When the 
precipitation is visible under UV light, the drop can be scored as a good precipitate. If 
heavy precipitate is seen in the drop under visible light and nothing is observed under UV 
light, the drop generally contains a bad precipitate. Crystals can be scored to their size or 
the amount nucleation that has taken place. Although quite subjective, “Bad form” crystals 
are usually overnucleated and form as a shower of microcrystals. “Harvestable crystals” 
can sometimes be badly formed but generally are large singular, three-dimensional 
crystals. Transparent clusters, round droplets, spherolite, phase separation or oil-like films 
are scored from the sub-categories of “Other” (Fig 3.6). 
 
   78 
 
 
Figure 3.5 Creating a protocol using the PhoenixTM liquid handling software. A list of commands are 
situated on the left of the screen to choose from when making a personalised protocol. The right of the screen 
shows the layout of plates on the PhoenixTM as well as what the command will do with respect to each plate.  
 
3.2.15  Setting up hanging drop crystallisation format for growth of TcoCATL (K39F; 
E44P) crystals 
In order to transfer TcoCATL (K39F; E44P) crystals into capillary tubes for shipment to 
Professor Wolf-Dieter Schubert (University of Western Cape) for data collection, the 
crystals were grown using the hanging-drop method. A volume of 900 μl of crystallant 
[18.8% (w/v) PEG 6000, 0.13 M Na-Citrate, pH 5.5] was placed into a well of a 24-well 
cell culture plate. Two μl of each crystallant and TcoCATL (K39F; E44P) were placed on a 
microscope coverslip. The coverslip was inverted and placed on top of the well. To ensure 
an air-tight seal between the coverslip and the well, a small amount of silicon was placed 
around the rim of the well before the coverslip was placed over the well. Crystals grown 
from the hanging drop were transferred into a capillary tube. The capillary tube was sealed 
on either ends with beeswax. 
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Figure 3.6 Scoring stored images on the CrystalTrakTM. Images are scored according to the scores 
categorised as clear, precipitate, crystal or other, as shown on the left of the screen. Each of the scores are 
sub-divided into different characteristics of the score. 
 
 
3.3  Results 
3.3.1  Expression and purification of TcoCATL and TviCATL 
TcoCATL was recombinantly expressed in P. pastoris. TcoCATL was observed as a band 
of approximately 27 kDa (Fig. 3.7, lanes 2, outlined by red box, and 3), showing that 
TcoCATL was actually processed to its mature form before being subjected to acidification 
to allow for autocatalytic cleavage of the propeptide (Boulangé et al., 2001; Serveau et al., 
2003; Vernet et al., 1995). Three phase partitioning, as an initial purification and 
concentration step for TcoCATL, allowed for TcoCATL to optimally precipitate in 40% 
ammonium sulfate. At 40% ammonium sulfate precipitation, two other proteins of 36 and 
38 kDa also precipitated (Fig. 3.7, lane 3). The presence of higher molecular weight 
contaminants required further purification steps. 
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TcoCATL started eluting at approximately 200 mM NaCl on a SP Sephadex C-25 column 
as shown by higher A280 readings of the fractions (Fig. 3.8, panel A). Fractions 18-28 were 
analysed on a SDS-PAGE gel (Fig. 3.9, panel B). Purification of TcoCATL was achieved 
using cation exchange chromatography which separated the TcoCATL from higher 
molecular weight contaminants observed after TPP (Fig. 3.8, panel B). TcoCATL could be 
observed as a doublet of 26 and 27 kDa on the SDS-PAGE gel. The faint lower molecular 
weight bands of 21.5 and 18 kDa were speculated to be degradation products of TcoCATL 
resulting from autocatalytic activity. 
 












Figure 3.7 Purification and concentration of TcoCATL from expression supernatant by three phase 
partitioning (TPP). TcoCATL from P. pastoris expression supernatant was purified and concentrated by 
TPP, using 40% ammonium sulfate, and analysed on a 12.5% reducing SDS-PAGE gel. Lane 1, molecular 
weight marker; lane 2, TcoCATL from expression supernatant; lane 3, TcoCATL precipitated using TPP. 
 
 
To further purify the TcoCATL sample, the fractions collected from cation exchange 
chromatography were pooled and concentrated by ultrafiltration before separation on the 
molecular exclusion chromatography column. Monitoring the absorbance of eluted 
samples at 280 nm and their hydrolysis of Z-Phe-Arg-AMC showed elution of TcoCATL 
at 27 kDa (Fig. 3.9). However, elution at a highly molecular weight has been previously 
shown. It was proven to be attributed to a dimeric TcoCATL conformation (Ndlovu, 2010). 
Lower molecular weight contamination was still present (Fig. 3.9), confirming that the 
lower molecular proteins could be degradation products of TcoCATL.  
 











































































Figure 3.8 Purification of TcoCATL by cation exchange chromatography. Panel A, elution of TcoCATL 
from an SP Sephadex C-25 column (1.5 × 10 cm, 0.5 cm/min) using a 0-1 M NaCl (   ) gradient in 50 mM 
sodium acetate buffer, pH 4.2. Fractions were monitored by reading the absorbance at 280 nm (   ) and 
measuring the hydrolysis of Z-Phe-Arg-AMC (▲). Panel B, analysis of the purity of the peak fractions by 
reducing SDS-PAGE (12.5%). Lanes 1 and 8, molecular weight marker and lanes 2-7 and 9-13, fractions 18-
23 and 24-28 eluted from the column. 
B 
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Fractions containing TcoCATL obtained from molecular exclusion chromatography were 
pooled and concentrated using ultrafiltration. The concentration of TcoCATL was 
calculated to be 7 mg/ml, giving a 7-fold higher yield than that obtained for the expression 
of TcoCATL in baculovirus (Boulangé et al., 2001). Both the ultrafiltration filtrate and the 
concentrated TcoCATL sample were analysed on a SDS-PAGE gel (Fig. 3.10, panel A). 
The 21.5 kDa band seen in the concentrated sample was recognised by the anti-TcoCATL 
N-terminal peptide IgY in a western blot (Fig. 3.10, panel B), verifying the autoproteolytic 
activity of TcoCATL under reducing conditions.  
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Figure 3.9 Purification of TcoCATL by molecular exclusion chromatography. Panel A, elution of 
TcoCATL from a Sephacryl S-200 column (25 x 650 mm, 12.2 cm/min) in 0.02 M Tris-HCl, pH 7.6, 0.02% 
(w/v) NaN3. Fractions were monitored by reading the absorbance at 280 nm (  ) and by measuring the 
hydrolysis of Z-Phe-Arg-AMC (---). Panel B, analysis of the purity of the peak fractions by reducing SDS-
PAGE gel (12.5%). Lanes 1 and 9, molecular weight marker and lanes 2-8 and 10-12,  fractions 26-32 and 
33-25 from Sephacryl S-200 column. 






















Figure 3.10 Analysis of concentrated TcoCATL by reducing SDS-PAGE gel and western blotting. 
Panel A, TcoCATL samples purified by molecular exclusion chromatography were pooled and concentrated 
by ultrafiltration and analysed on a reducing 12.5% SDS-PAGE gel. Lane 1, molecular weight marker; lane 
2, ultrafiltration filtrate; lane 3, concentrated TcoCATL sample. Panel B, western blot of concentrated 
TcoCATL probed with anti-TcoCATL N-terminal IgY (10 μg/ml). Secondary antibody was rabbit anti-IgY 
(1:10 000 dilution). Development was achieved with H2O2 and 4-chloro-1-naphthol. Lane 1, concentrated 
TcoCATL sample. 
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Since co-crystallisation performed with inhibitors can be favourable for crystallisation and 
reduce protein microheterogeneity through autoproteolysis (Ostermeier et al., 1997), 
TcoCATL was incubated with a range of concentrations of E-64 (Fig. 3.11, panel A). This 
active-site titration allowed calculation of the concentration of active TcoCATL. Twenty % 
of the TcoCATL was active which amounted to a concentration 1.4 mg/ml active enzyme. 
Consequently 0.1 mM E-64 (molar excess of active TcoCATL) was added to the TcoCATL 
sample and analysed on a SDS-PAGE gel, resulting in a single band of 27 kDa (Fig 3.11, 
panel B), evidence of inhibition of the autocatalytic activity of TcoCATL.  
 
TviCATL was expressed in the P. pastoris expression system. Analysis of the expression 
supernatant and the TPP sample showed that TviCATL expressed as two bands at 
approximately 29 and 33 kDa. As in the case of TcoCATL, autocatalytic cleavage of the 
propeptide occurred in the expression supernatant, prior to acidification for removal of 
propeptide (Fig. 3.12, panel A). Both bands were recognised when probed with anti-
ΔFLTviCATL IgY (Fig. 3.12, panel B). Treatment with endoglycosidase H has previously 
shown that a single band is obtained following deglycosylation of the possible 
glycosylation site at Asn288 (Vather, 2010). No further purification after TPP was needed 
for TviCATL. The TPP sample was concentrated to 10 mg/ml, adequate for crystallisation 
studies. 
 
A                                                                                                  B 















Figure 3.11 Active site titration of TcoCATL and reducing SDS-PAGE analysis of TcoCATL incubated 
with E-64. Panel A, TcoCATL (1 μM) was incubated with different concentrations of E-64 (0.1-1 μM) 
followed by measuring hydrolysis of Z-Phe-Arg-AMC. Panel B, analysis of TcoCATL inhibited with 0.1 
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Figure 3.12 Purification and concentration of TviCATL from expression supernatant by three phase 
partitioning (TPP). Panel A, TviCATL from P. pastoris expression supernatant was purified and 
concentrated by TPP, using 40% ammonium sulfate, and analysed on a 12.5% reducing SDS-PAGE gel. 
Lane 1, molecular weight marker; lane 2, TviCATL from expression supernatant; lane 3, precipitated 
TviCATL after TPP. Panel B, western blot of concentrated TviCATL probed with anti-ΔFLM TviCATL IgY 
(10 μg/ml) followed by rabbit anti-IgY-HRPO conjugate (1:10 000 dilution). Development was achieved 
with H2O2 and 4-chloro-1-naphthol. Lane 1, molecular weight marker; lane 2, concentrated TviCATL sample. 
 
3.3.2  Expression and purification of PGP 
E. coli JM109 cells carrying the recombinant pGEX4T1-PGP were grown in 2x YT liquid 
media and induced with IPTG. PGP expressed as a 51 kDa protein as can be seen when 
comparing induced and uninduced expression samples (Fig. 3.13, lanes 2 and 3). PGP was 
released from GST by thrombin cleavage during the purification which resulted in a 28 
kDa PGP sample (Fig. 3.13, lanes 5-10). Free GST was eluted at 25 kDa upon the addition 
of glutathione to the column (Fig. 3.13, lanes 19 and 20 and lanes 22-29). Samples 
containing PGP were reapplied to the regenerated GST-bind column as a means to remove 
contaminating proteins of sizes 35, 33, 25 and 20 kDa that coeluted with the first few 
purified PGP fractions (Fig. 3.13, lanes 5-10). PGP was concentrated by ultrafiltration and 
was analysed by direct visualisation on an SDS-PAGE gel with BSA standards (Fig 3.1). 
The purified PGP sample was calculated to be 7.5 mg/ml, adequate for crystallisation 
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Figure 3.13 Analysis of PGP purification on a reducing 12.5% SDS-PAGE gel. Glutathione S-
Transferase affinity chromatography purification. Lane 1, 11 and 22, molecular weight marker; lane 2, 
uninduced recombinant E. coli JM109 lysate; lane 3, induced recombinant E. coli JM109 (DE3) lysate; lane 
4, unbound lysate; lanes 5-15 eluted PGP fractions; lanes 16-29, elution of GST. 
 
3.3.3  Interpretation and scoring using a manual screen of TcoCATL crystallisation 
conditions 
Concentrated and purified recombinant TcoCATL precipitated in the precrystallisation 
trial, proving to be concentrated enough for crystallisation screening. The visible and UV 
light images for each drop in the manual crystallisation screen were analysed every second 
day. The five major aspects that were compared were the concentration range of sodium 
citrate (0.7-1.3 M), the pH range of imidazole (pH 6.5-8.5), the concentration range of 
ammonium sulfate (0.8-3.2 M), the pH range of HEPES (pH 6.5-8.5) and the concentration 
of PEG 6000 at lower ammonium sulfate concentrations. After 20 days, images from 
crystallisation drops were either ‘Clear’ or had ‘Phase separation’ (Fig. 3.14). ‘Clear’ was 
allocated to crystallisation drops where no nucleation event had occurred and the visible 
and UV light images for crystallisation drop remained clear. ‘Phase separation’ was shown 
by small droplets within the crystallisation drop. The concentration of sodium citrate 
affected the level of phase separation more than the pH range of imidazole. Phase 
separation was seen across the pH range of imidazole. However the level of phase 
separation steadily decreased over the increasing concentration of sodium citrate. Phase 
separation was found across the pH range of HEPES (pH 6.5-8.5) and ammonium sulfate 
(0.8-3.2 M). The most promising condition was the phase separation found for the 60:40 
ratio of protein: crystallant in the crystallising reagent of 1.4 M ammonium sulphate with 
0.1 M HEPES buffer, pH 7.17 (Fig. 3.14, C and D). All crystallisation drops that contained 
PEG 6000 at 20 and 25% (w/v) over the HEPES pH range (6.5-8.5) and ammonium sulfate 
concentration range (0.1-0.3 M) were scored as clear. Whether the PEG 6000 or lower 
concentration levels of ammonium sulfate caused the crystallisation drop to remain clear is 
still to be determined.  
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Figure 3.14 Scoring of crystallisation drop results from manual screen. Proteins were screened with 
conditions based on conditions of related proteins previously crystallised. After 20 days crystallisation drop 
images viewed under visible and ultraviolet (280 nm) light were scored according to appearance. A and B, 
clear drop; C and D, phase separation. 
 
 
3.3.4  Scoring images from commercial crystallisation screens 
The purified and concentrated TcoCATL, TcoCATL mutants, TviCATL and PGP were 
screened using the JSCG+ and PACT commercial screens. The images were looked at 
weekly and on day 30, images were scored. Images were scored according to the scoring 
table available on the Rigaku CrystalTrakTM software. As a reference, images were also 
compared to published images (Zeelen, 2009). Similarly to the manual screening, if no 
nucleation event had occurred and the visible and UV light images for crystallisation drop 
remained clear, the ‘clear’ score was then allocated (Fig. 3.15, panels A and B). However a 
‘Good precipitate’ was one where precipitate was seen in the crystallisation drop under 
visible light and the distinct protein precipitation absorbed ultraviolet (UV) light at 280 nm 
(Fig. 3. 15, panels C and D). On the other hand a ‘Bad precipitate’ was a dark protein 
precipitate observed under visible light which was not detected at 280 nm (Fig 3.15, panels 
E and F).  
The two hits, using the PACT screen, from TcoCATL (K39F; E44P) that were found at 30 
days after screening the six recombinant proteins with different screens, were scored as 
‘Crystals-bad form’ (Fig. 3.15, panels G and H and I and J) due to their needle-like, one-
dimension form. The crystallant from the two hits both contained 0.1 M sodium citrate 
buffer with a protein:precipitant ratio of 67:33. However, the one hit contained 20% (w/v) 
PEG 3350, with the sodium citrate buffer at pH 5.5 and the other contained 20% (w/v) 
PEG 6000, with the sodium citrate buffer at pH 5.0. The hits were generated at a 
temperature of ca 21°C. These were the only two conditions in the screen that had a pH of 
5 and 5.5.  
 
   87 
 
3.3.5  Optimisation of TcoCATL (K39F; E44P) crystals  
To improve the one-dimensional crystals of TcoCATL (K39F; E44P), the pH, protein 
concentration and PEG concentration (for both PEG 3350 and PEG 6000) were optimised. 
Crystals were grown within 3 days under many of the conditions (Fig. 3.16). Although 
most of the crystals were still needle-like there were variations within the size and diameter 
of the crystals. Overnucleation seemed to be a problem due to the shower of microcrystals 
in some of the drops. The optimisation screen containing PEG 6000 yielded slightly 
broader crystals than that of the PEG 3350 [Fig. 3.16 (g and i)]. One of the crystals 
produced here (Fig. 3.16 [g]) had more dimension than the one-dimensional needle-like 
crystals seen in Fig 3.15 (G and I). 
 
    Visible light                           UV                            Visible light                        UV  
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Figure 3.15 Scoring of crystallisation drop results from commercially available screens. Proteins were 
screened with different commercial screens and after 30 days crystallisation drop images observed under 
visible and ultraviolet (280 nm) light were scored according to appearance. A and B, clear drop; C and D, 
good precipitate; E and F, bad precipitate; G and H and I and J, crystals-bad form. 
 
To check whether some of the crystals could diffract under the X-ray beam, they were sent 
to Professor Wolf-Dieter Schubert, University of the Western Cape. The sitting-drop 
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crystallisation plate was not ideal for sending the crystals in a safe and secure manner and 
the crystals needed to be transferred into capillary tubes (1 mm diameter). Crystals were 
grown using the hanging drop method for 3 days at 21°C, with protein:crystallant ratio of 
80:20 and the total drop volume was 4 μl. The big size of the drop along with growing the 
crystals on the flat surface of the coverslip as opposed to the well of a sitting drop allowed 
for crystals to be transferred into capillary tubes via capillary action. Once the crystals 
were grown, an additional 3 μl of crystallant was added to the drop to bulk up the volume 
of the drop. The capillary tube was viewed under an Olympus CKX41 Inverted 
Microscope (Fig. 3.17). The capillary tube, sealed on either ends with beeswax, was sent to 
the University of Western Cape.  
 
      Visible light                        UV                            Visible light                          UV 
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Figure 3.16 Crystals from optimisation crystal screen of TcoCATL (K39F; E44P). Images were taken of 
drops under visible as well as ultraviolet (280 nm) light, these are from day 3. All drops contained a ratio of 
protein:crystallant of 80:20 with the total drop volume being 1 μl and all crystals were grown at a constant 
temperature of ca 21°C. The concentration used for each condition was 10 mg/ml. Panel A, contained PEG 
3350 and panel B contained PEG 6000. Panel A, a, b, 22% (w/v) PEG 3350, 0.1 M Na-citrate, pH 5.3; c, d, 
19.8% (w/v) PEG 3350, 0.09 M Na-citrate, pH 5.1; e, f, 25% (w/v) PEG 3350, 0.13 M Na-citrate, pH 5.0. 
Panel B, g, h, 20% (w/v) PEG, 0.1 M Na-citrate, pH5.0; i, j, 18.8% (w/v) PEG 6000, 0.13 M Na-citrate, pH 
5.5; k, l, 15% (w/v) PEG 6000, 0.13 M Na-citrate, pH 5.0.  
A                                                                            B 
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A single crystal was tested for its ability to diffract. The diffraction was, however, weak. 
Reflections on the diffraction map (results not shown) were all near the origin indicating 
that it was a protein crystal. If it was salt, one would expect to see only a hand full of 
reflections distributed all over the detector. However, there were three reflections defining 
a right-angled triangle. This would appear to indicate that at least one of the angles of the 




Figure 3.17 TcoCATL (K39F; E44P) crystals sealed in capillary tubes. Crystals were grown using the 
hanging drop technique at 21°C for 3 days. The protein:crystallant ratio was 80:20 in a total volume of 4 μl. 
Crystals were grown in 18.8% (w/v) PEG 6000, 0.13 M Na-citrate, pH 5.5. Crystals transferred into capillary 
tubes were viewed using the Olympus CKX41 Inverted Microscope (20x).  
 
 
3.4  Discussion 
Over most of sub-Saharan Africa, bovine trypanosomosis continues to be controlled 
primarily by trypanocidal compounds such as isometamidium chloride, homidium 
(bromide and chloride) and diaminazene (Holmes et al., 2004). The classification of 
trypanosomosis as being a neglected disease, by the World Health Organisation in 1975, 
has attracted researchers to the developments of more effective and new drugs. The vinyl 
sulfone inhibitor of TcrCATL, K11777, was effective in curing or alleviating T. cruzi 
infection in preclinical proof-of-concept studies and has now entered formal preclinical 
drug development for Chagas’ disease (McKerrow et al., 2009). This provides hope for 
chemical knockout of other pathogenic cysteine peptidases. Furthermore, the anti-disease 
vaccine approach targeting cysteine peptidase pathogenic factors (Authié, 1994) does, 
however, still hold promise. Based on the ability of trypanotolerant cattle to produce a 
higher antibody response to TcoCATL compared to trypanosusceptible cattle, 
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immunisation of cattle with baculovirus expressed TcoCATL provided evidence for cattle 
maintaining or gaining weight as well as less severe anaemia development (Authié et al., 
2001). It is therefore imperative that the structure of pathogenic factors, such as the 
peptidases, be determined to understand the resultant structure has on function and design 
better vaccines and chemotherapeutics. In this part of the study, TcoCATL, TcoCATL 
mutants, TviCATL and PGP cysteine peptidases were recombinantly expressed and 
purified for crystallisation. 
 
 Both catalytic domains of TcoCATL and TviCATL as well as the TcoCATL mutants were 
expressed and purified to homogeneity at sufficiently high concentrations for screening of 
crystallisation conditions. Although full-length TcoCATL has been expressed at 
concentrations of 2-4 mg/l in yeast, the peptidase has shown to be highly unstable 
(Boulangé et al., 2011). It is not clear why the full-length peptidase is unstable, however, it 
is known that the unique C-terminal extension of trypanosomal cysteine peptidases does 
not play a role in stability or activity of the active enzyme (Cazzulo et al., 1997). 
Moreover, the aim of the expression of the full-length TcrCATL by Alvarez et al (2002) 
was to determine the 3-D structure by X-ray diffraction of the C-terminal domain and to 
date, crystallisation has not been achieved possibly due to the instability of the C-terminus 
in the formation of ordered and packed crystals. The proregion was included in the 
constructs for these recombinant proteins as it plays a pivotal role in the correct folding of 
the expressed protein, as in the case for cathepsins (Vernet et al., 1995). Although failure 
to express TcoCATL in a bacterial system has been previously reported (Boulangé et al., 
2001), TcrCATL has been successfully expressed in a bacterial expression system as an 
active enzyme both in full-length and truncated forms (Eakin et al., 1993). Prior to 
TcoCATL expression in P. pastoris (Boulangé et al., 2011), TcoCATL was expressed in a 
baculovirus system, with a yield of 2 mg/ml (Boulangé et al., 2001). It was the relative 
complexity, incorrect folding of the expressed enzyme and cost of the baculovirus 
expression system that led to the use of the alternative P. pastoris expression system. Like 
the baculovirus system, and unlike the bacterial system, P. pastoris allows for post-
translational modifications such as proteolytic processing, folding, disulfide bond-
formation and glycosylation of protein (Wu and Letchworth, 2004).  
 
Both TcoCATL and TviCATL could be observed as doublets on reducing SDS-PAGE gels. 
The size difference between the protein bands for TviCATL is more prominent than those 
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of TcoCATL. Previous deglycosylation tests with endoglycosidase H have shown that the 
double band of TviCATL is changed to a single band on a reducing SDS-PAGE gel, 
suggesting that Asn288, a possible glycosylation site, becomes deglycosylated (Vather, 
2010). Glycosylation sites for TcoCATL are proposed to be located in the proregion. The 
proregion contains four asparagine residues (Asn67, Asn78, Asn102 and Asn119) that 
could be potentially glycosylated. However, because most of the proregion is removed 
during maturation, glycosylation is a less likely reason for the formation of a double band. 
It was previously shown that the TcoCATL proenzyme mutant (C25A) is glycosylated by 
performing the endoglycosidase H test (Ndlovu, 2010). The less prominent second band 
seen in the purification process of TcoCATL could possibly be a result of the several 
cleavage sites used during the in vitro maturation process of the proenzyme, as described 
for other cysteine peptidases (Vernet et al., 1995). Similar findings have been illustrated 
for TcrCATL (Eakin et al., 1993), TbrCATL (papain-like cysteine peptidase from T. b. 
rhodesiense) (Caffrey et al., 2001) and TcoCATL 1, a closely related cysteine peptidase of 
TcoCATL found in the T. congolense genome that shares 90% sequence identity with 
congopain (Boulangé et al., 2001). The higher molecular weight protein (29 kDa) of the 
TcoCATL 1 doublet contained 3 amino acids upstream of the predicted maturation site, 
while the lower band (28 kDa) corresponded to the catalytic domain and 1 amino acid of 
the proregion (Boulangé et al., 2001). The size difference between the two protein bands is 
similar for TcoCATL in the present study. This likely demonstrates processing of the 
TcoCATL proenzyme along a cleavage sites in the proenzyme. In the case of TcrCATL 
and TbrCATL, N-terminal sequencing revealed that the band of higher molecular weight 
band contained also 3 amino acids upstream of the cleavage of the proenzyme. However, 
after complete inhibition of TcoCATL by E-64, a single band was observed on the 
reducing SDS-PAGE gel.  
 
Similarly to TcoCATL, the TcoCATL mutants: TcoCATL (H43W) and TcoCATL (K39F; 
E44P), migrated as monomers of 27 kDa suggesting that their propeptides were cleaved off 
under acidic pH (Ndlovu, 2010). The inactive mutant TcoCATL (C25A), where the active 
site Cys residue was mutated does not undergo spontaneous cleavage when subjected to 
acidic pH (Boulangé et al., 2011). Full length recombinant TbrCATL and TbrCATL 
lacking the C-terminal extension were produced as already cleaved products in the yeast 
expression supernatant (Caffrey et al., 2001). Auto-activation had taken place in the 
expression medium and only a ‘clean up’ step was required at acidic pH to remove the very 
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small residual amounts of proenzyme. Analysis of the expression supernatant revealed that 
processing of the proregions of both TcoCATL and TviCATL did take place in the 
expression medium. As was the case for TbrCATL, the manual change of pH to an acidic 
pH facilitated a ‘clean up’ of the TcoCATL and TviCATL proform. The secretion of 
mature TbrCATL, TcoCATL and TviCATL contrasts with the production of CATF (Wang 
et al., 1998) and CATV (Brömme et al., 1999), which are produced as proenzymes in the 
same expression system. The TcoCATL mutants were also shown to be processed in the 
expression medium (Ndlovu, 2010). Maturation of TcoCATL has also been shown to occur 
at pH 8.0 in the presence of dextran sulfate, which for a papain-like enzyme is quite 
extraordinary (Serveau et al., 2003). It can merely be suggesed that TcoCATL could 
potentially be processed in the mammalian bloodstream of the infected host to its active 
form and as a result contribute to the pathogenesis of the disease (Serveau et al., 2003). In 
addition, TcoCATL, unlike TcoCATL 1 has shown to hydrolyse substrates over a wide pH 
range, from 4.0 to 8.5 (with the optimum being pH 6.0) (Lalmanach et al., 2002), adding 
further evidence of activity at physiological as well as lysosomal pH.  
 
The homogeneity of each of the peptidases was evaluated after the purification process. 
TPP proved very successful in concentrating protein from the large volume expression 
supernatants. TPP is very reproducible, cheap and saves a large amount of time for the 
purification and concentrating process (Pike and Dennison, 1989). In addition the t-butanol 
allows the protein to float on the aqueous layer because t-butanol bound protein lowers the 
protein density (Pike and Dennison, 1989), which is advantageous in relation to general 
salting out. Both cation exchange and molecular size exclusion chromatography proved 
successful in removing contaminating proteins as evident by the SDS-PAGE gels. It has 
been mentioned in numerous studies that the purer the biological macromolecule the better 
the chance of obtaining crystals for diffraction studies (Benvenuti and Mangani, 2007; 
Derewenda, 2004; Gilliland and Ladner, 1996). For commercial preparations of lysozyme, 
three classes of impurities have been classified that influence crystallisation behaviour: 
contaminating proteins, small molecules and heterogeneous forms of the enzyme (Ewing et 
al., 1996). Heterogeneous forms of lysozyme appeared to have the greatest perturbing 
influence on crystallisation behaviour. Glycosylation has been said to interfere with 
crystallisation as the flexible and heterogeneous carbohydrate moieties can account for a 
significant fraction of the surface area of the protein, interfering with the crystallisation 
process (Derewenda, 2010). However, in a number of cases glycoproteins have been 
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successfully crystallised and the carbohydrate groups have actually facilitated the 
crystallisation process as the deglycosylated counterparts fail to crystallise (Aleshin et al., 
1994; Mark et al., 2003). For the production of diffracting procathepsin L crystals, a 
T110A mutation was done to remove the O-linked glycosylation site (Coulombe et al., 
1996). In the case of TbrCATL crystals, the S172A mutation was made to remove the O-
linked glycosylation site (Caffrey et al., 2001). As previously mentioned, TviCATL and 
TcoCATL (C25A) are both glycosylated and as a starting point in the study, an 
investigation was undertaken to see whether the glycosylated proteins were also able to 
crystallise.  
 
The fact that TcoCATL, TcoCATL mutants and TviCATL were efficiently purified and 
yielded relatively high concentrations (> 5 mg/ml) allowed for crystallisation trials to be 
performed. The Rigaku crystallisation robotics has shown to increase the success rate of 
protein crystallisation, the major bottleneck to determining protein structure (Stevens, 
2000; Buba et al., 2008). Prior to initial screening, the E-64 treated TcoCATL was to be 
present as a single protein band on an SDS-PAGE gel. There were no contaminating 
proteins or degradation products of TcoCATL present in the TcoCATL-E-64 mixture. 
TviCATL was characterised as being glycosylated and active (activity not shown). The 
TcoCATL mutants and PGP were not inhibited since they were present as a single band of 
protein. These are important biophysical characterisations that were recorded as future 
crystallisation studies could start with the manipulation of the biophysical character of the 
enzyme. However, other biophysical characterisations are available which concentrate 
more on protein folding and structure to determine initial crystallising ability. Two of the 
customarily employed methods for biophysical characterisation include emission 
fluorescence and light scattering (Derewenda, 2010). Emission light scattering allows 
measurement of changes in the fluorescence as a protein unfolds and/or undergoes 
important conformational changes induced by ligand/inhibitor binding.  Dynamic light 
scattering is used in the monitoring of crystallisation trials because it detects the formation 
of aggregates or nuclei before they become visible using microscopy (Bergfors, 1999; 
Tessier and Lenhoff, 2003).  
 
The phase separation produced by the different crystallisation conditions employed for the 
manual screening did provide a starting point of further screening. Phase separation can 
give rise to very high protein concentrations, with the protein concentrating in one of the 
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phases than the other, leading to extremely high protein concentrations and subsequently 
high states of supersaturation (McPherson, 2009). Furthermore, phase separation creates a 
boundary between the two solvents, serving as a nucleation center (McPherson, 2009). 
Besides the further manual screening that did not provide substantially different results to 
the original manual screening, commercial screening was done. Commercial screening 
provides a considerably large variation of crystallant reagents. JCSG+ and the PACT 
screens are known as the evolution and intelligent design respectively (Newman, 2009). 
The JCSG+, originally designed as the Core screen (Page et al., 2003), composed of 67 
conditions that were extracted from 480 conditions, from 10 commercially available 
screens and tested on 539 proteins from Thermatogamaritima. This screen was expanded 
to the present 96 conditions (Page and Stevens, 2004). The PACT screen tests the effect of 
pH in 1 pH unit increments with multicomponent buffers. Furthermore, six cations and 12 
anions are tested. The sitting drop vapour diffusion method employed for the 
crystallisation trials with commercial screens, using the Rigaku robotics, allowed for each 
of the 96 conditions from each of the two screens to be explored at two different 
concentrations of protein (two subwells for each of the 96 conditions on the sitting-drop 
plate). Effectively, this amounted to 384 conditions that were initially tested for each 
protein. The sitting-drop technique has benefits over the hanging-drop plating method such 
as cost and efficiency (Bolanos-Garcia and Chayen, 2009). The nanodrop needle of the 
Rigaku PhoenixTM liquid dispensing unit, which works at a high throughput speed, is able 
to efficiently dispense protein on to the sitting-drop crystallisation plate using minimal 
protein sample, typically less than 5 μl. 
 
The two initial hits that were found for the double mutated TcoCATL (K39F; E44P) were 
one-dimensional needle-like crystals. It has been said that needles are sometimes big 
enough to be used at the microfocusing beam at the synchrotron for X-ray diffraction 
(Zeelen, 2009). Optimisation results showed some form of overnucleation where many of 
the conditions produced a shower of smaller, microcrystals. However some crystals did 
have more dimension than others. The hanging-drop technique was used to grow crystals 
for the transfer into capillary tubes that could be sealed and sent off to the University of 
Western Cape for X-ray diffraction. The hanging-drop technique reduced the occurrence of 
hardware crystal adherence, as has been described previously (Bolanos-Garcia and 
Chayen, 2009).  The weak diffraction pattern could have been attributed to the treatment of 
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the crystals, such as temperature and pressure variations as well as handling (Prof W.D 
Schubert, University of Western Cape, personal communication).  
 
The number, ultimate size and possibly the quality of crystals depend on the mechanisms 
and the rates of nuclei formation (McPherson, 2009). Limited overnucleation by the 
adjustment of the physical and chemical properties of the crystallisation solutions used in 
screens are being pursued at present. Higher levels of supersaturation are required for 
nuclei to form than for subsequent crystal growth (Luft and DeTitta, 1999). The “labile 
zone” (from a crystallisation phase diagram) is the phase where nucleation takes place. 
After spontaneous nucleation, a lower level of supersaturation, referred to as the 
“metastable zone” is sufficient to support crystal growth. The ideal experiment should 
uncouple nucleation from crystal growth to satisfy the requirements of the two-phase 
events. It has been shown that seeding, through either streak seeding (Stura and Wilson, 
1991) or microseeding (Luft and DeTitta, 1999) is the best method for uncoupling 
nucleation from crystal growth. Seeding should be carried out in the metastable zone of the 
phase diagram, which is generally achieved by placing seeds in a crystallisation drop of 
lower protein or crystallant concentration. Other chemical modifications that could also be 
evaluated involve additives such as detergents, reducing agents and heavy metal 
compounds. Mutations of residues involved in glycosylation and enzyme activity are being 
pursued. Furthermore, other inhibitors such as chloromethylketones and 
diazomethylketones for the cysteine peptidases are being used in complex with the enzyme 
for crystallisation screening. However every decision depends on the outcome of the 
previous crystallisation experiment which requires time to equilibrate and give positive and 
negative results. Moreover, between every experiment the protein sample ages which can 
have detrimental effects on the outcome of crystallisation. 
 
Trypanosomal cysteine peptidases were recombinantly expressed and purified to 
homogeneity. The concentration of the purified proteins was suitable for crystallisation 
screening. Manual crystallisation screening of TcoCATL, based on conditions of related 
proteins previously crystallised, produced promising results. Some crystallisation drops 
showed phase separation which can give rise to higher protein concentrations and creates a 
boundary between the two solvents serving as a nucleation center. Furthermore, one-
dimensional TcoCATL (K39F; E44P) crystals were grown in some crystallising reagents 
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of the PACT commercially available screen. Crystals collected after optimisation screening 
produced a weak diffraction pattern. Nonetheless, manipulations of crystallising conditions 
are still underway. The crystal structure of TcoCATL will be of major significance to the 
design of specific chemotherapeutic agents. In addition, understanding the dimeric 
conformation of TcoCATL is important for vaccine design as immune response are likely 























   97 
 
 
CHAPTER 4  
GENERAL DISCUSSION 
 
African animal trypanosomosis (Nagana) is a major limitation to livestock farming in 
Africa (Kristjanson et al., 1999). Ten million km2 are infested with the disease vector, 
tsetse flies (Kabayo, 2002) where at least 46 million cattle and 70 million small ruminants 
are exposed to the risk of contracting trypanosomosis (Kristjanson et al., 1999). This 
widespread disease affects 40 African countries and is costing the African continent US 
$4.75 billion per year (Van den Bossche et al., 2010). In the acute stages of the disease, 
livestock usually develop fever and anaemia. The chronic stage occurs when cattle develop 
cachexia and both milk production and the oestrous cycle are impaired. The chronic phase 
can lead to death or in some cases self-cure or a persistent carrier state (Taylor and Authié, 
2004).  
 
Isometamidium chloride, homidium (bromide and chloride) and diaminazene are used, 
over most of sub-Saharan Africa, as the primary control for bovine trypanosomosis 
(Holmes et al., 2004). However, these drugs have been used for more than 50 years 
(Kroubi et al., 2011) and there is a need to develop drugs that are more therapeutic, combat 
resistance and possess fewer side effects. Other strategies for controlling the disease 
include the eradication or control of the tsetses fly populations. Besides targets and traps 
being used extensively in small agriculture settings (Vale, 1993), insecticides, such as 
pyrethroids, are also being used (Allsopp and Hursey, 2004; Eisler et al., 2003). 
Furthermore, other approaches to tsetse control have involved the sterile insect technique, a 
genetic population suppression approach that involves sustained, systematic releases of 
irradiated sterile male insects among the wild population (Aksoy, 2003).  
 
Trypanosomes are able to continuously evade the host antibody response, with the 
generation of an inexhaustible collection of variable surface glycoproteins (VSGs) that 
cover the surface of the trypanosomes. Vaccination studies targeting VSGs of the parasite 
were proven to be ineffective as trypanosomes evade host antibody responses through the 
continuing changes in VSGs (Morrison et al., 1982). Other vaccination strategies have 
evaluated non-variable antigen-based vaccines. Trypanosomes express less variable 
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surface antigens such as invariant surface glycoproteins (ISGs). Although initial work on 
mice challenged with T. b. brucei after immunisation with ISG75 proved unsuccessful 
(Tran et al., 2008), other ISGs are being assessed. Alternatively, transmission blocking 
vaccines, aimed at reducing transmission of the trypanosome through immunisation of the 
host against insect parasite stages have been researched. However, the approach to this 
vaccine does have an ethical problem in that it does not protect the vaccinated individual 
against the infection but would however ultimately result in reduced numbers of infectious 
vectors. Anti-disease vaccines, have been considered as an promising approach in livestock 
(Authié, 1994). The purpose of an anti-disease vaccine is to reduce the symptoms of the 
disease rather than killing the parasite itself. Trypanotolerant cattle are able to protect 
themselves from the disease-associated symptoms (Authié et al., 2001). Trypanotolerant 
cattle mount an antibody response to the cysteine peptidase, TcoCATL. The artificial 
induction of antibodies against the peptidase could render a diseases-susceptible host more 
tolerant (Authié et al., 1992; Lalmanach et al., 2002). Using the idea of trypanotolerance 
attributed to antibody induction against TcoCATL, an anti-disease vaccine could be a 
possibility.  
 
Besides TcoCATL and its affect on trypanotolerance, other parasitic cysteine peptidases 
are also virulence factors and have been shown to contribute to disease pathogenesis 
including migration and nutrition (Caffrey and Steverding, 2009). TcrCATL, inhibited by 
the vinyl sulfone pseudopeptide inhibitor K11777, was effective in curing or alleviating T. 
cruzi infection in preclinical proof-of-concept studies and has now entered formal 
preclinical drug development (McKerrow et al., 2009). TcrCATL shares 59% identity with 
TbbCATL, 57% with TcoCATL and 45% with mammalian CATL (Eakin et al., 1992). 
Adding to the contribution to disease pathogenesis, TcoCATL degrades bovine fibrinogen 
and bovine serum albumin in vitro (Mbawa et al., 1992). TcoCATL is similar to TbbCATL 
and TcrCATL in that it is active at neutral pH allowing it to interact with host proteins in a 
physiological environment (Lalmanach et al., 2002). Furthermore, the recombinant 
catalytic domains of TviCATL (Vather, 2010) and TcoCATL (Pillay et al., 2010) are also 
active close to physiological pH. Although there are physiological natural cysteine 
peptidase inhibitors, incomplete enzyme inhibition with such inhibitors has been 
documented (Lonsdale-Eccles et al., 1995; Wiser et al., 1997). As seen on fibrinogen-
containing SDS-PAGE gels, TbbCATL and TcoCATL form active complexes of higher 
molecular weight when added to a rat kininogen-like cysteine peptidase inhibitor, 
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trypanopain modulator. Furthermore, the recombinant catalytic domain of TcoCATL forms 
a similar active complex when added to the cystatin inhibitor, stefin b, isolated from 
bovine liver (unpublished observation). Pyroglutamyl peptidase I (PGP), a cysteine 
peptidase with a slightly different catalytic triad (Glu instead of Asn); see below, is solely 
responsible for the reduced plasma half-life of thyrothrophin releasing hormone and 
partially responsible for the reduced half-life of gonadothrophin releasing hormone in T. b. 
brucei infected rodents (Morty et al., 2006). 
 
Trypanosomal cysteine peptidases, like mammalian CATL, are synthesised as pre-pro-
proteins (Cazzulo et al., 1989; Eakin et al., 1992; Sakanari et al., 1997). The catalytic 
domain, which contains the classical papain clan CA-like catalytic Cys, His and Asn triad, 
is linked to the 11-13 kDa C-terminal extension by a poly-threonine (TcrCATL and 
TviCATL) or poly-proline (TbbCATL and TcoCATL) tract. The C-terminal extension, for 
which a definitive biological function is not yet known (Caffrey et al., 2000), is unique to 
Trypanosomatidae. The overall 3-dimensional fold of cathepsin and papain-like cysteine 
peptidases is highly conserved. The prominent features of the structure consist of an L and 
R domain with a central α-helix and a β-barrel motif respectively (Turk et al., 2000).  
 
Understanding the enzymatic as well as structural character of the cysteine peptidases that 
act as pathogenic factors in trypanosomosis will provide information that will facilitate 
better drug selection or improved development of a multi-component vaccine. Determining 
whether T. vivax CATL-like peptidases are pathogenic factors and similar in structure, 
function and character to other pathogenic trypanosomal CATL-like peptidases would be 
pivotal to the design of a general inhibitor for trypanosomal cysteine peptidases. CATL-
like sequences from African and South American isolates of T. vivax have been evaluated 
for their suitability as genetic markers for population structure analysis and diagnosis 
(Cortez et al., 2009). The analysis of the CATL-like genes in that study did reveal that the 
T. vivax CATL-like sequences comprise the typical cysteine peptidase pre-, pro-, and 
central catalytic domain (with the Cys, His and Asn catalytic triad) as well as a C-terminal 
extension. 
 
Enzyme characterisation of native TviCATL is the first step to deciphering how similar, in 
character, is TviCATL to other trypanosomal CATL-like cysteine peptidases. 
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Characterisation includes substrate preference, inhibitor preference, pH stability and the 
ability to degrade physiological proteins.  
 
The functionally active full-length native TviCATL was purified from T. vivax strain Y486 
parasites that had been grown in BALB/c mice. TviCATL as the case with Clan CA, family 
C1 peptidases showed a general sensitivity to E-64 and cystatin and has a substrate 
specificity defined by the S2 pocket. Leu was preferred in the P2 position and basic and 
non-bulky hydrophobic residues were accepted in the P1 and P3 positions respectively. 
Similarly, native TcoCATL (Mbawa et al., 1992), TbbCATL (Troeberg et al., 1996) and 
TcrCATL (Chagas et al., 1997) have a distinct preference for a basic amino acid (Arg of 
Lys) in the P1 position. This is also a feature common to many mammalian and protozoan 
cysteine peptidases (Mbawa et al., 1992). Furthermore, the recombinant catalytic domain 
of TviCATL (Vather, 2010) and TcoCATL (Pillay et al., 2010) have similar amino acid 
preferences for the P1 position. Native TviCATL favours a leucyl or phenylalanyl and not 
an arginyl residue in the P2 position. Similar results were reported for the recombinant 
catalytic domains of TviCATL (Vather, 2010) and TcoCATL (Pillay et al., 2010), native 
TcoCATL (Mbawa et al., 1992), native TbbCATL (Troeberg et al., 1996) and recombinant 
TbrCATL (Caffrey et al., 2001).  
 
TviCATL exhibited no activity towards the CATB-like substrate, Z-Arg-Arg-AMC but 
was able to hydrolyse Z-Phe-Arg-AMC, the CATL-like substrate. The hydrophobic pocket 
of the S2 subsite of TcrCATL is lined with residues Leu189, Met190, Ala258, Leu282 and 
Glu333. In the case of TcoCATL, a leucyl residue, which shifts on solvent exposure, is 
found at the bottom of the hydrophobic pocket instead of Glu333 (Lecaille et al., 2001). 
The substitution of a glutamyl by a leucyl residue does not allow for the accommodation of 
Arg in the P2 position of TcoCATL. Sequence alignments also showed that TviCATL 
possesses a Leu instead of a Glu at this position, suggesting the inability of TviCATL to 
hydrolyse Z-Arg-Arg-AMC. In the case of TbrCATL, an Ala occupies this position and 
Caffrey et al (2001) have demonstrated the incapability of TbrCATL to degrade substrates 
with an Arg in the P2 position.  
 
TcrCATL accepts Phe and Leu in the P2 position with only a slight preference for Leu 
(Lima et al., 2001). However, recombinant TcrCATL2 (a cysteine peptidase isoform) has a 
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marked preference for Leu over Phe (dos Reis et al., 2006). This suggests that the S2 
pocket of TcrCATL2 might be more restricted than that of TcrCATL. Structural studies of 
TcrCATL have shown that, when in complex with irreversible inhibitors, Leu189, Ala258 
and Leu282 line the S2 pocket and readily accommodate the Phe residue at P2, which 
interacts with the enzyme’s backbone via the carbonyl of Gly188 (Brinen et al., 2000). A 
Ser substituted for Ala at position 258 and the proximal change of Met190 (found in 
TcrCATL) to Ser190 in recombinant TcrCATL2 may ultimately influence the enzyme’s S2 
specificity (dos Reis et al., 2006). Based on a sequence alignment with TcrCATL, residues 
lining the S2 pocket of TviCATL are similar to those of TcrCATL and do not have the 
relative amino acid substitutions found in TcrCATL2. This supports the observation that 
TviCATL has only a slight preference for Leu over Phe in the S2 position.  
 
TviCATL was optimally active at pH 7.5. Slightly lower pH values have been reported for 
the optimal activity of native TcrCATL (Chagas et al., 1997), TcoCATL (Chagas et al., 
1997; Mbawa et al., 1992) and TbbCATL (Troeberg et al., 1996). However these 
trypanosomal peptidases do possess activity at physiological pH. The only variation 
between native TviCATL and the recombinant catalytic domain of TviCATL (Vather, 
2010) is the ability of the recombinant catalytic domain of TviCATL to remain active at 
acidic pH. Whether or not the C-terminal extension of TviCATL influences the activity at 
acidic pH values is still to be determined. It has, however, been shown that full length 
TbrCATL as well as truncated TbrCATL (without the C-terminal extension) have very 
similar pH profiles (Caffrey et al., 2001).  
 
TviCATL, like other trypanosomal cysteine peptidases, was able to digest bovine 
fibrinogen. Additionally, TviCATL was effectively inhibited by chicken egg white 
cystatin, similar to native TcoCATL (Mbawa et al., 1992) and TcrCATL (Lima et al., 
2001). It was previously speculated that because of conserved sequences amongst 
cystatins, and the highly similar sequences of trypanosomal cysteine peptidases to those of 
the mammalian hosts, trypanosomal cysteine peptidases are likely to be inhibited by 
cystatins in the bloodstream of mammalian hosts (Troeberg et al., 1996). Peptidyl-
diazomethane inhibitors such as, Z-RLVG-CHN2, based on the cystatin-conserved QxVxG 
sequence, which forms part of the first β-hairpin loop and wedges into the papain-like 
cysteine peptidase substrate pocket (Auerswald et al., 1992), has been able to successfully 
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inhibit native TcoCATL and TcrCATL (Chagas et al., 1997). However, the mammalian 
homologs such as CATB and CATL are inhibited to a greater extent with such peptidyl-
diazomethane inhibitors. Attempts were made to overcome the limitations of cysteine 
peptidase inhibitors, specific for parasites, by labelling the N-terminus of substrates 
derived from the conserved residues from the N-terminal region of the cystatin 
superfamily. Labelling included biotin or using a spacer arm (6-aminohexanoic acid, Ahx) 
to increase the distance between the biotin and the peptidyl core of the inhibitor. 
Lalmanach et al. (1996) investigated the underlying premise that cysteine peptidases of the 
mammalian host and parasite might have different active site topologies that could favour 
or restrict the access of the biotinylated inhibitor to the active site cleft. This idea stemmed 
from the fact that the N-terminal, or Cbz group, of fluoromethylketone inhibitors protrudes 
from the active site of TcrCATL into the solvent, making no contacts with the enzyme 
(McGrath et al., 1995). Biotinylated methylketone inhibitors have shown more specificity 
for TcrCATL than mammalian CATL. The hydrophobic nature of the P2-binding subsite 
was further confirmed by the ability of both chloromethyl ketones, Z-Gly-Leu-Phe-CMK 
and H-D-Val-Phe-Lys-CMK, to inhibit native TviCATL. As has been previously 
demonstrated for native TcoCATL, Z-Leu-Met-CHN2 and Z-Leu-Lys-CHN2 hydrophobic 
groups in P2 (Leu) are very potent inhibitors (Mbawa et al., 1992). Similarly, Z-Phe-Phe-
CMK and Z-Phe-Ala-FMK were potent inhibitors of TbbCATL (Troeberg et al., 1999). 
Furthermore, K11777, the vinyl sulfone with a homophenyl group in P1 and a phenyl group 
in the P2 position was the most effective trypanocidal agent for cultured T. b. brucei and 
purified TbbCATL (Troeberg et al., 1999). As mentioned earlier, K11777 has entered 
preclinical drug development investigations for curing T. cruzi infection.  
 
It is important to know if the characteristics of mammalian cysteine peptidases differ from 
those of parasite homologs. Optimising the interaction of the active site of TviCATL with 
natural amino acid substrates has made considerable contributions to the development of 
inhibitors. Determining further structural and functional characteristics as well as whether 
TviCATL, like the T. congolense, T.cruzi and T. b. brucei homologs, TcoCATL, TcrCATL 
and TbbCATL respectively, acts as a pathogenic factor, would be essential for the 
designing of specific chemotherapeutic agents. However, phylogenetic analysis of 
sequences from East and West African T. vivax isolates, corresponding to CATL-like 
catalytic domains, revealed substantial polymorphism (Cortez et al., 2009). Furthermore, a 
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preliminary analysis of the organisation of CATL genes in the T. vivax genome showed 
that there is an array of 11 CATL-like genes organised in tandem array (Cortez et al., 
2009). This tandem array for CATL genes is also found in the T. congolense (Kakundi, 
2009), T. cruzi (Lima et al., 1994), T. b. rhodesiense (Mottram et al., 1989) and 
Leishmania mexicana genome (Mottram et al., 1997). As the characterisation of genes 
encoding such peptidases in T. vivax is the first step towards peptidase characterisation, 
which might contribute to the definition of targets for chemotherapy and/or vaccines, it is 
important that the organisation of the CATL genes is known. If TviCATL is proven to be 
pathogenic, then the other CATL-like peptidases encoded for in the T. vivax genome need 
be taken into consideration. These other CATL-like peptidases will need to be 
characterised and their structures determined. One of the most recurring substitutions of 
the TcoCATL isoforms is that of the active site Cys and His with Ser and Tyr respectively 
(Pillay et al., 2010). Although two TcoCATL isoforms have been shown to be active 
against classical cysteine peptidase substrates and inhibited by E-64, they differ slightly 
from one another and from the recombinant catalytic domain of TcoCATL in substrate 
preferences (Pillay et al., 2010). As previously mentioned, TcrCATL2 does differ 
substantially from TcrCATL regarding the S2 subsite (Lima et al., 1994). Although 
methylketone inhibitors were able to inhibit purified native TviCATL, the ability of such 
inhibitors to effectively reduce T. vivax numbers in culture should also be tested. 
Furthermore, diazomethylketone inhibitors are relatively non-selective inhibitors and this 
to validate the target of methlyketone inhibitors and the biological role of TviCATL, RNAi 
on TviCATL should also be done to see whether there is a significantly different 
phenotypic feature in cultured T. vivax. 
 
 To date, TcrCATL (Eakin et al., 1993; McGrath et al., 1995) and TbrCATL (Kerr et al., 
2009) are the only trypanosomal CATL-like cysteine peptidases that have been crystallised 
and their structures solved. Both structures follow a common two-domain fold of the 
papain superfamily. McGrath et al. (1995) reported that the active site of TcrCATL 
extends over seven substrate-binding sites, four of which (S1-S4) are located on the acyl 
side of the cleaved bond and three (S1’-S3’) on the amino side. The crystal structure of 
recombinant TcrCATL in complex with K11017 (Mu-Leu-Hph-VSPh) shows that the 
hydrophobic residue in the P2 position is able to make contact with the S2 subsite of 
TcrCATL as the S2 subsite is lined with non-polar residues (Bryant et al., 2009; Kerr et al., 
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2009). The advantage of structural analysis has allowed for the directed design of synthetic 
peptidase inhibitors.  
 
The amino acid residues Lys39 and Glu44 have been shown to be involved in TcoCATL 
dimerisation. At acidic pH, the side chains of Lys39 and His43 are positively charged, 
whereas Glu44 is negatively charged and as a result, a salt bridge could be formed between 
His43 and Glu44, forming an α-helix (Ndlovu, 2010). However at physiological pH the 
His43 is deprotonated resulting in a salt bridge between Lys39 and Glu44, thus forming a 
β-turn, giving the protein dimeric conformation (Ndlovu, 2010). Mutating Lys39 and 
Glu44 to Phe39 and Pro44, prevents a salt bridge formation and therefore making 
TcoCATL exist as a monomer. Furthermore as previously speculated, mutating His43 to 
Trp43 forces the protein to exist as a dimer (Ndlovu, 2010). Consequently, structural 
determination is required to understand this dimerisation mechanism so that protective 
epitopes may be mapped. This will be valuable information needed for the development of 
an effective anti-disease vaccine against bovine trypanosomosis. Furthermore, details 
about the structure-function of TcoCATL will be of significance in the design of 
chemotherapeutic agents.  
 
The last part of the study involved expression and purification of the recombinant catalytic 
domain of TviCATL and TcoCATL, TcoCATL dimerisation mutants and the full length 
PGP for crystallisation conditions screening. Using the Rigaku robotic crystallisation suite, 
purified proteins were screened with manual screens designed using variations of 
crystallising reagent conditions that have been used to previously crystallise related 
proteins. Furthermore, commercially available screens, with a large variation of 
crystallising reagents, were also used to screen the recombinant proteins. Crystals grown in 
the commercially available screens were used for X-ray diffraction. 
 
The catalytic domain of TcoCATL and TviCATL were recombinantly expressed in P. 
pastoris and purified to homogeneity. PGP from T. congolense was recombinantly 
expressed in E. coli BL21 (DE3) cells and also purified to homogeneity. Purified cysteine 
peptidases along with previously purified TcoCATL dimerisation mutants, TcoCATL 
(H43W), TcoCATL (C25A), which contains the proenzyme, and TcoCATL (K39F; E44P) 
were screened for crystallisation conditions using the Rigaku robotic crystallisation suite. 
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Manual screens involved recording conditions from related proteins such as native papain 
(Kamphuis et al., 1984), native papain in complex with a recombinant cysteine peptidase 
inhibitor derived from T. b. brucei (Alphey and Hunter, 2006), native papain-E-64 
complex (Varughese et al., 1989), human CATL-E-64 complex (Fujishima et al., 1997), 
recombinant TcrCATL in complex with Z-Phe-Arg-CH2F (McGrath et al., 1995) and 
K11777 (Kerr et al., 2009), recombinant TbrCATL (without the C-terminal extension) in 
complex with K11777 and falcipain-3 (cysteine peptidase from Plasmodium falciparum) in 
complex with K11017 (Kerr et al., 2009). CrysPred predictor (Kantardjieff and Rupp, 
2004) was also used to explore possible pH values for crystallisation, based on the 
proteins’ pI values. Many of the results from the manual screen showed ‘phase separation.’ 
In a numerical scoring system, ‘phase separation’ scores five out of a possible ten (Zeelen, 
2009).  
 
Whilst manual optimisation screening is still underway, the commercial screens, JSCG+ 
and PACT, were used as another option. The two hits, using the PACT screen, found for 
TcoCATL (K39F; E44P) were further optimised. The crystals formed were one-
dimensional needle-like and in order to get ‘better’ crystals with more dimension, 
conditions such as protein and crystallant concentration as well as buffer pH were varied. 
Analysis of a TcoCATL (K39F; E44P) crystal by X-ray diffraction confirmed that the 
crystal was protein however, the diffraction pattern was very weak and required further 
optimisation of crystal conditions to improve crystal quality. Whether or not the mutations 
of amino acid residues thought to be involved in the dimerisation, facilitated the 
crystallisation of TcoCATL (K39F; E44P) is still to be determined. However, TcrCATL, 
which is always a monomer, has been successfully crystallised (Eakin et al., 1993; 
McGrath et al., 1995). Nonetheless, it has been demonstrated that the dimerisation 
mechanism of TcoCATL does involve more amino acid residues (Ndlovu, 2010). Most of 
the crystals of TcoCATL (K39F; E44P) were overnucleated. This was evident from the 
shower of needle-like one-dimensional crystals formed in crystallisation drops. Higher 
levels of supersaturation are required for crystallisation nuclei to form than for subsequent 
crystal growth (Luft and DeTitta, 1999). It has been shown that seeding, through either 
streak seeding (Stura and Wilson, 1991) or microseeding (Luft and DeTitta, 1999) is the 
most popular way for uncoupling nucleation, formed in the labile zone of the phase 
diagram (Fig. 1.9, chapter 1), from crystal growth, formed in metastable zone. Seeding 
techniques are still being pursued for crystallisation of the recombinant proteins.  
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Although all proteins were concentrated to >5mg/ml, which is sufficient for crystallisation, 
the inability of TviCATL and TcoCATL (C25A) to crystallise could have been attributed to 
glycosylation. Glycosylation has been said to interfere with crystallisation as the flexible 
and heterogeneous carbohydrate moieties can account for a significant fraction of the 
surface area of the protein, interfering with the crystallisation process (Derewenda, 2010). 
However, proteinase A of Saccharomyces cerevisae (Li et al., 2007) and HIV gp120 
envelope protein (Kwong et al., 1998) have been crystallised in spite of the glycosylation. 
In the case of TbrCATL crystallisation, however, the S172A mutation was made to remove 
the O-linked glycosylation site (Caffrey et al., 2001). 
 
Although TcoCATL has pathogenic roles and provides insight into the better immune 
response of trypanotolerant cattle and hope for an anti-disease vaccine, trypanotolerance 
has been suggested to be multi-factorial, involving both non-immunological and 
immunological mechanisms (Authié, 1994). Furthermore, as previously mentioned, like 
that of CATL genes of T. cruzi (Lima et al., 1994) T. b. rhodesiense (Mottram et al., 1989), 
T. vivax (Cortez et al., 2009) and L. mexicana genome (Mottram et al., 1997), TcoCATL is 
organised in the genome of the parasite as a tandem array of multiple variants (Kakundi, 
2009). Additionally, two of the variants of TcoCATL have been characterised and differ in 
substrate preference compared to TcoCATL (Pillay et al., 2010). Although the variants, 
like that of TcoCATL, prefer a hydrophobic amino acid, such as Leu or Phe, in the P2 
position, unlike TcoCATL, a small neutral amino acid, rather than a bulky cyclic amino 
acid such as proline, is required for the P3 position (Pillay et al., 2010). As a result of these 
slight substrate preference differences, structural analysis is required as the substrate 
binding pockets may be different in size, character and geometry. These differences would 
be needed to be taken into consideration for proper drug and vaccine design. This unveils 
future work which would require structural studies on the variants of TcoCATL.  
 
The initial studies on TviCATL were important preliminary studies to learn more about the 
relationship of the major cysteine peptidase of T. vivax with other trypanosomal cysteine 
peptidases, especially since to date, no such study has been done. Provided that TviCATL 
does play a role in pathogenesis, the commonality of enzymatic characteristics between 
TviCATL and those of TcoCATL, TbbCATL, TbrCATL and TcrCATL does give hope for 
the design of a broader based drug. The crystal structure of TcoCATL, with some of the 
residues involved in dimerisation mutated, will be pivotal in understanding the 
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dimerisation model. This insight will be valuable towards therapies such as vaccine design 
and chemotherapeutics. Understanding the structure and function of the CATL-like 
cysteine peptidases of African trypanosomes is of major importance and significance to the 
control of African animal trypanosomosis. 
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APPENDIX 1:  Screening conditions used in JSCG+ and PACT commercial screens 
 
JSCG+ screen: 
Tube No.  Salt Buffer pH Precipitant  
1  0.2 M lithium sulfate  0.1 M sodium acetate  4.5  50 % v/v PEG 400  
2  None  0.1 M sodium citrate  5.5  20 % w/v PEG 3000  
3  0.2 M di-ammonium 
hydrogen citrate  
None  -  20 % w/v PEG 3350  
4  0.02 M calcium chloride  0.1 M sodium acetate  4.6  30 % v/v MPD  
5  0.2 M magnesium 
formate  
None  -  20 % w/v PEG 3350  
6  0.2 M lithium sulfate  0.1 M phosphate/citrate  4.2  20 % w/v PEG 1000  
7  None  0.1 M CHES  9.5  20 % w/v PEG 8000  
8  0.2 M ammonium 
formate  
None  -  20 % w/v PEG 3350  
9  0.2 M ammonium 
chloride  
None  -  20 % w/v PEG 3350  
10  0.2 M potassium formate  None  -  20 % w/v PEG 3350  
11  0.2 M ammonium 
dihydrogen phosphate  
0.1 M Tris  8.5  50 % v/v MPD  
12  0.2 M potassium nitrate  None  -  20 % w/v PEG 3350  
13  None  0.1 M citrate  4.0  0.8 M ammonium sulfate  
14  0.2 M sodium 
thiocyanate  
None  -  20 % w/v PEG 3350  
15  None  0.1 M Bicine  9.0  20 % w/v PEG 6000  
16  None  0.1 M HEPES  7.5  10 % w/v PEG 8000/ 8 
% v/v Ethylene glycol  
17  None  0.1 M sodium cacodylate  6.5  40 % v/v MPD/ 5 % w/v 
PEG 8000  
18  None  0.1 M phosphate/citrate  4.2  40 % v/v Ethanol/ 5 % 
w/v PEG 1000  
19  None  0.1 M sodium acetate  4.6  8 % w/v PEG 4000  
20  0.2 M magnesium 
chloride  
0.1 M Tris  7.0  10 % w/v PEG 8000  
21  None  0.1 M citrate  5.0  20 % w/v PEG 6000  
22  0.2 M magnesium 
chloride  
0.1 M sodium cacodylate  6.5  50 % v/v PEG 200  
23  None  None  6.5  1.6 M tri-sodium citrate  
24  0.2 M tri-potassium 
citrate  
None  -  20 % w/v PEG 3350  
25  0.2 M sodium chloride  0.1 M phosphate/citrate  4.2  20 % w/v PEG 8000  
26  1.0 M lithium chloride  0.1 M Na citrate  4.0  20 % w/v PEG 6000  
27  0.2 M ammonium nitrate  None  -  20 % w/v PEG 3350  
28  None  0.1 M Na HEPES  7.0  10 % w/v PEG 6000  
29  None  0.1 M Na HEPES  7.5  0.8 M sodium 
dihydrogen phosphate  
0.8 M potassium 
dihydrogen phosphate  
30  None  0.1 M phosphate/citrate  4.2  40 % v/v PEG 300  
31  0.2 M zinc acetate  0.1 M sodium acetate  4.5  10 % w/v PEG 3000  
32  None  0.1 M Tris  8.5  20 % v/v Ethanol  
33  None  0.1 M Na/K phosphate  6.2  25 % v/v 1,2-
propanediol  
10 % v/v Glycerol  
34  None  0.1 M Bicine  9.0  10 % w/v PEG 20,000/ 
2% v/v Dioxane  
35  None  0.1 M sodium acetate  4.6  2.0 M ammonium sulfate  
36  None  None  -  10 % w/v PEG 1000/ 10 
% w/v PEG 8000  
37  None  None  -  24 % w/v PEG 1500/ 20 
% v/v Glycerol  
38  0.2 M magnesium 
chloride  
0.1 M Na HEPES  7.5  30 % v/v PEG 400  
39  0.2 M sodium chloride  0.1 M Na/K phosphate  6.2  50 % v/v PEG 200  
40  0.2 M lithium sulfate  0.1 M sodium acetate  4.5  30 % w/v PEG 8000  
41  None  0.1 M HEPES  7.5  70 % v/v MPD  
42  0.2 M magnesium 
chloride  
0.1 M Tris  8.5  20 % w/v PEG 8000  
43  0.2 M lithium sulfate  0.1 M Tris  8.5  40 % v/v PEG 400  
44  None  0.1 M Tris  8.0  40 % v/v MPD  
45  0.17 M ammonium None  -  25.5 % w/v PEG 4000/ 
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sulfate  15 % v/v Glycerol  
46  0.2 M calcium acetate  0.1 M sodium cacodylate  6.5  40 % v/v PEG 300  
47  0.14 M calcium chloride  0.07 M sodium acetate  4.6  14 % v/v 2-propanol/ 30 
% v/v Glycerol  
48  0.04 M potassium 
dihydrogen phosphate  
None  -  16 % w/v PEG 8000/ 20 
% v/v Glycerol  
     
49  None  0.1 M sodium cacodylate  6.5  1.0 M tri-sodium citrate  
50  0.2 M sodium chloride  0.1 M sodium cacodylate  6.5  2.0 M ammonium sulfate  
51  0.2 M sodium chloride  0.1 M HEPES  7.5  10 % v/v 2-propanol  
52  0.2 M lithium sulfate  0.1 M Tris  8.5  1.26 M ammonium 
sulfate  
53  None  0.1 M CAPS  10.5  40 % v/v MPD  
54  0.2 M zinc acetate  0.1 M imidazole  8.0  20 % w/v PEG 3000  
55  0.2 M zinc acetate  0.1 M sodium cacodylate  6.5  10 % v/v 2-propanol  
56  None  0.1 M sodium acetate  4.5  1.0 M di-ammonium 
hydrogen phosphate  
57  None  0.1 M MES  6.5  1.6 M magnesium sulfate  
58  None  0.1 M Bicine  9.0  10 % w/v PEG 6000  
59  0.16 M calcium acetate  0.08 M sodium 
cacodylate  
6.5  14.4 % w/v PEG 8000/ 
20 % v/v glycerol  
60  None  0.1 M imidazole  8.0  10 % w/v PEG 8000  
61  0.05 M caesium chloride  0.1 M MES  6.5  30 % v/v Jeffamine M-
600  
62  None  0.1 M Na Citrate  5.0  3.2 M ammonium sulfate  
63  None  0.1 M Tris  8.0  20 % v/v MPD  
64  None  0.1 M HEPES  7.5  20 % v/v Jeffamine M-
600  
65  0.2 M magnesium 
chloride  
0.1 M Tris  8.5  50 % v/v ethylene glycol  
66  None  0.1 M Bicine  9.0  10 % v/v MPD  
67  None  None  7.0  0.8 M succinic acid  
68  None  None  7.0  2.1 M DL-malic acid  
69  None  None  7.0  2.4 M sodium malonate  
70  1.1 M sodium malonate  0.1 M HEPES  7.0  0.5 % v/v Jeffamine ED-
2001  
71  1.0 M succinic acid  0.1 M HEPES  7.0  1 % w/v PEG 2000 MME 
72  None  0.1 M HEPES  7.0  30 % v/v Jeffamine M-
600  
73  None  0.1 M HEPES  7.0  30 % v/v Jeffamine ED-
2001  
74  0.02 M magnesium 
chloride  
0.1 M HEPES  7.5  22 % w/v polyacrylic 
acid 5100 sodium salt  
75  0.01 M cobalt chloride  0.1 M Tris  8.5  20 % w/v 
polyvinylpyrrolidone 
K15  
76  0.2 M tri-methylamine N-
oxide  
0.1 M Tris  8.5  20 % w/v PEG 2000 
MME  
77  0.005 M cobalt chloride  
0.005 M cadmium 
chloride  
0.005 M magnesium 
chloride  
0.005 M nickel chloride  
0.1 M HEPES  7.5  12 % w/v PEG 3350  
78  0.2 M sodium malonate  None  7.0  20 % w/v PEG 3350  
79  0.1 M succinic acid  None  7.0  15 % w/v PEG 3350  
80  0.15 M DL - malic acid  None  7.0  20 % w/v PEG 3350  
81  0.1 M potassium 
thiocyanate  
None  -  30 % w/v PEG 2000 
MME  
82  0.15 M potassium 
bromide  
None  -  30 % w/v PEG 2000 
MME  
83  None  0.1 M Bis Tris  5.5  2.0 M ammonium sulfate  
84  None  0.1 M Bis Tris  5.5  3.0 M sodium chloride  
85  None  0.1 M Bis Tris  5.5  0.3 M magnesium 
formate  
86  1.0 M ammonium sulfate  0.1 M Bis Tris  5.5  1 % w/v PEG 3350  
87  None  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
88  0.2 M calcium chloride  0.1 M Bis Tris  5.5  45 % v/v MPD  
89  0.2 M ammonium acetate  0.1 M Bis Tris  5.5  45 % v/v MPD  
90  0.1 M ammonium acetate  0.1 M Bis Tris  5.5  17 % w/v PEG 10000  
91  0.2 M ammonium sulfate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
92  0.2 M sodium chloride  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
93  0.2 M lithium sulfate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
94  0.2 M ammonium acetate  0.1 M Bis Tris  5.5  25 % w/v PEG 3350  
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95  0.2 M magnesium 
chloride  
0.1 M Bis Tris  5.5  25 % w/v PEG 3350  




Tube No.  Salt Buffer pH Precipitant  
 
1  0.1 M SPG buffer  4    25% (w/v) PEG 1500  
2   0.1 M SPG buffer 5     25% (w/v) PEG 1500  
3   0.1 M SPG buffer  6    25% (w/v) PEG 1500  
4   0.1 M SPG buffer  7    25% (w/v) PEG 1500  
5   0.1 M SPG buffer  8    25% (w/v) PEG 1500  
6   0.1 M SPG buffer 9    25% (w/v) PEG 1500  
7  0.2 M Sodium chloride 0.1 M Sodium acetate  5   20% (w/v) PEG 6000  
8  0.2 M Ammonium chloride  0.1 M Sodium acetate  5    20% (w/v) PEG 6000  
9 0.2 M Lithium chloride  0.1 M Sodium acetate  5    20% (w/v) PEG 6000  
10  0.2 M Magnesium chloride  0.1 M Sodium acetate  5   20% (w/v) PEG 6000  
11  0.2 M Calcium chloride 0.1 M Sodium acetate  5    20% (w/v) PEG 6000  
12 0.01 M Zinc chloride 0.1 M Sodium acetate  5    20% (w/v) PEG 6000  
13  0.1 M MIB buffer  4    25% (w/v) PEG 1500  
14  0.1 M MIB buffer  5    25% (w/v) PEG 1500  
15  0.1 M MIB buffer  6    25% (w/v) PEG 1500  
16  0.1 M MIB buffer  7    25% (w/v) PEG 1500  
17  0.1 M MIB buffer  8    25% (w/v) PEG 1500  
18  0.1 M MIB buffer  9    25% (w/v) PEG 1500  
19  0.2 M Sodium chloride  0.1 M MES  6    20% (w/v) PEG 6000  
20  0.2 M Ammonium chloride  0.1 M MES  6    20% (w/v) PEG 6000  
21  0.2 M Lithium chloride  0.1 M MES  6    20% (w/v) PEG 6000  
22 0.2 M Magnesium chloride  0.1 M MES  6    20% (w/v) PEG 6000  
23 0.2 M Calcium chloride  0.1 M MES  6    20% (w/v) PEG 6000  
24  0.01 M Zinc chloride  0.1 M MES  6    20% (w/v) PEG 6000  
25    0.1 M PCB buffer  4    25% (w/v) PEG 1500  
26    0.1 M PCB buffer  5    25% (w/v) PEG 1500  
27    0.1 M PCB buffer  6    25% (w/v) PEG 1500  
28    0.1 M PCB buffer  7    25% (w/v) PEG 1500  
29    0.1 M PCB buffer  8    25% (w/v) PEG 1500  
30    0.1 M PCB buffer  9    25% (w/v) PEG 1500  
31  0.2 M Sodium chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
32  0.2 M Ammonium chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
33  0.2 M Lithium chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
34  0.2 M Magnesium chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
35  0.2 M Calcium chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
36  0.01 M Zinc chloride  0.1 M HEPES  7    20% (w/v) PEG 6000  
37    0.1 M MMT buffer  4    25% (w/v) PEG 1500  
38    0.1 M MMT buffer  5    25% (w/v) PEG 1500  
39    0.1 M MMT buffer  6    25% (w/v) PEG 1500  
40    0.1 M MMT buffer  7    25% (w/v) PEG 1500  
41    0.1 M MMT buffer  8    25% (w/v) PEG 1500  
42    0.1 M MMT buffer  9    25% (w/v) PEG 1500  
43  0.2 M Sodium chloride  0.1 M Tris  8    20% (w/v) PEG 6000  
44  0.2 M Ammonium chloride  0.1 M Tris  8   20% (w/v) PEG 6000  
45  0.2 M Lithium chloride  0.1 M Tris  8    20% (w/v) PEG 6000  
46  0.2 M Magnesium chloride  0.1 M Tris  8    20% (w/v) PEG 6000  
47  0.2 M Calcium chloride  0.1 M Tris  8    20% (w/v) PEG 6000  
48      0.1 M Tris  8    20% (w/v) PEG 6000  
49  0.2 M Sodium fluoride       20% (w/v) PEG 3350  
50  0.2 M Sodium bromide       20% (w/v) PEG 3350  
51  0.2 M Sodium iodide       20% (w/v) PEG 3350  
52  0.2 M Potassium thiocyanate      20% (w/v) PEG 3350  
53  0.2 M Sodium nitrate       20% (w/v) PEG 3350  
54  0.2 M Sodium formate       20% (w/v) PEG 3350  
55 0.2 M Sodium acetate       20% (w/v) PEG 3350  
56  0.2 M Sodium sulfate       20% (w/v) PEG 3350  
57  0.2 M Potassium/sodium tartrate      20% (w/v) PEG 3350  
58  0.2 M Sodium/potassium phosphate      20% (w/v) PEG 3350  
59  0.2 M Sodium citrate       20% (w/v) PEG 3350  
60  0.2 M Sodium malonate     20% (w/v) PEG 3350  
61  0.2 M Sodium fluoride  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
62 0.2 M Sodium bromide  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
63  0.2 M Sodium iodide  0.1 M Bis Tris propane   6.5   20% (w/v) PEG 3350  
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64  0.2 M Potassium thiocyanate 0.1 M Bis Tris propane  6.5   20% (w/v) PEG 3350  
65  0.2 M Sodium nitrate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
66  0.2 M Sodium formate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
67  0.2 M Sodium acetate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
68  0.2 M Sodium sulfate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
69  0.2 M Potassium/sodium tartrate 0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
70  0.2 M Sodium/potassium phosphate 0.1 M Bis Tris propane  6.5   20% (w/v) PEG 3350  
71  0.2 M Sodium citrate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
72  0.2 M Sodium malonate  0.1 M Bis Tris propane  6.5    20% (w/v) PEG 3350  
73  0.2 M Sodium fluoride  0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
74 0.2 M Sodium bromide  0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
75 0.2 M Sodium iodide  0.1 M Bis Tris propane  7.5   20% (w/v) PEG 3350  
76 0.2 M Potassium thiocyanate 0.1 M Bis Tris propane  7.5   20% (w/v) PEG 3350  
77  0.2 M Sodium nitrate  0.1 M Bis Tris propane  7.5   20% (w/v) PEG 3350  
78  0.2 M Sodium formate  0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
79  0.2 M Sodium acetate  0.1 M Bis Tris propane 7.5    20% (w/v) PEG 3350  
80  0.2 M Sodium sulfate 0.1 M Bis Tris propane 7.5    20% (w/v) PEG 3350  
81  0.2 M Potassium/sodium tartrate 0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
82  0.2 M Sodium/potassium phosphate 0.1 M Bis Tris propane 7.5   20% (w/v) PEG 3350  
83  0.2 M Sodium citrate  0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
84  0.2 M Sodium malonate  0.1 M Bis Tris propane  7.5    20% (w/v) PEG 3350  
85 0.2 M Sodium fluoride  0.1 M Bis Tris propane   8.5   20% (w/v) PEG 3350  
86  0.2 M Sodium bromide  0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
87  0.2 M Sodium iodide  0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
88  0.2 M Potassium thiocyanate 0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
89  0.2 M Sodium nitrate  0.1 M Bis Tris propane  8.5   20% (w/v) PEG 3350  
90  0.2 M Sodium formate 0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
91 0.2 M Sodium acetate  0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
92  0.2 M Sodium sulfate 0.1 M Bis Tris propane 8.5    20% (w/v) PEG 3350  
93  0.2 M Potassium/sodium tartrate 0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350  
94  0.2 M Sodium/potassium phosphate 0.1 M Bis Tris propane 8.5   20% (w/v) PEG 3350  
95  0.2 M Sodium citrate  0.1 M Bis Tris propane   8.5    20% (w/v) PEG 3350  
96  0.2 M sodium malonate  0.1 M Bis Tris propane  8.5    20% (w/v) PEG 3350 
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PEG 3350/PEG 6000 (36%-15%) 
  pH of 0.1 M Sodium citrate buffer (pH 5.0-5.5  for A-
D and pH 5.0-5.5 for E-H) 
  
Protein:crystallant in subwells: 
 80:20 subwell 1 (size of drop is 0.6 μl) 
47:20 subwell 2 (size of drop is 0.6 μl) 
 40:20 subwell 1 (size of drop is 0.6 μl) 
30:20 subwell 2 (size of drop is 0.6 μl) 
  
 The top half of the plate (A-D) had protein:crystallant ratio of 80:20 and 47:20. The second half of the plate 
(E-H) had 40:20 and 30:20 ratios. The range of buffer pH was also split for each half of the plate (increments 
of 0.17 in pH value) . The PEG concentration decreased over the 12 columns. Two plates were prepared, one 
for PEG 3350 and the other for PEG 6000. 
 
 
